10000001|t|Laboratory Tests Response to Plenaxis should be monitored by measuring serum total testosterone concentrations just prior to administration on Day 29 and every 8 weeks thereafter.
10000001	29	37	Plenaxis	brand	Drug_0
10000001	83	95	testosterone	drug	Drug_1

10000002|t|Population pharmacokinetic analyses revealed that MTX, NSAIDs, corticosteroids, and TNF blocking agents did not influence abatacept clearance.
10000002	50	53	MTX	drug	Drug_0
10000002	55	61	NSAIDs	group	Drug_1
10000002	63	78	corticosteroids	group	Drug_2
10000002	84	103	TNF blocking agents	group	Drug_3
10000002	122	131	abatacept	drug	Drug_4

10000003|t|The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
10000003	115	122	ORENCIA	brand	Drug_0
10000003	124	127	MTX	drug	Drug_1
10000003	129	135	NSAIDs	group	Drug_2
10000003	137	152	corticosteroids	group	Drug_3
10000003	154	173	TNF blocking agents	group	Drug_4
10000003	175	187	azathioprine	drug	Drug_5
10000003	189	200	chloroquine	drug	Drug_6
10000003	202	206	gold	drug	Drug_7
10000003	208	226	hydroxychloroquine	drug	Drug_8
10000003	228	239	leflunomide	drug	Drug_9
10000003	241	254	sulfasalazine	drug	Drug_10
10000003	260	268	anakinra	drug	Drug_11

10000004|t|Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.
10000004	31	45	TNF antagonist	group	Drug_0
10000004	51	58	ORENCIA	brand	Drug_1
10000004	179	194	TNF antagonists	group	Drug_2
10000004	effect	Drug_0	Drug_1

10000005|t|Concurrent therapy with ORENCIA and TNF antagonists is not recommended.
10000005	24	31	ORENCIA	brand	Drug_0
10000005	36	51	TNF antagonists	group	Drug_1
10000005	advise	Drug_0	Drug_1

10000006|t|There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.
10000006	70	77	ORENCIA	brand	Drug_0
10000006	109	117	anakinra	drug	Drug_1
10000006	advise	Drug_0	Drug_1

10000007|t|These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.
10000007	32	39	heparin	drug	Drug_0
10000007	41	49	warfarin	drug	Drug_1
10000007	51	84	beta-adrenergic receptor blockers	group	Drug_2
10000007	86	113	calcium channel antagonists	group	Drug_3
10000007	115	155	angiotensin converting enzyme inhibitors	group	Drug_4
10000007	178	186	nitrates	group	Drug_5
10000007	188	199	ticlopidine	drug	Drug_6
10000007	205	212	aspirin	brand	Drug_7

10000008|t|Heparin, other anticoagulants, thrombolytics, and anti platelet agents are associated with an increase in bleeding.
10000008	0	7	Heparin	drug	Drug_0
10000008	15	29	anticoagulants	group	Drug_1
10000008	31	44	thrombolytics	group	Drug_2
10000008	50	70	anti platelet agents	group	Drug_3

10000009|t|Patients with HACA titers may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.
10000009	98	145	diagnostic monoclonal antibodies	group	Drug_0
10000009	112	145	therapeutic monoclonal antibodies	group	Drug_1

10000010|t|The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate.
10000010	97	104	alcohol	drug	Drug_0
10000010	108	119	acamprosate	drug	Drug_1

10000011|t|Pharmacokinetic studies indicate that administration of disulfiram or diazepam does not affect the pharmacokinetics of acamprosate.
10000011	56	66	disulfiram	drug	Drug_0
10000011	70	78	diazepam	drug	Drug_1
10000011	119	130	acamprosate	drug	Drug_2

10000012|t|Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.
10000012	21	31	naltrexone	drug	Drug_0
10000012	114	125	acamprosate	drug	Drug_1
10000012	mechanism	Drug_0	Drug_1

10000013|t|The pharmacokinetics of naltrexone and its major metabolite 6-beta-naltrexol were unaffected following co-administration with Acamprosate.
10000013	24	34	naltrexone	drug	Drug_0
10000013	60	76	6-beta-naltrexol	drug_n	Drug_1
10000013	126	137	Acamprosate	drug	Drug_2

10000014|t|Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.
10000014	93	104	Acamprosate	drug	Drug_0
10000014	124	135	anxiolytics	group	Drug_1
10000014	137	146	hypnotics	group	Drug_2
10000014	151	160	sedatives	group	Drug_3
10000014	172	187	benzodiazepines	group	Drug_4
10000014	193	214	non-opioid analgesics	group	Drug_5

10000015|t|Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.
10000015	16	27	Acamprosate	drug	Drug_0
10000015	47	62	antidepressants	group	Drug_1
10000015	effect	Drug_0	Drug_1

10000016|t|These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
10000016	24	33	thiazides	group	Drug_0
10000016	44	53	diuretics	group	Drug_1
10000016	55	70	corticosteroids	group	Drug_2
10000016	72	86	phenothiazines	group	Drug_3
10000016	88	104	thyroid products	group	Drug_4
10000016	106	115	estrogens	group	Drug_5
10000016	122	136	contraceptives	group	Drug_6
10000016	138	147	phenytoin	drug	Drug_7
10000016	149	163	nicotinic acid	drug	Drug_8
10000016	165	181	sympathomimetics	group	Drug_9
10000016	183	213	calcium channel-blocking drugs	group	Drug_10
10000016	219	228	isoniazid	drug	Drug_11

10000017|t|When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia.
10000017	54	62	Acarbose	drug	Drug_0
10000017	83	96	sulfonylureas	group	Drug_1
10000017	100	107	insulin	drug	Drug_2

10000018|t|Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.
10000018	0	21	Intestinal adsorbents	group	Drug_0
10000018	30	38	charcoal	drug	Drug_1
10000018	44	73	digestive enzyme preparations	group	Drug_2
10000018	124	131	amylase	drug	Drug_3
10000018	133	143	pancreatin	drug	Drug_4
10000018	170	178	Acarbose	drug	Drug_5
10000018	mechanism	Drug_4	Drug_5
10000018	mechanism	Drug_0	Drug_5
10000018	mechanism	Drug_3	Drug_5
10000018	mechanism	Drug_1	Drug_5

10000019|t|Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.
10000019	0	8	Acarbose	drug	Drug_0
10000019	111	118	digoxin	drug	Drug_1
10000019	mechanism	Drug_0	Drug_1

10000020|t|Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.
10000020	46	54	Acarbose	drug	Drug_0
10000020	123	130	digoxin	drug	Drug_1
10000020	132	142	nifedipine	drug	Drug_2
10000020	144	155	propranolol	drug	Drug_3
10000020	160	170	ranitidine	drug	Drug_4

10000021|t|Acarbose did not interfere with the absorption or disposition of the sulfonylurea glyburide in diabetic patients.
10000021	0	8	Acarbose	drug	Drug_0
10000021	69	81	sulfonylurea	drug	Drug_1
10000021	82	91	glyburide	drug	Drug_2

10000022|t|Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).
10000022	0	8	Acarbose	drug	Drug_0
10000022	240	247	digoxin	drug	Drug_1

10000023|t|The amount of metformin absorbed while taking Acarbose was bioequivalent to the amount absorbed when taking placebo, as indicated by the plasma AUC values.
10000023	14	23	metformin	drug	Drug_0
10000023	46	54	Acarbose	drug	Drug_1

10000024|t|However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.
10000024	141	150	metformin	drug	Drug_0
10000024	89	97	Acarbose	drug	Drug_1
10000024	mechanism	Drug_1	Drug_0
10000024	mechanism	Drug_0	Drug_1

10000025|t|There is little if any clinically significant interaction between Acarbose and metformin.
10000025	66	74	Acarbose	drug	Drug_0
10000025	79	88	metformin	drug	Drug_1

10000026|t|Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.
10000026	0	29	Catecholamine-depleting drugs	group	Drug_0
10000026	39	48	reserpine	drug	Drug_1
10000026	94	114	beta-blocking agents	group	Drug_2
10000026	effect	Drug_1	Drug_2
10000026	effect	Drug_0	Drug_2

10000027|t|Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.
10000027	22	32	acebutolol	drug	Drug_0
10000027	38	61	catecholamine depletors	group	Drug_1
10000027	advise	Drug_0	Drug_1

10000028|t|Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.
10000028	79	106	beta-adrenergic antagonists	group	Drug_0
10000028	111	138	alpha-adrenergic stimulants	group	Drug_1
10000028	effect	Drug_0	Drug_1

10000029|t|Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.
10000029	43	76	beta-adrenoceptor blocking agents	group	Drug_0
10000029	80	116	nonsteroidal anti-inflammatory drugs	group	Drug_1
10000029	effect	Drug_0	Drug_1

10000030|t|No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.
10000030	33	40	digoxin	drug	Drug_0
10000030	42	61	hydrochlorothiazide	drug	Drug_1
10000030	63	74	hydralazine	drug	Drug_2
10000030	76	90	sulfinpyrazone	drug	Drug_3
10000030	97	111	contraceptives	group	Drug_4
10000030	113	124	tolbutamide	drug	Drug_5
10000030	129	137	warfarin	drug	Drug_6

10000031|t|DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.
10000031	0	6	DIAMOX	brand	Drug_0
10000031	68	77	phenytoin	drug	Drug_1
10000031	mechanism	Drug_0	Drug_1
10000031	mechanism	Drug_0	Drug_1

10000032|t|By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.
10000032	104	113	primidone	drug	Drug_0
10000032	60	66	DIAMOX	brand	Drug_1
10000032	mechanism	Drug_1	Drug_0

10000033|t|Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.
10000033	74	80	DIAMOX	brand	Drug_0
10000033	103	112	primidone	drug	Drug_1
10000033	advise	Drug_0	Drug_1

10000034|t|Acetazolamide may increase the effects of other folic acid antagonists.
10000034	0	13	Acetazolamide	drug	Drug_0
10000034	48	70	folic acid antagonists	group	Drug_1
10000034	effect	Drug_0	Drug_1

10000035|t|Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.
10000035	0	13	Acetazolamide	drug	Drug_0
10000035	45	56	amphetamine	drug	Drug_1
10000035	mechanism	Drug_0	Drug_1

10000036|t|Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.
10000036	0	13	Acetazolamide	drug	Drug_0
10000036	43	52	quinidine	drug	Drug_1
10000036	mechanism	Drug_0	Drug_1

10000037|t|Acetazolamide may prevent the urinary antiseptic effect of methenamine.
10000037	0	13	Acetazolamide	drug	Drug_0
10000037	59	70	methenamine	drug	Drug_1
10000037	effect	Drug_0	Drug_1

10000038|t|Acetazolamide increases lithium excretion and the lithium may be decreased.
10000038	0	13	Acetazolamide	drug	Drug_0
10000038	50	57	lithium	drug	Drug_1
10000038	mechanism	Drug_0	Drug_1

10000039|t|Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.
10000039	0	13	Acetazolamide	drug	Drug_0
10000039	18	36	sodium bicarbonate	drug	Drug_1
10000039	effect	Drug_0	Drug_1

10000040|t|Acetazolamide may elevate cyclosporine levels.
10000040	0	13	Acetazolamide	drug	Drug_0
10000040	26	38	cyclosporine	drug	Drug_1
10000040	mechanism	Drug_0	Drug_1

10000041|t|Concomitant use with iron supplements may result in the reduced absorption of iron.
10000041	21	36	iron supplement	group	Drug_0
10000041	78	82	iron	drug	Drug_1

10000042|t|Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.
10000042	21	31	probenecid	drug	Drug_0
10000042	37	46	acyclovir	drug	Drug_1
10000042	mechanism	Drug_0	Drug_1

10000043|t|Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.
10000043	109	116	ethanol	drug	Drug_0
10000043	41	51	etretinate	drug	Drug_1
10000043	95	104	acitretin	drug	Drug_2
10000043	mechanism	Drug_2	Drug_0

10000044|t|Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.
10000044	125	138	glibenclamide	drug	Drug_0
10000044	56	65	acitretin	drug	Drug_1
10000044	142	154	sulfonylurea	group	Drug_2
10000044	166	180	chlorpropamide	drug	Drug_3
10000044	effect	Drug_1	Drug_0

10000045|t|Repeating the study with 6 healthy male volunteers in the absence of glibenclamide did not detect an effect of acitretin on glucose tolerance.
10000045	69	82	glibenclamide	drug	Drug_0
10000045	111	120	acitretin	drug	Drug_1

10000046|t|Hormonal Contraceptives: It has not been established if there is a pharmacokinetic interaction between acitretin and combined oral contraceptives.
10000046	0	23	Hormonal Contraceptives	group	Drug_0
10000046	103	112	acitretin	drug	Drug_1
10000046	117	145	combined oral contraceptives	group	Drug_2

10000047|t|However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.
10000047	38	47	acitretin	drug	Drug_0
10000047	103	112	progestin	drug	Drug_1
10000047	effect	Drug_0	Drug_1

10000048|t|Microdosed minipill progestin preparations are not recommended for use with Soriatane.
10000048	20	29	progestin	drug	Drug_0
10000048	76	85	Soriatane	drug	Drug_1
10000048	advise	Drug_0	Drug_1

10000049|t|It is not known whether other progestational contraceptives, such as implants and injectables, are adequate methods of contraception during acitretin therapy.
10000049	30	59	progestational contraceptives	group	Drug_0
10000049	140	149	acitretin	drug	Drug_1

10000050|t|Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.
10000050	94	106	methotrexate	drug	Drug_0
10000050	111	121	etretinate	drug	Drug_1
10000050	effect	Drug_0	Drug_1

10000051|t|Consequently, the combination of methotrexate with acitretin is also contraindicated.
10000051	33	45	methotrexate	drug	Drug_0
10000051	51	60	acitretin	drug	Drug_1
10000051	advise	Drug_0	Drug_1

10000052|t|Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.
10000052	85	94	phenytoin	drug	Drug_0
10000052	14	23	acitretin	drug	Drug_1
10000052	mechanism	Drug_1	Drug_0

10000053|t|Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.
10000053	40	53	tetracyclines	group	Drug_0
10000053	26	35	acitretin	drug	Drug_1
10000053	effect	Drug_1	Drug_0

10000054|t|Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
10000054	60	69	vitamin A	group	Drug_0
10000054	88	97	retinoids	group	Drug_1
10000054	103	112	acitretin	drug	Drug_2
10000054	advise	Drug_1	Drug_2
10000054	advise	Drug_0	Drug_2

10000055|t|Other: There appears to be no pharmacokinetic interaction between acitretin and cimetidine, digoxin, or glyburide.
10000055	66	75	acitretin	drug	Drug_0
10000055	80	90	cimetidine	drug	Drug_1
10000055	92	99	digoxin	drug	Drug_2
10000055	104	113	glyburide	drug	Drug_3

10000056|t|Investigations into the effect of acitretin on the protein binding of anticoagulants of the coumarin type (warfarin) revealed no interaction.
10000056	34	43	acitretin	drug	Drug_0
10000056	70	105	anticoagulants of the coumarin type	group	Drug_1
10000056	107	115	warfarin	drug	Drug_2

10000057|t|Methotrexate: HUMIRA has been studied in rheumatoid arthritis patients taking concomitant MTX.
10000057	0	12	Methotrexate	drug	Drug_0
10000057	14	20	HUMIRA	brand	Drug_1
10000057	90	93	MTX	drug	Drug_2

10000058|t|The data do not suggest the need for dose adjustment of either HUMIRA or MTX.
10000058	63	69	HUMIRA	brand	Drug_0
10000058	73	76	MTX	drug	Drug_1

10000059|t|Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
10000059	39	47	anakinra	drug	Drug_0
10000059	52	76	interleukin-1 antagonist	group	Drug_1
10000059	90	108	TNF-blocking agent	group	Drug_2
10000059	effect	Drug_1	Drug_2
10000059	effect	Drug_0	Drug_2

10000060|t|The safety and efficacy of anakinra used in combination with HUMIRA has not been studied.
10000060	27	35	anakinra	drug	Drug_0
10000060	61	67	HUMIRA	brand	Drug_1

10000061|t|Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.
10000061	30	38	anakinra	drug	Drug_0
10000061	50	69	TNF-blocking agents	group	Drug_1
10000061	81	87	HUMIRA	brand	Drug_2
10000061	effect	Drug_0	Drug_2
10000061	effect	Drug_0	Drug_1

10000062|t|Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with DIFFERIN Gel.
10000062	72	78	sulfur	drug	Drug_0
10000062	80	90	resorcinol	drug	Drug_1
10000062	95	109	salicylic acid	drug	Drug_2
10000062	130	138	DIFFERIN	brand	Drug_3

10000063|t|Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.
10000063	138	153	aminoglycosides	group	Drug_0
10000063	161	171	gentamicin	drug	Drug_1
10000063	173	181	amikacin	drug	Drug_2
10000063	184	198	amphotericin B	drug	Drug_3
10000063	200	212	cyclosporine	drug	Drug_4
10000063	214	245	non-steroidal anti-inflammatory	group	Drug_5
10000063	259	268	ibuprofen	drug	Drug_6
10000063	271	281	tacrolimus	drug	Drug_7
10000063	283	293	vancomycin	drug	Drug_8

10000064|t|Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.
10000064	12	21	Adenocard	brand	Drug_0
10000064	23	32	adenosine	drug	Drug_1
10000064	121	130	quinidine	drug	Drug_2
10000064	132	163	beta-adrenergic blocking agents	group	Drug_3
10000064	165	196	calcium channel blocking agents	group	Drug_4
10000064	202	242	angiotensin converting enzyme inhibitors	group	Drug_5

10000065|t|Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.
10000065	0	7	Digoxin	drug	Drug_0
10000065	12	21	verapamil	drug	Drug_1
10000065	100	109	Adenocard	brand	Drug_2
10000065	effect	Drug_0	Drug_2
10000065	effect	Drug_1	Drug_2

10000066|t|The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.
10000066	11	20	Adenocard	brand	Drug_0
10000066	43	52	digitalis	group	Drug_1
10000066	effect	Drug_0	Drug_1

10000067|t|The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.
10000067	15	24	adenosine	drug	Drug_0
10000067	44	59	methylxanthines	group	Drug_1
10000067	68	76	caffeine	drug	Drug_2
10000067	81	93	theophylline	drug	Drug_3
10000067	effect	Drug_0	Drug_3
10000067	effect	Drug_0	Drug_2
10000067	effect	Drug_0	Drug_1

10000068|t|In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.
10000068	25	40	methylxanthines	group	Drug_0
10000068	87	96	adenosine	drug	Drug_1
10000068	advise	Drug_0	Drug_1
10000068	advise	Drug_0	Drug_1

10000069|t|Adenosine effects are potentiated by dipyridamole.
10000069	0	9	Adenosine	drug	Drug_0
10000069	37	49	dipyridamole	drug	Drug_1
10000069	effect	Drug_0	Drug_1

10000070|t|Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.
10000070	23	32	adenosine	drug	Drug_0
10000070	69	81	dipyridamole	drug	Drug_1
10000070	effect	Drug_0	Drug_1

10000071|t|As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.
10000071	25	34	adenosine	drug	Drug_0
10000071	148	161	carbamazepine	drug	Drug_1
10000071	effect	Drug_0	Drug_1

10000072|t|Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended.
10000072	23	40	antifungal agents	group	Drug_0
10000072	49	61	ketoconazole	drug	Drug_1
10000072	65	77	itraconazole	drug	Drug_2

10000073|t|Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).
10000073	0	10	Nafazodone	drug	Drug_0
10000073	12	23	fluvoxamine	drug	Drug_1
10000073	25	35	cimetidine	drug	Drug_2
10000073	46	51	Xanax	brand	Drug_3
10000073	advise	Drug_1	Drug_3
10000073	advise	Drug_0	Drug_3
10000073	advise	Drug_2	Drug_3

10000074|t|Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution).
10000074	0	10	Fluoxetine	drug	Drug_0
10000074	12	15	OCs	group	Drug_1
10000074	17	27	sertraline	drug	Drug_2
10000074	29	38	diltiazem	drug	Drug_3
10000074	40	61	macrolide antibiotics	group	Drug_4

10000075|t|Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.
10000075	107	120	dexamethasone	drug	Drug_0
10000075	53	74	albendazole sulfoxide	drug	Drug_1
10000075	158	169	albendazole	drug	Drug_2
10000075	mechanism	Drug_0	Drug_2

10000076|t|Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.
10000076	32	44	praziquantel	drug	Drug_0
10000076	128	149	albendazole sulfoxide	drug	Drug_1
10000076	245	256	albendazole	drug	Drug_2
10000076	mechanism	Drug_0	Drug_1

10000077|t|The pharmacokinetics of praziquantel were unchanged following coadministration with albendazole (400 mg).
10000077	24	36	praziquantel	drug	Drug_0
10000077	84	95	albendazole	drug	Drug_1

10000078|t|Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).
10000078	142	152	cimetidine	drug	Drug_0
10000078	12	33	Albendazole sulfoxide	drug	Drug_1
10000078	188	199	albendazole	drug	Drug_2
10000078	mechanism	Drug_1	Drug_0

10000079|t|Theophylline: The pharmacokinetics of theophylline (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of albendazole (400 mg) in 6 healthy subjects.
10000079	38	50	theophylline	drug	Drug_0
10000079	52	65	aminophylline	drug	Drug_1
10000079	148	159	albendazole	drug	Drug_2

10000080|t|Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, antiemetics, sedatives, tranquilizers).
10000080	76	94	psychotropic drugs	group	Drug_0
10000080	102	111	narcotics	group	Drug_1
10000080	113	123	analgesics	group	Drug_2
10000080	125	136	antiemetics	group	Drug_3
10000080	138	147	sedatives	group	Drug_4
10000080	149	162	tranquilizers	group	Drug_5

10000081|t|Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
10000081	65	80	aminoglycosides	group	Drug_0
10000081	82	94	indomethacin	drug	Drug_1
10000081	115	124	cytotoxic	group	Drug_2
10000081	159	170	doxorubicin	drug	Drug_3
10000081	194	206	methotrexate	drug	Drug_4
10000081	208	220	asparaginase	drug	Drug_5
10000081	235	244	PROLEUKIN	brand	Drug_6
10000081	effect	Drug_2	Drug_6
10000081	effect	Drug_5	Drug_6
10000081	effect	Drug_4	Drug_6
10000081	effect	Drug_0	Drug_6
10000081	effect	Drug_1	Drug_6
10000081	effect	Drug_3	Drug_6

10000082|t|The safety and efficacy of PROLEUKIN in combination with any antineoplastic agents have not been established.
10000082	27	36	PROLEUKIN	brand	Drug_0
10000082	61	82	antineoplastic agents	group	Drug_1

10000083|t|Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
10000083	121	130	PROLEUKIN	brand	Drug_0
10000083	135	156	antineoplastic agents	group	Drug_1
10000083	172	183	dacarbazine	drug	Drug_2
10000083	185	197	cis-platinum	drug	Drug_3
10000083	199	208	tamoxifen	drug	Drug_4
10000083	213	228	interferon-alfa	drug	Drug_5
10000083	effect	Drug_0	Drug_5
10000083	effect	Drug_0	Drug_2
10000083	effect	Drug_0	Drug_3
10000083	effect	Drug_0	Drug_1
10000083	effect	Drug_0	Drug_4

10000084|t|Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.
10000084	161	170	PROLEUKIN	brand	Drug_0
10000084	175	190	interferon-alfa	drug	Drug_1
10000084	effect	Drug_0	Drug_1

10000085|t|Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.
10000085	140	155	interferon-alfa	drug	Drug_0
10000085	160	169	PROLEUKIN	brand	Drug_1
10000085	effect	Drug_0	Drug_1

10000086|t|Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
10000086	9	24	glucocorticoids	group	Drug_0
10000086	388	397	PROLEUKIN	brand	Drug_1
10000086	305	318	Beta-blockers	group	Drug_2
10000086	329	346	antihypertensives	group	Drug_3
10000086	effect	Drug_3	Drug_1
10000086	effect	Drug_0	Drug_1
10000086	effect	Drug_2	Drug_1

10000087|t|Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.
10000087	29	53	Iodinated Contrast Media	group	Drug_0
10000087	154	167	interleukin-2	drug	Drug_1
10000087	223	260	radiographic iodinated contrast media	group	Drug_2
10000087	effect	Drug_1	Drug_2

10000088|t|The duration of the period following treatment with AMEVIVE  before one should consider starting other immunosuppressive therapy has not been evaluated.
10000088	52	59	AMEVIVE	brand	Drug_0
10000088	103	120	immunosuppressive	group	Drug_1

10000089|t|An immune response to Campath may interfere with subsequent diagnostic serum tests that utilize antibodies
10000089	22	29	Campath	brand	Drug_0
10000089	96	106	antibodies	group	Drug_1

10000090|t|Intravenous ranitidine was shown to double the bioavailability of oral alendronate.
10000090	12	22	ranitidine	drug	Drug_0
10000090	71	82	alendronate	drug	Drug_1
10000090	mechanism	Drug_0	Drug_1

10000091|t|Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.
10000091	20	27	calcium	drug	Drug_0
10000091	38	57	multivalent cations	drug	Drug_1
10000091	99	110	alendronate	drug	Drug_2
10000091	mechanism	Drug_1	Drug_2
10000091	mechanism	Drug_0	Drug_2

10000092|t|Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
10000092	106	113	ALFENTA	brand	Drug_0
10000092	156	171	CNS depressants	group	Drug_1
10000092	180	192	barbiturates	group	Drug_2
10000092	194	207	tranquilizers	group	Drug_3
10000092	209	216	opioids	group	Drug_4
10000092	240	251	anesthetics	group	Drug_5
10000092	effect	Drug_0	Drug_2
10000092	effect	Drug_0	Drug_4
10000092	effect	Drug_0	Drug_3
10000092	effect	Drug_0	Drug_5
10000092	effect	Drug_0	Drug_1

10000093|t|Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
10000093	60	91	volatile inhalation anesthetics	group	Drug_0
10000093	253	260	ALFENTA	brand	Drug_1
10000093	201	213	erythromycin	drug	Drug_2
10000093	mechanism	Drug_2	Drug_1
10000093	mechanism	Drug_0	Drug_1

10000094|t|Cimetidine reduces the clearance of ALFENTA.
10000094	0	10	Cimetidine	drug	Drug_0
10000094	36	43	ALFENTA	brand	Drug_1
10000094	mechanism	Drug_0	Drug_1

10000095|t|Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between UROXATRAL and other alpha-blockers have not been determined.
10000095	85	94	UROXATRAL	brand	Drug_0
10000095	105	119	alpha-blockers	group	Drug_1

10000096|t|However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.
10000096	43	52	UROXATRAL	brand	Drug_0
10000096	98	112	alpha-blockers	group	Drug_1
10000096	advise	Drug_0	Drug_1

10000097|t|Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
10000097	21	31	lovastatin	drug	Drug_0
10000097	33	41	atenolol	drug	Drug_1
10000097	43	51	warfarin	drug	Drug_2
10000097	53	63	furosemide	drug	Drug_3
10000097	65	72	digoxin	drug	Drug_4
10000097	74	83	celecoxib	drug	Drug_5
10000097	85	104	hydrochlorothiazide	drug	Drug_6
10000097	106	114	ramipril	drug	Drug_7
10000097	116	125	valsartan	drug	Drug_8
10000097	127	136	metformin	drug	Drug_9
10000097	141	151	amlodipine	drug	Drug_10
10000097	206	215	aliskiren	drug	Drug_11

10000098|t|Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.
10000098	21	31	irbesartan	drug	Drug_0
10000098	40	49	aliskiren	drug	Drug_1
10000098	mechanism	Drug_0	Drug_1

10000099|t|Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.
10000099	21	33	atorvastatin	drug	Drug_0
10000099	70	79	aliskiren	drug	Drug_1
10000099	mechanism	Drug_0	Drug_1

10000100|t|Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.
10000100	54	66	ketoconazole	drug	Drug_0
10000100	142	151	aliskiren	drug	Drug_1
10000100	mechanism	Drug_0	Drug_1

10000101|t|Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
10000101	21	30	aliskiren	drug	Drug_0
10000101	84	94	lovastatin	drug	Drug_1
10000101	96	103	digoxin	drug	Drug_2
10000101	105	114	valsartan	drug	Drug_3
10000101	116	126	amlodipine	drug	Drug_4
10000101	128	137	metformin	drug	Drug_5
10000101	139	148	celecoxib	drug	Drug_6
10000101	150	158	atenolol	drug	Drug_7
10000101	160	172	atorvastatin	drug	Drug_8
10000101	174	182	ramipril	drug	Drug_9
10000101	186	205	hydrochlorothiazide	drug	Drug_10

10000102|t|Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated in a well-controlled clinical trial.
10000102	38	46	warfarin	drug	Drug_0
10000102	25	34	aliskiren	drug	Drug_1

10000103|t|Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.
10000103	84	94	furosemide	drug	Drug_0
10000103	17	26	aliskiren	drug	Drug_1
10000103	mechanism	Drug_1	Drug_0

10000104|t|Patients who are applying Panretin gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products.
10000104	26	34	Panretin	brand	Drug_0
10000104	89	93	DEET	drug	Drug_1
10000104	98	119	N-diethyl-m-toluamide	drug	Drug_2
10000104	advise	Drug_0	Drug_2
10000104	advise	Drug_0	Drug_1

10000105|t|Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral agents, including protease inhibitors, macrolide antibiotics, and azole antifungals, the effect of Panretin gel on the steady-state concentrations of these drugs is not known.
10000105	109	130	antiretroviral agents	group	Drug_0
10000105	142	161	protease inhibitors	group	Drug_1
10000105	163	184	macrolide antibiotics	group	Drug_2
10000105	190	207	azole antifungals	group	Drug_3
10000105	223	231	Panretin	brand	Drug_4

10000106|t|Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.
10000106	77	91	mercaptopurine	drug	Drug_0
10000106	96	108	azathioprine	drug	Drug_1
10000106	29	40	Allopurinol	drug	Drug_2
10000106	112	127	6-thiouric acid	drug	Drug_3
10000106	mechanism	Drug_2	Drug_0
10000106	mechanism	Drug_2	Drug_1

10000107|t|In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
10000107	239	253	mercaptopurine	drug	Drug_0
10000107	38	48	Purinethol	brand	Drug_1
10000107	257	269	azathioprine	drug	Drug_2
10000107	67	73	Imuran	brand	Drug_3
10000107	124	135	allopurinol	drug	Drug_4
10000107	advise	Drug_4	Drug_0
10000107	advise	Drug_4	Drug_2

10000108|t|Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects.
10000108	34	48	mercaptopurine	drug	Drug_0
10000108	52	64	azathioprine	drug	Drug_1

10000109|t|Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.
10000109	94	103	dicumarol	drug	Drug_0
10000109	37	48	allopurinol	drug	Drug_1
10000109	79	92	anticoagulant	group	Drug_2
10000109	mechanism	Drug_1	Drug_0

10000110|t|The clinical basis of this drug interaction has not been established but should be noted when allopurinol is given to patients already on dicumarol therapy.
10000110	94	105	allopurinol	drug	Drug_0
10000110	138	147	dicumarol	drug	Drug_1

10000111|t|Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.
10000111	82	99	uricosuric agents	group	Drug_0
10000111	185	195	oxipurinol	drug	Drug_1
10000111	mechanism	Drug_0	Drug_1

10000112|t|The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.
10000112	34	51	uricosuric agents	group	Drug_0
10000112	243	254	allopurinol	drug	Drug_1
10000112	mechanism	Drug_0	Drug_1

10000113|t|Although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on allopurinol alone or in combination with uricosuric agents, the possibility should be kept in mind.
10000113	112	123	allopurinol	drug	Drug_0
10000113	153	170	uricosuric agents	group	Drug_1

10000114|t|Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
10000114	76	94	thiazide diuretics	group	Drug_0
10000114	132	143	allopurinol	drug	Drug_1
10000114	effect	Drug_1	Drug_0

10000115|t|Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..
10000115	172	190	thiazide diuretics	group	Drug_0
10000115	195	206	allopurinol	drug	Drug_1
10000115	advise	Drug_0	Drug_1

10000116|t|Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
10000116	109	119	ampicillin	drug	Drug_0
10000116	123	134	amoxicillin	drug	Drug_1
10000116	153	164	allopurinol	drug	Drug_2
10000116	effect	Drug_1	Drug_2
10000116	effect	Drug_0	Drug_2

10000117|t|Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.
10000117	81	97	cytotoxic agents	group	Drug_0
10000117	54	70	cyclophosphamide	drug	Drug_1
10000117	192	203	allopurinol	drug	Drug_2
10000117	effect	Drug_0	Drug_2
10000117	effect	Drug_1	Drug_2

10000118|t|However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine and/or mechlorethamine.
10000118	86	97	allopurinol	drug	Drug_0
10000118	160	176	cyclophosphamide	drug	Drug_1
10000118	178	189	doxorubicin	drug	Drug_2
10000118	191	200	bleomycin	drug	Drug_3
10000118	202	214	procarbazine	drug	Drug_4
10000118	222	237	mechlorethamine	drug	Drug_5

10000119|t|Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.
10000119	104	118	chlorpropamide	drug	Drug_0
10000119	88	99	allopurinol	drug	Drug_1
10000119	mechanism	Drug_0	Drug_1
10000119	mechanism	Drug_1	Drug_0

10000120|t|The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.
10000120	73	84	allopurinol	drug	Drug_0
10000120	89	103	chlorpropamide	drug	Drug_1
10000120	effect	Drug_0	Drug_1

10000121|t|Cyclosporin: Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.
10000121	0	11	Cyclosporin	drug	Drug_0
10000121	35	47	cyclosporine	drug	Drug_1
10000121	106	124	allopurinol sodium	drug	Drug_2
10000121	mechanism	Drug_1	Drug_2

10000122|t|Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.
10000122	80	90	ergotamine	drug	Drug_0
10000122	105	127	ergot-type medications	group	Drug_1
10000122	134	151	dihydroergotamine	drug	Drug_2
10000122	155	167	methysergide	drug	Drug_3
10000122	173	178	AXERT	brand	Drug_4
10000122	advise	Drug_3	Drug_4
10000122	advise	Drug_2	Drug_4
10000122	advise	Drug_0	Drug_4
10000122	advise	Drug_1	Drug_4

10000123|t|Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.
10000123	0	28	Monoamine Oxidase Inhibitors	group	Drug_0
10000123	50	61	moclobemide	drug	Drug_1
10000123	92	103	almotriptan	drug	Drug_2
10000123	mechanism	Drug_1	Drug_2

10000124|t|Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.
10000124	50	68	5-HT1B/1D agonists	group	Drug_0
10000124	103	108	AXERT	brand	Drug_1
10000124	advise	Drug_0	Drug_1

10000125|t|Propanolol: The pharmacokinetics of almotriptan were not affected by coadministration of propranolol.
10000125	0	10	Propanolol	drug	Drug_0
10000125	36	47	almotriptan	drug	Drug_1
10000125	89	100	propranolol	drug	Drug_2

10000126|t|Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
10000126	0	39	Selective Serotonin Reuptake Inhibitors	group	Drug_0
10000126	49	54	SSRIs	group	Drug_1
10000126	62	72	fluoxetine	drug	Drug_2
10000126	74	85	fluvoxamine	drug	Drug_3
10000126	87	97	paroxetine	drug	Drug_4
10000126	99	109	sertraline	drug	Drug_5
10000126	215	229	5-HT1 agonists	group	Drug_6
10000126	effect	Drug_2	Drug_6
10000126	effect	Drug_3	Drug_6
10000126	effect	Drug_4	Drug_6
10000126	effect	Drug_1	Drug_6
10000126	effect	Drug_5	Drug_6

10000127|t|If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised.
10000127	30	35	AXERT	brand	Drug_0
10000127	43	47	SSRI	group	Drug_1
10000127	advise	Drug_0	Drug_1

10000128|t|Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.
10000128	47	56	verapamil	drug	Drug_0
10000128	112	123	almotriptan	drug	Drug_1
10000128	mechanism	Drug_1	Drug_0

10000129|t|Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.
10000129	235	246	almotriptan	drug	Drug_0
10000129	64	76	ketoconazole	drug	Drug_1
10000129	mechanism	Drug_0	Drug_1

10000130|t|Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
10000130	208	219	almotriptan	drug	Drug_0
10000130	87	99	itraconazole	drug	Drug_1
10000130	101	110	ritonavir	drug	Drug_2
10000130	116	128	erythromycin	drug	Drug_3
10000130	advise	Drug_3	Drug_0
10000130	advise	Drug_1	Drug_0
10000130	advise	Drug_2	Drug_0

10000131|t|In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 to 200 mg per day for 16 days, with coadministration of alosetron 1 mg on the last day.
10000131	64	75	fluvoxamine	drug	Drug_0
10000131	160	169	alosetron	drug	Drug_1

10000132|t|Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.
10000132	0	11	Fluvoxamine	drug	Drug_0
10000132	27	36	alosetron	drug	Drug_1
10000132	mechanism	Drug_0	Drug_1

10000133|t|Concomitant administration of alosetron and fluvoxamine is contraindicated.
10000133	30	39	alosetron	drug	Drug_0
10000133	44	55	fluvoxamine	drug	Drug_1
10000133	advise	Drug_0	Drug_1

10000134|t|Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
10000134	30	39	alosetron	drug	Drug_0
10000134	82	103	quinolone antibiotics	group	Drug_1
10000134	108	118	cimetidine	drug	Drug_2
10000134	advise	Drug_0	Drug_2
10000134	advise	Drug_0	Drug_1

10000135|t|In a pharmacokinetic study, 38 healthy female subjects received ketoconazole 200 mg twice daily for 7 days, with coadministration of alosetron 1 mg on the last day.
10000135	64	76	ketoconazole	drug	Drug_0
10000135	133	142	alosetron	drug	Drug_1

10000136|t|Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.
10000136	0	12	Ketoconazole	drug	Drug_0
10000136	28	37	alosetron	drug	Drug_1
10000136	mechanism	Drug_0	Drug_1

10000137|t|Caution should be used when alosetron and ketoconazole are administered concomitantly.
10000137	28	37	alosetron	drug	Drug_0
10000137	42	54	ketoconazole	drug	Drug_1
10000137	advise	Drug_0	Drug_1

10000138|t|Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
10000138	20	29	alosetron	drug	Drug_0
10000138	68	82	clarithromycin	drug	Drug_1
10000138	84	97	telithromycin	drug	Drug_2
10000138	99	118	protease inhibitors	group	Drug_3
10000138	120	132	voriconazole	drug	Drug_4
10000138	138	150	itraconazole	drug	Drug_5
10000138	advise	Drug_0	Drug_3
10000138	advise	Drug_0	Drug_4
10000138	advise	Drug_0	Drug_2
10000138	advise	Drug_0	Drug_1
10000138	advise	Drug_0	Drug_5

10000139|t|Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.
10000139	26	35	alosetron	drug	Drug_0
10000139	131	140	isoniazid	drug	Drug_1
10000139	142	154	procainamide	drug	Drug_2
10000139	160	171	hydralazine	drug	Drug_3
10000139	effect	Drug_0	Drug_3
10000139	effect	Drug_0	Drug_1
10000139	effect	Drug_0	Drug_2

10000140|t|Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates).
10000140	26	35	alosetron	drug	Drug_0
10000140	110	130	contraceptive agents	group	Drug_1
10000140	131	148	ethinyl estradiol	drug	Drug_2
10000140	153	167	levonorgestrel	drug	Drug_3

10000141|t|A clinical interaction study was also conducted with alosetron and the CYP3A4 substrate cisapride.
10000141	53	62	alosetron	drug	Drug_0
10000141	88	97	cisapride	drug	Drug_1

10000142|t|The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
10000142	4	19	benzodiazepines	group	Drug_0
10000142	31	41	alprazolam	drug	Drug_1
10000142	115	139	psychotropic medications	group	Drug_2
10000142	141	156	anticonvulsants	group	Drug_3
10000142	158	173	antihistaminics	group	Drug_4
10000142	175	182	ethanol	drug	Drug_5
10000142	effect	Drug_0	Drug_5
10000142	effect	Drug_1	Drug_5
10000142	effect	Drug_1	Drug_4
10000142	effect	Drug_1	Drug_2
10000142	effect	Drug_0	Drug_3
10000142	effect	Drug_1	Drug_3
10000142	effect	Drug_0	Drug_4
10000142	effect	Drug_0	Drug_2

10000143|t|The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.
10000143	42	52	imipramine	drug	Drug_0
10000143	57	68	desipramine	drug	Drug_1
10000143	182	192	alprazolam	drug	Drug_2
10000143	mechanism	Drug_1	Drug_2
10000143	mechanism	Drug_0	Drug_2

10000144|t|Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
10000144	290	300	alprazolam	drug	Drug_0
10000144	217	227	fluoxetine	drug	Drug_1
10000144	mechanism	Drug_1	Drug_0

10000145|t|Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.
10000145	20	32	propoxyphene	drug	Drug_0
10000145	79	89	alprazolam	drug	Drug_1
10000145	mechanism	Drug_0	Drug_1

10000146|t|Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18%, decreased clearance by 22%, and increased half-life by 29%.
10000146	25	39	contraceptives	group	Drug_0
10000146	86	96	alprazolam	drug	Drug_1
10000146	mechanism	Drug_0	Drug_1

10000147|t|Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
10000147	342	357	benzodiazepines	group	Drug_0
10000147	421	431	alprazolam	drug	Drug_1
10000147	451	460	diltiazem	drug	Drug_2
10000147	462	471	isoniazid	drug	Drug_3
10000147	473	494	macrolide antibiotics	group	Drug_4
10000147	503	515	erythromycin	drug	Drug_5
10000147	520	534	clarithromycin	drug	Drug_6
10000147	int	Drug_1	Drug_4
10000147	int	Drug_1	Drug_3
10000147	int	Drug_1	Drug_5
10000147	int	Drug_1	Drug_2
10000147	int	Drug_1	Drug_6

10000148|t|Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.
10000148	82	92	alprazolam	drug	Drug_0
10000148	112	122	sertraline	drug	Drug_1
10000148	127	137	paroxetine	drug	Drug_2
10000148	int	Drug_0	Drug_2
10000148	int	Drug_0	Drug_1

10000149|t|Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
10000149	30	45	benzodiazepines	group	Drug_0
10000149	57	67	alprazolam	drug	Drug_1
10000149	123	133	ergotamine	drug	Drug_2
10000149	135	147	cyclosporine	drug	Drug_3
10000149	149	159	amiodarone	drug	Drug_4
10000149	161	172	nicardipine	drug	Drug_5
10000149	178	188	nifedipine	drug	Drug_6
10000149	int	Drug_1	Drug_6
10000149	int	Drug_0	Drug_3
10000149	int	Drug_1	Drug_3
10000149	int	Drug_1	Drug_5
10000149	int	Drug_0	Drug_4
10000149	int	Drug_0	Drug_2
10000149	int	Drug_0	Drug_5
10000149	int	Drug_0	Drug_6
10000149	int	Drug_1	Drug_4
10000149	int	Drug_1	Drug_2

10000150|t|Standard therapy includes antibiotics, such as penicillin and gentamicin;
10000150	26	37	antibiotics	group	Drug_0
10000150	47	57	penicillin	drug	Drug_1
10000150	62	72	gentamicin	drug	Drug_2

10000151|t|vasopressors, such as dopamine and isoproterenol;
10000151	0	12	vasopressors	group	Drug_0
10000151	22	30	dopamine	drug	Drug_1
10000151	35	48	isoproterenol	drug	Drug_2

10000152|t|and diuretics, such as furosemide.
10000152	4	13	diuretics	group	Drug_0
10000152	23	33	furosemide	drug	Drug_1

10000153|t|Caverject: The potential for pharmacokinetic drug-drug interactions between alprostadil and other agents has not been formally studied.
10000153	0	9	Caverject	brand	Drug_0
10000153	76	87	alprostadil	drug	Drug_1

10000154|t|In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
10000154	40	47	heparin	drug	Drug_0
10000154	52	73	vitamin K antagonists	group	Drug_1
10000154	119	139	acetylsalicylic acid	drug	Drug_2
10000154	141	153	dipyridamole	drug	Drug_3
10000154	158	167	Abciximab	drug	Drug_4
10000154	246	254	Activase	brand	Drug_5
10000154	effect	Drug_1	Drug_5
10000154	effect	Drug_4	Drug_5
10000154	effect	Drug_0	Drug_5
10000154	int	Drug_2	Drug_5
10000154	effect	Drug_3	Drug_5

10000155|t|Use of Antithrombotics Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.
10000155	7	22	Antithrombotics	group	Drug_0
10000155	23	30	Aspirin	brand	Drug_1
10000155	35	42	heparin	drug	Drug_2
10000155	112	120	Activase	brand	Drug_3

10000156|t|Because heparin, aspirin, or Activase may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.
10000156	8	15	heparin	drug	Drug_0
10000156	17	24	aspirin	brand	Drug_1
10000156	29	37	Activase	brand	Drug_2

10000157|t|The concomitant use of heparin or aspirin during the first 24 hours following symptom onset were prohibited in The NINDS t-PA Stroke Trial.
10000157	23	30	heparin	drug	Drug_0
10000157	34	41	aspirin	brand	Drug_1

10000158|t|Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.
10000158	29	36	HEXALEN	brand	Drug_0
10000158	41	83	antidepressants of the MAO inhibitor class	group	Drug_1
10000158	125	135	Cimetidine	drug	Drug_2
10000158	191	202	altretamine	drug	Drug_3
10000158	effect	Drug_0	Drug_1
10000158	mechanism	Drug_2	Drug_3

10000159|t|Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;
10000159	32	39	HEXALEN	brand	Drug_0
10000159	44	53	cisplatin	drug	Drug_1
10000159	112	122	pyridoxine	drug	Drug_2
10000159	effect	Drug_0	Drug_1

10000160|t|however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1
10000160	65	75	pyridoxine	drug	Drug_0
10000160	108	115	HEXALEN	brand	Drug_1
10000160	123	132	cisplatin	drug	Drug_2
10000160	advise	Drug_0	Drug_2
10000160	advise	Drug_0	Drug_1

10000161|t|Careful observation is required when amantadine is administered concurrently with central nervous system stimulants.
10000161	37	47	amantadine	drug	Drug_0
10000161	82	115	central nervous system stimulants	group	Drug_1
10000161	advise	Drug_0	Drug_1

10000162|t|Special consideration should be given to the administration of ETHYOL in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.
10000162	63	69	ETHYOL	brand	Drug_0
10000162	92	120	antihypertensive medications	group	Drug_1
10000162	advise	Drug_0	Drug_1

10000163|t|When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, the risk of hyperkalemia may be increased.
10000163	5	14	amiloride	drug	Drug_0
10000163	57	96	angiotensin-converting enzyme inhibitor	group	Drug_1
10000163	effect	Drug_0	Drug_1

10000164|t|Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.
10000164	0	7	Lithium	drug	Drug_0
10000164	43	52	diuretics	group	Drug_1
10000164	advise	Drug_0	Drug_1

10000165|t|In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
10000165	42	79	non-steroidal anti-inflammatory agent	group	Drug_0
10000165	150	196	loop diuretics	group	Drug_1
10000165	156	196	potassium-sparing diuretics	group	Drug_2
10000165	178	196	thiazide diuretics	group	Drug_3
10000165	effect	Drug_0	Drug_3
10000165	effect	Drug_0	Drug_1
10000165	effect	Drug_0	Drug_2

10000166|t|Therefore, when MIDAMOR and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
10000166	16	23	MIDAMOR	brand	Drug_0
10000166	28	66	non-steroidal anti-inflammatory agents	group	Drug_1
10000166	172	180	diuretic	group	Drug_2
10000166	advise	Drug_0	Drug_1

10000167|t|Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.
10000167	6	18	indomethacin	drug	Drug_0
10000167	23	50	potassium-sparing diuretics	group	Drug_1
10000167	62	69	MIDAMOR	brand	Drug_2
10000167	effect	Drug_0	Drug_1
10000167	effect	Drug_0	Drug_2

10000168|t|Cytadren accelerates the metabolism of dexamethasone;
10000168	0	8	Cytadren	brand	Drug_0
10000168	39	52	dexamethasone	drug	Drug_1
10000168	mechanism	Drug_0	Drug_1

10000169|t|therefore, if glucocorticoid replacement is needed, hydrocortisone should be prescribed.
10000169	14	28	glucocorticoid	group	Drug_0
10000169	52	66	hydrocortisone	drug	Drug_1

10000170|t|Aminoglutethimide diminishes the effect of coumarin and warfarin.
10000170	0	17	Aminoglutethimide	drug	Drug_0
10000170	43	51	coumarin	group	Drug_1
10000170	56	64	warfarin	drug	Drug_2
10000170	effect	Drug_0	Drug_2
10000170	effect	Drug_0	Drug_1

10000171|t|Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.
10000171	32	35	PAH	drug	Drug_0
10000171	103	115	sulfonamides	group	Drug_1
10000171	117	125	procaine	drug	Drug_2
10000171	130	145	thiazolesulfone	drug	Drug_3
10000171	effect	Drug_0	Drug_2
10000171	effect	Drug_0	Drug_3
10000171	effect	Drug_0	Drug_1

10000172|t|Probenecid depresses tubular secretion of certain weak acids such as PAH.
10000172	0	10	Probenecid	drug	Drug_0
10000172	69	72	PAH	drug	Drug_1
10000172	mechanism	Drug_0	Drug_1

10000173|t|Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.
10000173	30	40	probenecid	drug	Drug_0
10000173	79	82	PAH	drug	Drug_1
10000173	effect	Drug_0	Drug_1

10000174|t|It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
10000174	61	84	photosensitizing agents	group	Drug_0
10000174	93	105	griseofulvin	drug	Drug_1
10000174	107	125	thiazide diuretics	group	Drug_2
10000174	127	140	sulfonylureas	group	Drug_3
10000174	142	156	phenothiazines	group	Drug_4
10000174	158	170	sulfonamides	group	Drug_5
10000174	175	188	tetracyclines	group	Drug_6
10000174	272	289	LEVULAN KERASTICK	brand	Drug_7
10000174	effect	Drug_0	Drug_7
10000174	effect	Drug_3	Drug_7
10000174	effect	Drug_1	Drug_7
10000174	effect	Drug_5	Drug_7
10000174	effect	Drug_6	Drug_7
10000174	effect	Drug_4	Drug_7
10000174	effect	Drug_2	Drug_7

10000175|t|Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.
10000175	0	19	Aminosalicylic acid	drug	Drug_0
10000175	47	54	digoxin	drug	Drug_1
10000175	56	63	Lanoxin	brand	Drug_2
10000175	65	75	Lanoxicaps	drug	Drug_3
10000175	mechanism	Drug_0	Drug_2
10000175	mechanism	Drug_0	Drug_1

10000176|t|In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.
10000176	90	97	digoxin	drug	Drug_0
10000176	53	72	aminosalicylic acid	drug	Drug_1
10000176	advise	Drug_0	Drug_1

10000177|t|Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.
10000177	0	19	Aminosalicylic acid	drug	Drug_0
10000177	56	67	vitamin B12	drug	Drug_1
10000177	mechanism	Drug_0	Drug_1

10000178|t|Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.
10000178	33	44	vitamin B12	drug	Drug_0
10000178	69	88	aminosalicylic acid	drug	Drug_1
10000178	advise	Drug_0	Drug_1

10000179|t|Amiodarone is metabolized to desethylamiodarone by the cytochrome P450 (CYP450) enzyme group, specifically cytochromes P450 3A4 (CYP3A4) and CYP2C8.
10000179	0	10	Amiodarone	drug	Drug_0
10000179	29	47	desethylamiodarone	drug	Drug_1

10000180|t|A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.
10000180	118	128	amiodarone	drug	Drug_0
10000180	58	67	indinavir	drug	Drug_1
10000180	mechanism	Drug_0	Drug_1

10000181|t|Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.
10000181	61	71	amiodarone	drug	Drug_0
10000181	111	129	protease inhibitor	group	Drug_1
10000181	advise	Drug_0	Drug_1

10000182|t|Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.
10000182	0	24	Histamine H2 antagonists	group	Drug_0
10000182	26	36	Cimetidine	drug	Drug_1
10000182	76	86	amiodarone	drug	Drug_2
10000182	mechanism	Drug_0	Drug_1

10000183|t|Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4.
10000183	0	10	Amiodarone	drug	Drug_0
10000183	58	64	CYP1A2	drug	Drug_1
10000183	66	72	CYP2C9	drug	Drug_2
10000183	74	80	CYP2D6	drug	Drug_3
10000183	86	92	CYP3A4	drug	Drug_4

10000184|t|Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.
10000184	61	78	Immunosuppressive	drug	Drug_0
10000184	314	326	cyclosporine	drug	Drug_1
10000184	95	101	CYP3A4	drug	Drug_2
10000184	151	161	amiodarone	drug	Drug_3

10000185|t|HMG-CoA Reductase Inhibitors: Simvastatin (CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.
10000185	0	28	HMG-CoA Reductase Inhibitors	drug	Drug_0
10000185	30	41	Simvastatin	drug	Drug_1
10000185	43	49	CYP3A4	drug	Drug_2
10000185	81	91	amiodarone	drug	Drug_3

10000186|t|Cardiovasculars: Cardiac glycosides: In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.
10000186	17	35	Cardiac glycosides	drug	Drug_0
10000186	152	159	digoxin	drug	Drug_1
10000186	99	109	amiodarone	drug	Drug_2

10000187|t|Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day.
10000187	0	10	Amiodarone	drug	Drug_0
10000187	64	71	digoxin	drug	Drug_1

10000188|t|On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.
10000188	26	36	amiodarone	drug	Drug_0
10000188	51	60	digitalis	group	Drug_1
10000188	advise	Drug_0	Drug_1

10000189|t|Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.
10000189	0	15	Antiarrhythmics	drug	Drug_0
10000189	23	37	antiarrhythmic	drug	Drug_1
10000189	53	62	quinidine	drug	Drug_2
10000189	64	76	procainamide	drug	Drug_3
10000189	78	90	disopyramide	drug	Drug_4
10000189	96	105	phenytoin	drug	Drug_5
10000189	140	150	amiodarone	drug	Drug_6

10000190|t|There have been case reports of increased steady-state levels of quinidine, procainamide, and phenytoin during concomitant therapy with amiodarone.
10000190	65	74	quinidine	drug	Drug_0
10000190	76	88	procainamide	drug	Drug_1
10000190	94	103	phenytoin	drug	Drug_2
10000190	136	146	amiodarone	drug	Drug_3

10000191|t|Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days.
10000191	0	10	Amiodarone	drug	Drug_0
10000191	56	65	quinidine	drug	Drug_1

10000192|t|Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.
10000192	0	10	Amiodarone	drug	Drug_0
10000192	135	147	procainamide	drug	Drug_1

10000193|t|Quinidine and procainamide doses should be reduced by one-third when either is administered with amiodarone.
10000193	0	9	Quinidine	drug	Drug_0
10000193	97	107	amiodarone	drug	Drug_1

10000194|t|Plasma levels of flecainide have been reported to increase in the presence of oral amiodarone;
10000194	17	27	flecainide	drug	Drug_0
10000194	83	93	amiodarone	drug	Drug_1

10000195|t|because of this, the dosage of flecainide should be adjusted when these drugs are administered concomitantly.
10000195	31	41	flecainide	drug	Drug_0
10000195	72	77	drugs	drug	Drug_1

10000196|t|Combination of amiodarone with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.
10000196	218	228	amiodarone	drug	Drug_0
10000196	37	51	antiarrhythmic	drug	Drug_1

10000197|t|The continued need for the other antiarrhythmic agent should be reviewed after the effects of amiodarone have been established, and discontinuation ordinarily should be attempted.
10000197	33	47	antiarrhythmic	drug	Drug_0
10000197	94	104	amiodarone	drug	Drug_1

10000198|t|In amiodarone-treated patients who require additional antiarrhythmic therapy, the initial dose of such agents should be approximately half of the usual recommended dose.
10000198	3	13	amiodarone	drug	Drug_0
10000198	54	68	antiarrhythmic	drug	Drug_1

10000199|t|Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
10000199	0	17	Antihypertensives	drug	Drug_0
10000199	19	29	Amiodarone	drug	Drug_1
10000199	82	90	receptor	drug	Drug_2
10000199	114	125	propranolol	drug	Drug_3
10000199	233	239	CYP3A4	drug	Drug_4
10000199	150	165	calcium channel	drug	Drug_5
10000199	185	194	verapamil	drug	Drug_6
10000199	220	229	diltiazem	drug	Drug_7

10000200|t|Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
10000200	0	14	Anticoagulants	drug	Drug_0
10000200	32	40	warfarin	drug	Drug_1
10000200	47	53	CYP2C9	drug	Drug_2
10000200	58	64	CYP3A4	drug	Drug_3
10000200	76	89	anticoagulant	drug	Drug_4
10000200	143	153	amiodarone	drug	Drug_5

10000201|t|Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.
10000201	40	48	warfarin	drug	Drug_0
10000201	54	64	amiodarone	drug	Drug_1
10000201	139	152	anticoagulant	drug	Drug_2

10000202|t|Some drugs/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A4 (enzyme induction).
10000202	5	10	drugs	drug	Drug_0
10000202	64	74	amiodarone	drug	Drug_1
10000202	107	113	CYP3A4	drug	Drug_2

10000203|t|Reported examples of this interaction include the following: Antibiotics: Rifampin is a potent inducer of CYP3A4.
10000203	61	72	Antibiotics	drug	Drug_0
10000203	74	82	Rifampin	drug	Drug_1
10000203	106	112	CYP3A4	drug	Drug_2

10000204|t|Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.
10000204	18	26	rifampin	drug	Drug_0
10000204	127	137	amiodarone	drug	Drug_1
10000204	142	160	desethylamiodarone	drug	Drug_2

10000205|t|Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels.
10000205	156	166	amiodarone	drug	Drug_0
10000205	36	42	CYP3A4	drug	Drug_1

10000206|t|Other reported interactions with amiodarone: Fentanyl (CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.
10000206	93	103	amiodarone	drug	Drug_0
10000206	45	53	Fentanyl	drug	Drug_1
10000206	55	61	CYP3A4	drug	Drug_2

10000207|t|Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine (CYP3A4 substrate) given for local anesthesia.
10000207	46	56	amiodarone	drug	Drug_0
10000207	77	86	lidocaine	drug	Drug_1
10000207	88	94	CYP3A4	drug	Drug_2
10000207	122	132	anesthesia	drug	Drug_3

10000208|t|Seizure, associated with increased lidocaine concentrations, has been reported with concomitant administration of intravenous amiodarone.
10000208	35	44	lidocaine	drug	Drug_0
10000208	126	136	amiodarone	drug	Drug_1

10000209|t|Dextromethorphan is a substrate for both CYP2D6 and CYP3A4.
10000209	0	16	Dextromethorphan	drug	Drug_0
10000209	41	47	CYP2D6	drug	Drug_1
10000209	52	58	CYP3A4	drug	Drug_2

10000210|t|Amiodarone inhibits CYP2D6.
10000210	0	10	Amiodarone	drug	Drug_0
10000210	20	26	CYP2D6	drug	Drug_1

10000211|t|Cholestyramine increases enterohepatic elimination of amiodarone and may reduce its serum levels and t1/2.
10000211	0	14	Cholestyramine	drug	Drug_0
10000211	54	64	amiodarone	drug	Drug_1
10000211	101	103	t1	drug	Drug_2

10000212|t|Fluoroquinolones, macrolide antibiotics, and azoles are known to cause QTc prolongation.
10000212	0	16	Fluoroquinolones	drug	Drug_0
10000212	18	39	macrolide antibiotics	drug	Drug_1

10000213|t|There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones, macrolide antibiotics, or azoles were administered concomitantly.
10000213	85	95	amiodarone	drug	Drug_0
10000213	101	117	fluoroquinolones	drug	Drug_1
10000213	119	140	macrolide antibiotics	drug	Drug_2

10000214|t|Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with propranolol, diltiazem, and verapamil.
10000214	110	121	propranolol	drug	Drug_0
10000214	123	132	diltiazem	drug	Drug_1
10000214	138	147	verapamil	drug	Drug_2

10000215|t|In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of phenytoin, dextromethorphan, and methotrexate.
10000215	70	79	Cordarone	drug	Drug_0
10000215	117	126	phenytoin	drug	Drug_1
10000215	128	144	dextromethorphan	drug	Drug_2
10000215	150	162	methotrexate	drug	Drug_3

10000216|t|Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
10000216	69	94	tricyclic antidepressants	group	Drug_0
10000216	96	100	TCAs	group	Drug_1

10000217|t|cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
10000217	0	10	cimetidine	drug	Drug_0
10000217	66	81	antidepressants	group	Drug_1
10000217	83	97	phenothiazines	group	Drug_2
10000217	107	130	Type 1C antiarrhythmics	group	Drug_3
10000217	131	142	propafenone	drug	Drug_4
10000217	147	157	flecainide	drug	Drug_5

10000218|t|While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
10000218	24	53	serotonin reuptake inhibitors	group	Drug_0
10000218	55	60	SSRIs	group	Drug_1
10000218	69	79	fluoxetine	drug	Drug_2
10000218	81	91	sertraline	drug	Drug_3
10000218	97	107	paroxetine	drug	Drug_4

10000219|t|The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
10000219	141	145	SSRI	group	Drug_0
10000219	25	28	TCA	group	Drug_1
10000219	effect	Drug_0	Drug_1

10000220|t|Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.
10000220	62	66	TCAs	group	Drug_0
10000220	83	88	SSRIs	group	Drug_1
10000220	advise	Drug_0	Drug_1

10000221|t|Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
10000221	19	44	tricyclic antidepressants	group	Drug_0
10000221	156	180	tricyclic antidepressant	group	Drug_1

10000222|t|Monoamine Oxidase Inhibitors: Guanethidine or similarly acting compounds;
10000222	0	28	Monoamine Oxidase Inhibitors	drug	Drug_0
10000222	30	42	Guanethidine	drug	Drug_1

10000223|t|alcohol, barbiturates and other CNS depressants;
10000223	0	7	alcohol	drug	Drug_0
10000223	9	21	barbiturates	drug	Drug_1
10000223	32	47	CNS depressants	drug	Drug_2

10000224|t|and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.
10000224	4	14	disulfiram	drug	Drug_0
10000224	20	37	amitriptyline HCl	drug	Drug_1
10000224	52	67	anticholinergic	drug	Drug_2
10000224	78	93	sympathomimetic	drug	Drug_3
10000224	111	122	epinephrine	drug	Drug_4
10000224	143	154	anesthetics	drug	Drug_5

10000225|t|Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.
10000225	36	53	amitriptyline HCl	drug	Drug_0
10000225	75	90	anticholinergic	drug	Drug_1
10000225	106	117	neuroleptic	drug	Drug_2
10000225	effect	Drug_0	Drug_1

10000226|t|Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs.
10000226	45	70	tricyclic antidepressants	drug	Drug_0
10000226	91	106	anticholinergic	drug	Drug_1
10000226	effect	Drug_0	Drug_1

10000227|t|Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs.
10000227	0	10	Cimetidine	drug	Drug_0
10000227	63	88	tricyclic antidepressants	drug	Drug_1
10000227	171	176	drugs	drug	Drug_2
10000227	mechanism	Drug_0	Drug_1

10000228|t|Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.
10000228	59	84	tricyclic antidepressants	drug	Drug_0
10000228	114	124	cimetidine	drug	Drug_1
10000228	effect	Drug_0	Drug_1

10000229|t|Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.
10000229	30	55	tricyclic antidepressants	drug	Drug_0
10000229	121	136	anticholinergic	drug	Drug_1
10000229	162	172	cimetidine	drug	Drug_2
10000229	190	194	drug	drug	Drug_3
10000229	mechanism	Drug_0	Drug_2

10000230|t|Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.
10000230	98	108	cimetidine	drug	Drug_0
10000230	68	93	tricyclic antidepressants	drug	Drug_1
10000230	160	175	antidepressants	drug	Drug_2
10000230	mechanism	Drug_1	Drug_0

10000231|t|Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 - 150 mg of amitriptyline HCl.
10000231	83	96	ethchlorvynol	drug	Drug_0
10000231	116	133	amitriptyline HCl	drug	Drug_1
10000231	effect	Drug_0	Drug_1

10000232|t|When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents: may enhance the potential for renal toxicity, bronchospasm and hypotension.
10000232	70	84	amphotericin B	drug	Drug_0
10000232	86	107	Antineoplastic agents	group	Drug_1
10000232	effect	Drug_0	Drug_1

10000233|t|Antineoplastic agents (e. g., nitrogen mustard, etc.) should be given concomitantly only with great caution.
10000233	0	21	Antineoplastic agents	group	Drug_0
10000233	30	46	nitrogen mustard	drug	Drug_1

10000234|t|Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.
10000234	0	15	Corticosteroids	group	Drug_0
10000234	20	33	Corticotropin	drug	Drug_1
10000234	35	39	ACTH	group	Drug_2
10000234	57	71	amphotericin B	drug	Drug_3
10000234	effect	Drug_1	Drug_3
10000234	effect	Drug_2	Drug_3
10000234	effect	Drug_0	Drug_3

10000235|t|Digitalis glycosides: amphotericin B-induced hypokalemia may potentiate digitalis toxicity.
10000235	0	20	Digitalis glycosides	group	Drug_0
10000235	22	36	amphotericin B	drug	Drug_1
10000235	72	81	digitalis	group	Drug_2
10000235	effect	Drug_1	Drug_2

10000236|t|Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.
10000236	130	141	flucytosine	drug	Drug_0
10000236	51	65	amphotericin B	drug	Drug_1
10000236	effect	Drug_1	Drug_0

10000237|t|Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.
10000237	174	184	imidazoles	group	Drug_0
10000237	19	31	ketoconazole	drug	Drug_1
10000237	33	43	miconazole	drug	Drug_2
10000237	45	57	clotrimazole	drug	Drug_3
10000237	59	70	fluconazole	drug	Drug_4
10000237	217	231	amphotericin B	drug	Drug_5
10000237	effect	Drug_0	Drug_5

10000238|t|Other nephrotoxic medications: agents such as aminoglycosides, cyclosporine, and pentamidine may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.
10000238	46	61	aminoglycosides	group	Drug_0
10000238	63	75	cyclosporine	drug	Drug_1
10000238	81	92	pentamidine	drug	Drug_2

10000239|t|Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).
10000239	99	124	skeletal muscle relaxants	group	Drug_0
10000239	27	41	amphotericin B	drug	Drug_1
10000239	132	144	tubocurarine	drug	Drug_2
10000239	effect	Drug_1	Drug_2
10000239	effect	Drug_1	Drug_0

10000240|t|Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions.
10000240	120	142	leukocyte transfusions	drug_n	Drug_0
10000240	101	115	amphotericin B	drug	Drug_1
10000240	effect	Drug_1	Drug_0

10000241|t|Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.
10000241	0	26	Bacteriostatic Antibiotics	group	Drug_0
10000241	28	43	Chloramphenicol	drug	Drug_1
10000241	45	58	erythromycins	drug	Drug_2
10000241	60	72	sulfonamides	group	Drug_3
10000241	77	90	tetracyclines	group	Drug_4
10000241	137	148	penicillins	group	Drug_5
10000241	effect	Drug_4	Drug_5
10000241	effect	Drug_2	Drug_5
10000241	effect	Drug_3	Drug_5
10000241	effect	Drug_1	Drug_5

10000242|t|Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.
10000242	0	10	Probenecid	drug	Drug_0
10000242	106	116	ampicillin	drug	Drug_1
10000242	mechanism	Drug_0	Drug_1

10000243|t|Drug/Laboratory Test Interaction After treatment with ampicillin, a false-positive reaction for glucose in the urine may occur with copper sulfate tests (Benedicts solution, Fehlings solution, or Clinitest tablets) but not with enzyme based tests such as Clinistix and Glucose Enzymatic Test Strip USP.
10000243	54	64	ampicillin	drug	Drug_0
10000243	132	146	copper sulfate	drug_n	Drug_1

10000244|t|HIV Protease Inhibitors: The effect of amprenavir on total drug concentrations of other HIV protease inhibitors in subjects receiving both agents was evaluated using comparisons to historical data.
10000244	88	111	HIV protease inhibitors	group	Drug_0
10000244	39	49	amprenavir	drug	Drug_1

10000245|t|Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.
10000245	0	9	Indinavir	drug	Drug_0
10000245	109	119	amprenavir	drug	Drug_1
10000245	mechanism	Drug_0	Drug_1

10000246|t|Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.
10000246	0	10	Saquinavir	drug	Drug_0
10000246	127	137	amprenavir	drug	Drug_1
10000246	mechanism	Drug_0	Drug_1

10000247|t|Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.
10000247	0	10	Nelfinavir	drug	Drug_0
10000247	110	120	amprenavir	drug	Drug_1
10000247	mechanism	Drug_0	Drug_1

10000248|t|Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.
10000248	86	95	methadone	drug	Drug_0
10000248	31	41	amprenavir	drug	Drug_1
10000248	effect	Drug_1	Drug_0

10000249|t|Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.
10000249	148	158	amprenavir	drug	Drug_0
10000249	35	44	methadone	drug	Drug_1
10000249	mechanism	Drug_0	Drug_1

10000250|t|Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.
10000250	37	47	Amprenavir	drug	Drug_0
10000250	61	70	ritonavir	drug	Drug_1
10000250	effect	Drug_0	Drug_1

10000251|t|Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.
10000251	97	107	Amprenavir	drug	Drug_0
10000251	112	121	ritonavir	drug	Drug_1
10000251	advise	Drug_0	Drug_1

10000252|t|For comprehensive information concerning laboratory test alterations associated with ritonavir, physicians should refer to the complete prescribing information for NORVIR (ritonavir).
10000252	172	181	ritonavir	drug	Drug_0
10000252	164	170	NORVIR	brand	Drug_1

10000253|t|Taking amyl nitrite after drinking alcohol may worsen side effects and may cause severe hypotension and cardiovascular collapse.
10000253	7	19	amyl nitrite	drug	Drug_0
10000253	35	42	alcohol	drug	Drug_1
10000253	effect	Drug_0	Drug_1

10000254|t|In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide, nor does anagrelide affect the PK properties of digoxin or warfarin.
10000254	177	184	digoxin	drug	Drug_0
10000254	188	196	warfarin	drug	Drug_1
10000254	138	148	anagrelide	drug	Drug_2

10000255|t|Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.
10000255	122	132	anagrelide	drug	Drug_0
10000255	157	164	aspirin	brand	Drug_1
10000255	166	179	acetaminophen	drug	Drug_2
10000255	181	191	furosemide	drug	Drug_3
10000255	193	197	iron	drug	Drug_4
10000255	199	209	ranitidine	drug	Drug_5
10000255	211	222	hydroxyurea	drug	Drug_6
10000255	228	239	allopurinol	drug	Drug_7

10000256|t|An in vivo interaction study in humans demonstrated that a single 1mg dose of anagrelide administered concomitantly with a single 900 mg dose of aspirin was generally well tolerated.
10000256	78	88	anagrelide	drug	Drug_0
10000256	145	152	aspirin	brand	Drug_1

10000257|t|No clinically relevant pharmacokinetic interactions between anagrelide and acetylsalicylic acid were observed.
10000257	60	70	anagrelide	drug	Drug_0
10000257	75	95	acetylsalicylic acid	drug	Drug_1

10000258|t|Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.
10000258	0	10	Anagrelide	drug	Drug_0
10000258	123	130	aspirin	brand	Drug_1
10000258	effect	Drug_0	Drug_1

10000259|t|It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.
10000259	78	89	fluvoxamine	drug	Drug_0
10000259	176	186	anagrelide	drug	Drug_1
10000259	mechanism	Drug_0	Drug_1

10000260|t|Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.
10000260	0	10	Anagrelide	drug	Drug_0
10000260	213	225	theophylline	drug	Drug_1
10000260	mechanism	Drug_0	Drug_1

10000261|t|The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
10000261	76	85	milrinone	drug	Drug_0
10000261	87	96	enoximone	drug	Drug_1
10000261	98	106	amrinone	drug	Drug_2
10000261	108	117	olprinone	drug_n	Drug_3
10000261	122	132	cilostazol	drug	Drug_4
10000261	155	165	anagrelide	drug	Drug_5
10000261	effect	Drug_0	Drug_5
10000261	effect	Drug_2	Drug_5
10000261	effect	Drug_1	Drug_5
10000261	effect	Drug_4	Drug_5
10000261	effect	Drug_3	Drug_5

10000262|t|There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.
10000262	51	61	sucralfate	drug	Drug_0
10000262	81	91	anagrelide	drug	Drug_1
10000262	mechanism	Drug_0	Drug_1

10000263|t|Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either methotrexate or Kineret when the two agents were administered together.
10000263	132	144	methotrexate	drug	Drug_0
10000263	148	155	Kineret	brand	Drug_1

10000264|t|In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).
10000264	92	99	Kineret	brand	Drug_0
10000264	211	221	etanercept	drug	Drug_1
10000264	effect	Drug_0	Drug_1

10000265|t|Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC  1 x 109/L).
10000265	50	57	Kineret	brand	Drug_0
10000265	62	72	etanercept	drug	Drug_1
10000265	effect	Drug_0	Drug_1

10000266|t|Anastrozole did not alter the pharmacokinetics of antipyrine.
10000266	0	11	Anastrozole	drug	Drug_0
10000266	50	60	antipyrine	drug	Drug_1

10000267|t|Although there have been no formal interaction studies other than with antipyrine, based on these in vivo and in vitro studies, it is unlikely that co-administration of a 1 mg dose of ARIMIDEX with other drugs will result in clinically significant drug inhibition of cytochrome P450-mediated metabolism of the other drugs.
10000267	71	81	antipyrine	drug	Drug_0
10000267	184	192	ARIMIDEX	brand	Drug_1

10000268|t|An interaction study with warfarin showed no clinically significant effect of anastrozole on warfarin pharmacokinetics or anticoagulant activity.
10000268	93	101	warfarin	drug	Drug_0
10000268	78	89	anastrozole	drug	Drug_1

10000269|t|At a median follow-up of 33 months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation.
10000269	55	63	ARIMIDEX	brand	Drug_0
10000269	138	147	tamoxifen	drug	Drug_1

10000270|t|Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).
10000270	67	76	tamoxifen	drug	Drug_0
10000270	109	120	anastrozole	drug	Drug_1
10000270	advise	Drug_0	Drug_1

10000271|t|Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.
10000271	141	152	anastrozole	drug	Drug_0
10000271	37	46	tamoxifen	drug	Drug_1
10000271	mechanism	Drug_0	Drug_1

10000272|t|Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.
10000272	0	8	Estrogen	group	Drug_0
10000272	54	62	ARIMIDEX	brand	Drug_1
10000272	advise	Drug_0	Drug_1

10000273|t|Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.
10000273	32	43	anileridine	drug	Drug_0
10000273	73	80	opioids	group	Drug_1
10000273	82	91	sedatives	group	Drug_2
10000273	93	107	phenothiazines	group	Drug_3
10000273	112	123	anesthetics	group	Drug_4
10000273	advise	Drug_0	Drug_3
10000273	advise	Drug_0	Drug_4
10000273	advise	Drug_0	Drug_1
10000273	advise	Drug_0	Drug_2

10000274|t|Addition or deletion of any drug from the therapeutic regimen of patients receiving oral anticoagulants may affect patient response to the anticoagulant.
10000274	89	103	anticoagulants	group	Drug_0
10000274	139	152	anticoagulant	group	Drug_1

10000275|t|For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K, the net effects are unpredictable.
10000275	19	33	cholestyramine	drug	Drug_0
10000275	94	108	anticoagulants	group	Drug_1
10000275	113	122	vitamin K	group	Drug_2
10000275	mechanism	Drug_0	Drug_2
10000275	mechanism	Drug_0	Drug_1

10000276|t|Chloral hydrate may cause an increased prothrombin response by displacing the anticoagulant from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction, thus leading to inter-patient variation in ultimate prothrombin effect.
10000276	0	15	Chloral hydrate	drug	Drug_0
10000276	78	91	anticoagulant	group	Drug_1
10000276	mechanism	Drug_0	Drug_1

10000277|t|Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;
10000277	47	60	anticoagulant	group	Drug_0
10000277	143	166	adrenocortical steroids	group	Drug_1
10000277	effect	Drug_0	Drug_1

10000278|t|Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
10000278	47	60	anticoagulant	group	Drug_0
10000278	143	166	adrenocortical steroids	group	Drug_1
10000278	167	174	alcohol	drug	Drug_2
10000278	176	184	antacids	group	Drug_3
10000278	185	199	antihistamines	group	Drug_4
10000278	200	212	barbiturates	group	Drug_5
10000278	213	226	carbamazepine	drug	Drug_6
10000278	227	242	chloral hydrate	drug	Drug_7
10000278	244	260	chlordiazepoxide	drug	Drug_8
10000278	261	275	cholestyramine	drug	Drug_9
10000278	289	298	vitamin K	group	Drug_10
10000278	299	308	diuretics	group	Drug_11
10000278	310	323	ethchlorvynol	drug	Drug_12
10000278	324	336	glutethimide	drug	Drug_13
10000278	337	349	griseofulvin	drug	Drug_14
10000278	350	361	haloperidol	drug	Drug_15
10000278	362	373	meprobamate	drug	Drug_16
10000278	379	393	contraceptives	group	Drug_17
10000278	394	405	paraldehyde	drug	Drug_18
10000278	406	415	primidone	drug	Drug_19
10000278	416	426	ranitidine	drug	Drug_20
10000278	428	436	rifampin	drug	Drug_21
10000278	480	489	vitamin C	drug	Drug_22
10000278	490	505	warfarin sodium	drug	Drug_23
10000278	effect	Drug_0	Drug_14
10000278	effect	Drug_0	Drug_5
10000278	effect	Drug_0	Drug_13
10000278	effect	Drug_0	Drug_6
10000278	effect	Drug_0	Drug_4
10000278	effect	Drug_0	Drug_7
10000278	effect	Drug_0	Drug_15
10000278	effect	Drug_0	Drug_20
10000278	effect	Drug_0	Drug_10
10000278	effect	Drug_0	Drug_12
10000278	effect	Drug_0	Drug_9
10000278	effect	Drug_0	Drug_3
10000278	effect	Drug_0	Drug_1
10000278	effect	Drug_0	Drug_22
10000278	effect	Drug_0	Drug_16
10000278	effect	Drug_0	Drug_8
10000278	effect	Drug_0	Drug_11
10000278	effect	Drug_0	Drug_18
10000278	effect	Drug_0	Drug_21
10000278	effect	Drug_0	Drug_23
10000278	effect	Drug_0	Drug_17
10000278	effect	Drug_0	Drug_2
10000278	effect	Drug_0	Drug_19

10000279|t|Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;
10000279	40	53	anticoagulant	group	Drug_0
10000279	115	122	alcohol	drug	Drug_1
10000279	effect	Drug_0	Drug_1

10000280|t|salicylates;sulfinpyrazone;
10000280	0	11	salicylates	group	Drug_0
10000280	12	26	sulfinpyrazone	drug	Drug_1

10000281|t|trimethoprim/sulfamethoxazole;
10000281	0	12	trimethoprim	drug	Drug_0
10000281	13	29	sulfamethoxazole	drug	Drug_1

10000282|t|Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
10000282	40	53	anticoagulant	group	Drug_0
10000282	115	122	alcohol	drug	Drug_1
10000282	124	135	allopurinol	drug	Drug_2
10000282	136	155	aminosalicylic acid	drug	Drug_3
10000282	156	166	amiodarone	drug	Drug_4
10000282	167	184	anabolic steroids	group	Drug_5
10000282	185	196	antibiotics	group	Drug_6
10000282	197	207	bromelains	drug	Drug_7
10000282	208	223	chloral hydrate	drug	Drug_8
10000282	225	239	chlorpropamide	drug	Drug_9
10000282	240	252	chymotrypsin	drug	Drug_10
10000282	253	263	cimetidine	drug	Drug_11
10000282	264	274	cinchophen	drug	Drug_12
10000282	275	285	clofibrate	drug	Drug_13
10000282	286	293	dextran	drug	Drug_14
10000282	294	309	dextrothyroxine	drug	Drug_15
10000282	310	319	diazoxide	drug	Drug_16
10000282	341	351	diflunisal	drug	Drug_17
10000282	352	362	disulfiram	drug	Drug_18
10000282	394	409	ethacrynic acid	drug	Drug_19
10000282	410	420	fenoprofen	drug	Drug_20
10000282	421	429	glucagon	drug	Drug_21
10000282	448	457	ibuprofen	drug	Drug_22
10000282	458	470	indomethacin	drug	Drug_23
10000282	471	494	influenza virus vaccine	group	Drug_24
10000282	506	517	anesthetics	group	Drug_25
10000282	518	532	mefenamic acid	drug	Drug_26
10000282	533	543	methyldopa	drug	Drug_27
10000282	544	559	methylphenidate	drug	Drug_28
10000282	560	573	metronidazole	drug	Drug_29
10000282	574	584	miconazole	drug	Drug_30
10000282	585	613	monoamine oxidase inhibitors	group	Drug_31
10000282	614	628	nalidixic acid	drug	Drug_32
10000282	629	637	naproxen	drug	Drug_33
10000282	638	651	oxolinic acid	drug	Drug_34
10000282	652	667	oxyphenbutazone	drug	Drug_35
10000282	668	682	pentoxifylline	drug	Drug_36
10000282	683	697	phenylbutazone	drug	Drug_37
10000282	698	710	phenyramidol	drug_n	Drug_38
10000282	711	720	phenytoin	drug	Drug_39
10000282	743	762	prolonged narcotics	group	Drug_40
10000282	763	774	pyrazolones	group	Drug_41
10000282	775	784	quinidine	drug	Drug_42
10000282	785	792	quinine	drug	Drug_43
10000282	793	803	ranitidine	drug	Drug_44
10000282	805	816	salicylates	group	Drug_45
10000282	817	831	sulfinpyrazone	drug	Drug_46
10000282	832	844	sulfonamides	group	Drug_47
10000282	858	866	sulindac	drug	Drug_48
10000282	867	880	thyroid drugs	group	Drug_49
10000282	881	892	tolbutamide	drug	Drug_50
10000282	893	909	triclofos sodium	drug	Drug_51
10000282	910	922	trimethoprim	drug	Drug_52
10000282	923	939	sulfamethoxazole	drug	Drug_53
10000282	983	998	warfarin sodium	drug	Drug_54
10000282	effect	Drug_0	Drug_51
10000282	effect	Drug_0	Drug_22
10000282	effect	Drug_0	Drug_26
10000282	effect	Drug_0	Drug_25
10000282	effect	Drug_0	Drug_17
10000282	effect	Drug_0	Drug_8
10000282	effect	Drug_0	Drug_6
10000282	effect	Drug_0	Drug_35
10000282	effect	Drug_0	Drug_15
10000282	effect	Drug_0	Drug_49
10000282	effect	Drug_0	Drug_3
10000282	effect	Drug_0	Drug_18
10000282	effect	Drug_0	Drug_13
10000282	effect	Drug_0	Drug_28
10000282	effect	Drug_0	Drug_20
10000282	effect	Drug_0	Drug_4
10000282	effect	Drug_0	Drug_32
10000282	effect	Drug_0	Drug_7
10000282	effect	Drug_0	Drug_42
10000282	effect	Drug_0	Drug_29
10000282	effect	Drug_0	Drug_38
10000282	effect	Drug_0	Drug_9
10000282	effect	Drug_0	Drug_23
10000282	effect	Drug_0	Drug_44
10000282	effect	Drug_0	Drug_54
10000282	effect	Drug_0	Drug_2
10000282	effect	Drug_0	Drug_53
10000282	effect	Drug_0	Drug_46
10000282	effect	Drug_0	Drug_14
10000282	effect	Drug_0	Drug_16
10000282	effect	Drug_0	Drug_40
10000282	effect	Drug_0	Drug_50
10000282	effect	Drug_0	Drug_11
10000282	effect	Drug_0	Drug_1
10000282	effect	Drug_0	Drug_30
10000282	effect	Drug_0	Drug_48
10000282	effect	Drug_0	Drug_12
10000282	effect	Drug_0	Drug_19
10000282	effect	Drug_0	Drug_33
10000282	effect	Drug_0	Drug_47
10000282	effect	Drug_0	Drug_36
10000282	effect	Drug_0	Drug_41
10000282	effect	Drug_0	Drug_27
10000282	effect	Drug_0	Drug_52
10000282	effect	Drug_0	Drug_39
10000282	effect	Drug_0	Drug_5
10000282	effect	Drug_0	Drug_43
10000282	effect	Drug_0	Drug_45
10000282	effect	Drug_0	Drug_24
10000282	effect	Drug_0	Drug_10
10000282	effect	Drug_0	Drug_37
10000282	effect	Drug_0	Drug_21
10000282	effect	Drug_0	Drug_31
10000282	effect	Drug_0	Drug_34

10000283|t|Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.
10000283	5	19	anticoagulants	group	Drug_0
10000283	62	81	hypoglycemic agents	group	Drug_1
10000283	87	98	tolbutamide	drug	Drug_2
10000283	103	117	chlorpropamide	drug	Drug_3
10000283	mechanism	Drug_0	Drug_3
10000283	mechanism	Drug_0	Drug_2
10000283	mechanism	Drug_0	Drug_1

10000284|t|Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.
10000284	13	27	anticoagulants	group	Drug_0
10000284	160	169	phenytoin	drug	Drug_1
10000284	104	118	anticonvulsant	group	Drug_2
10000284	142	155	anticoagulant	group	Drug_3
10000284	mechanism	Drug_0	Drug_1
10000284	mechanism	Drug_3	Drug_1

10000285|t|Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
10000285	91	112	antineoplastic agents	group	Drug_0
10000285	160	167	aspirin	brand	Drug_1
10000285	178	215	non-steroidal anti-inflammatory drugs	group	Drug_2
10000285	217	229	dipyridamole	drug	Drug_3
10000285	231	247	hydrochloroquine	drug	Drug_4
10000285	249	259	clofibrate	drug	Drug_5
10000285	261	268	dextran	drug	Drug_6
10000285	317	331	anticoagulants	group	Drug_7
10000285	effect	Drug_4	Drug_7
10000285	effect	Drug_5	Drug_7
10000285	effect	Drug_1	Drug_7
10000285	effect	Drug_2	Drug_7
10000285	effect	Drug_3	Drug_7
10000285	effect	Drug_0	Drug_7
10000285	effect	Drug_6	Drug_7

10000286|t|The beneficial effects on arterial thrombus formation from combined therapy with antiplatelet and anticoagulant medication must be weighed against an increased risk of inducing hemorrhage.
10000286	81	122	antiplatelet medication	group	Drug_0
10000286	98	122	anticoagulant medication	group	Drug_1
10000286	advise	Drug_0	Drug_1

10000287|t|Drug/Laboratory Test Interferences: Dicumarol and indanedione anticoagulants, including anisindione, or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.
10000287	36	45	Dicumarol	drug	Drug_0
10000287	50	76	indanedione anticoagulants	group	Drug_1
10000287	88	99	anisindione	drug	Drug_2

10000288|t|5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
10000288	0	16	5HT3 Antagonists	group	Drug_0
10000288	160	171	apomorphine	drug	Drug_1
10000288	237	248	ondansetron	drug	Drug_2
10000288	190	211	5HT3 antagonist class	group	Drug_3
10000288	250	261	granisetron	drug	Drug_4
10000288	263	273	dolasetron	drug	Drug_5
10000288	275	287	palonosetron	drug	Drug_6
10000288	293	302	alosetron	drug	Drug_7
10000288	advise	Drug_1	Drug_5
10000288	advise	Drug_1	Drug_7
10000288	effect	Drug_1	Drug_2
10000288	advise	Drug_1	Drug_6
10000288	advise	Drug_1	Drug_4
10000288	advise	Drug_1	Drug_3
10000288	advise	Drug_1	Drug_2

10000289|t|Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.
10000289	0	27	Antihypertensive Medication	group	Drug_0
10000289	173	185	vasodilators	group	Drug_1
10000289	141	169	antihypertensive medications	group	Drug_2
10000289	effect	Drug_2	Drug_1

10000290|t|Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
10000290	83	103	dopamine antagonists	group	Drug_0
10000290	28	39	apomorphine	drug	Drug_1
10000290	45	61	dopamine agonist	group	Drug_2
10000290	117	129	neuroleptics	group	Drug_3
10000290	131	145	phenothiazines	group	Drug_4
10000290	147	161	butyrophenones	group	Drug_5
10000290	163	176	thioxanthenes	group	Drug_6
10000290	181	195	metoclopramide	drug	Drug_7
10000290	231	237	APOKYN	brand	Drug_8
10000290	effect	Drug_6	Drug_8
10000290	effect	Drug_4	Drug_8
10000290	effect	Drug_5	Drug_8
10000290	effect	Drug_7	Drug_8
10000290	effect	Drug_0	Drug_7

10000291|t|Patients with major psychotic disorders, treated with neuroleptics, should be treated with dopamine agonists only if the potential benefits outweigh the risks.
10000291	54	66	neuroleptics	group	Drug_0
10000291	91	108	dopamine agonists	group	Drug_1
10000291	advise	Drug_0	Drug_1

10000292|t|Apraclonidine should not be used in patients receiving MAO inhibitors..
10000292	0	13	Apraclonidine	drug	Drug_0
10000292	55	69	MAO inhibitors	group	Drug_1
10000292	advise	Drug_0	Drug_1

10000293|t|Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
10000293	130	138	IOPIDINE	brand	Drug_0
10000293	224	239	CNS depressants	group	Drug_1
10000293	241	248	alcohol	drug	Drug_2
10000293	250	262	barbiturates	group	Drug_3
10000293	264	271	opiates	group	Drug_4
10000293	273	282	sedatives	group	Drug_5
10000293	284	295	anesthetics	group	Drug_6
10000293	advise	Drug_0	Drug_4
10000293	advise	Drug_0	Drug_1
10000293	advise	Drug_0	Drug_5
10000293	advise	Drug_0	Drug_6
10000293	advise	Drug_0	Drug_2
10000293	advise	Drug_0	Drug_3

10000294|t|Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.
10000294	0	25	Tricyclic antidepressants	group	Drug_0
10000294	89	98	clonidine	drug	Drug_1
10000294	effect	Drug_0	Drug_1

10000295|t|An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.
10000295	82	91	clonidine	drug	Drug_0
10000295	96	107	neuroleptic	group	Drug_1
10000295	effect	Drug_0	Drug_1

10000296|t|Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.
10000296	6	19	apraclonidine	drug	Drug_0
10000296	88	101	beta-blockers	group	Drug_1
10000296	129	146	antihypertensives	group	Drug_2
10000296	152	170	cardiac glycosides	group	Drug_3
10000296	advise	Drug_0	Drug_1
10000296	advise	Drug_0	Drug_3
10000296	advise	Drug_0	Drug_2

10000297|t|Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.
10000297	0	10	Aprepitant	drug	Drug_0
10000297	54	67	S(-) warfarin	drug	Drug_1
10000297	72	83	tolbutamide	drug	Drug_2
10000297	mechanism	Drug_0	Drug_2
10000297	mechanism	Drug_0	Drug_1

10000298|t|Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.
10000298	20	30	Aprepitant	drug	Drug_0
10000298	115	124	phenytoin	drug	Drug_1
10000298	mechanism	Drug_0	Drug_1

10000299|t|Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of Aprepitant with digoxin in a clinical drug interaction study.
10000299	148	158	Aprepitant	drug	Drug_0
10000299	164	171	digoxin	drug	Drug_1

10000300|t|5-HT3 antagonists: In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron or granisetron.
10000300	0	17	5-HT3 antagonists	group	Drug_0
10000300	57	67	aprepitant	drug	Drug_1
10000300	137	148	ondansetron	drug	Drug_2
10000300	152	163	granisetron	drug	Drug_3

10000301|t|Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
10000301	0	15	Corticosteroids	group	Drug_0
10000301	267	280	dexamethasone	drug	Drug_1
10000301	141	151	Aprepitant	drug	Drug_2
10000301	mechanism	Drug_2	Drug_1
10000301	mechanism	Drug_2	Drug_1

10000302|t|The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.
10000302	129	142	dexamethasone	drug	Drug_0
10000302	194	204	Aprepitant	drug	Drug_1
10000302	advise	Drug_0	Drug_1

10000303|t|The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.
10000303	134	147	dexamethasone	drug	Drug_0
10000303	70	80	Aprepitant	drug	Drug_1
10000303	mechanism	Drug_0	Drug_1

10000304|t|Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.
10000304	0	10	Aprepitant	drug	Drug_0
10000304	200	218	methylprednisolone	drug	Drug_1
10000304	mechanism	Drug_0	Drug_1

10000305|t|The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
10000305	207	225	methylprednisolone	drug	Drug_0
10000305	277	287	Aprepitant	drug	Drug_1
10000305	advise	Drug_0	Drug_1
10000305	advise	Drug_0	Drug_1

10000306|t|Warfarin: A single 125-mg dose of Aprepitant was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic warfarin therapy.
10000306	152	160	warfarin	drug	Drug_0
10000306	34	44	Aprepitant	drug	Drug_1

10000307|t|Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.
10000307	335	345	Aprepitant	drug	Drug_0
10000307	64	85	R(+) warfarin	drug	Drug_1
10000307	72	85	S(-) warfarin	drug	Drug_2
10000307	135	147	S(-)warfarin	drug	Drug_3
10000307	mechanism	Drug_3	Drug_0

10000308|t|In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.
10000308	23	31	warfarin	drug	Drug_0
10000308	193	203	Aprepitant	drug	Drug_1
10000308	advise	Drug_0	Drug_1

10000309|t|Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
10000309	212	223	tolbutamide	drug	Drug_0
10000309	308	318	Aprepitant	drug	Drug_1
10000309	mechanism	Drug_0	Drug_1

10000310|t|Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
10000310	5	19	contraceptives	group	Drug_0
10000310	21	31	Aprepitant	drug	Drug_1
10000310	100	113	contraceptive	group	Drug_2
10000310	201	218	ethinyl estradiol	drug	Drug_3
10000310	252	265	norethindrone	drug	Drug_4
10000310	mechanism	Drug_1	Drug_4
10000310	mechanism	Drug_1	Drug_3

10000311|t|therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.
10000311	32	46	contraceptives	group	Drug_0
10000311	72	82	Aprepitant	drug	Drug_1
10000311	effect	Drug_0	Drug_1

10000312|t|Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.
10000312	28	38	Aprepitant	drug	Drug_0
10000312	69	83	contraceptives	group	Drug_1
10000312	advise	Drug_0	Drug_1

10000313|t|Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.
10000313	155	164	midazolam	drug	Drug_0
10000313	224	234	Aprepitant	drug	Drug_1
10000313	mechanism	Drug_1	Drug_0

10000314|t|The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
10000314	60	69	midazolam	drug	Drug_0
10000314	79	94	benzodiazepines	group	Drug_1
10000314	119	129	alprazolam	drug	Drug_2
10000314	131	140	triazolam	drug	Drug_3
10000314	202	212	Aprepitant	drug	Drug_4
10000314	advise	Drug_0	Drug_4
10000314	advise	Drug_1	Drug_4
10000314	advise	Drug_3	Drug_4
10000314	advise	Drug_2	Drug_4

10000315|t|In another study with intravenous administration of midazolam, Aprepitant was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and midazolam 2 mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15.
10000315	138	147	midazolam	drug	Drug_0
10000315	218	228	Aprepitant	drug	Drug_1

10000316|t|Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.
10000316	135	145	Aprepitant	drug	Drug_0
10000316	83	92	midazolam	drug	Drug_1
10000316	mechanism	Drug_0	Drug_1
10000316	mechanism	Drug_0	Drug_1

10000317|t|Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
10000317	44	54	Aprepitant	drug	Drug_0
10000317	92	104	ketoconazole	drug	Drug_1
10000317	106	118	itraconazole	drug	Drug_2
10000317	120	130	nefazodone	drug	Drug_3
10000317	132	146	troleandomycin	drug	Drug_4
10000317	148	162	clarithromycin	drug	Drug_5
10000317	164	173	ritonavir	drug	Drug_6
10000317	175	185	nelfinavir	drug	Drug_7
10000317	advise	Drug_0	Drug_6
10000317	advise	Drug_0	Drug_1
10000317	advise	Drug_0	Drug_2
10000317	advise	Drug_0	Drug_4
10000317	advise	Drug_0	Drug_3
10000317	advise	Drug_0	Drug_5
10000317	advise	Drug_0	Drug_7

10000318|t|Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.
10000318	42	51	diltiazem	drug	Drug_0
10000318	107	117	aprepitant	drug	Drug_1
10000318	advise	Drug_0	Drug_1

10000319|t|therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
10000319	232	242	Aprepitant	drug	Drug_0
10000319	97	105	rifampin	drug	Drug_1
10000319	107	120	carbamazepine	drug	Drug_2
10000319	122	131	phenytoin	drug	Drug_3
10000319	mechanism	Drug_0	Drug_3
10000319	mechanism	Drug_0	Drug_1
10000319	mechanism	Drug_0	Drug_0

10000320|t|Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a
10000320	0	12	Ketoconazole	drug	Drug_0
10000320	43	53	Aprepitant	drug	Drug_1

10000321|t|Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.
10000321	116	128	ketoconazole	drug	Drug_0
10000321	245	255	aprepitant	drug	Drug_1
10000321	mechanism	Drug_1	Drug_0

10000322|t|Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.
10000322	112	120	rifampin	drug	Drug_0
10000322	158	168	aprepitant	drug	Drug_1
10000322	mechanism	Drug_1	Drug_0

10000323|t|Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.
10000323	309	318	diltiazem	drug	Drug_0
10000323	254	264	aprepitant	drug	Drug_1
10000323	mechanism	Drug_1	Drug_0

10000324|t|Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.
10000324	285	295	paroxetine	drug	Drug_0
10000324	270	280	aprepitant	drug	Drug_1
10000324	mechanism	Drug_1	Drug_0

10000325|t|Beta-adrenergic blocking agents: concurrent use may blunt the response to arbutamine.
10000325	0	31	Beta-adrenergic blocking agents	group	Drug_0
10000325	74	84	arbutamine	drug	Drug_1

10000326|t|Beta-adrenergic blocking agents should be withdrawn at least 48 hours before conducting an arbutamine-mediated stress test.
10000326	0	31	Beta-adrenergic blocking agents	group	Drug_0
10000326	91	101	arbutamine	drug	Drug_1
10000326	advise	Drug_0	Drug_1

10000327|t|Antiarrhythmic agents, class I (such as flecainide, lidocaine, or quinidine): concurrent use with arbutamine may have a proarrhythmic effect.
10000327	0	30	Antiarrhythmic agents, class I	drug	Drug_0
10000327	40	50	flecainide	drug	Drug_1
10000327	52	61	lidocaine	drug	Drug_2
10000327	66	75	quinidine	drug	Drug_3
10000327	98	108	arbutamine	drug	Drug_4

10000328|t|Antidepressants (tricyclic), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.
10000328	0	15	Antidepressants	group	Drug_0
10000328	17	26	tricyclic	group	Drug_1
10000328	29	37	atropine	drug	Drug_2
10000328	47	69	anticholinergic agents	group	Drug_3
10000328	74	94	digitalis glycosides	group	Drug_4
10000328	116	126	arbutamine	drug	Drug_5

10000329|t|Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
10000329	0	14	Anticoagulants	group	Drug_0
10000329	75	106	platelet aggregation inhibitors	group	Drug_1
10000329	115	151	nonsteroidal anti-inflammatory drugs	group	Drug_2
10000329	153	159	NSAIDs	group	Drug_3
10000329	166	173	aspirin	brand	Drug_4
10000329	245	254	ardeparin	drug	Drug_5
10000329	effect	Drug_0	Drug_5
10000329	effect	Drug_1	Drug_5
10000329	effect	Drug_3	Drug_5
10000329	effect	Drug_4	Drug_5
10000329	effect	Drug_2	Drug_5

10000330|t|If additional adrenergic drugs are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of BROVANA may be potentiated.
10000330	14	30	adrenergic drugs	group	Drug_0
10000330	166	173	BROVANA	brand	Drug_1
10000330	advise	Drug_0	Drug_1

10000331|t|When paroxetine, a potent inhibitor of CYP2D6, was co-administered with BROVANA at steady-state, exposure to either drug was not altered.
10000331	5	15	paroxetine	drug	Drug_0
10000331	72	79	BROVANA	brand	Drug_1

10000332|t|Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
10000332	27	42	methylxanthines	group	Drug_0
10000332	44	57	aminophylline	drug	Drug_1
10000332	59	71	theophylline	drug	Drug_2
10000332	74	82	steroids	group	Drug_3
10000332	87	96	diuretics	group	Drug_4
10000332	138	157	adrenergic agonists	group	Drug_5
10000332	effect	Drug_0	Drug_5
10000332	effect	Drug_2	Drug_5
10000332	effect	Drug_4	Drug_5
10000332	effect	Drug_1	Drug_5
10000332	effect	Drug_3	Drug_5

10000333|t|The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
10000333	78	109	non-potassium sparing diuretics	group	Drug_0
10000333	119	145	loop diuretics	group	Drug_1
10000333	127	145	thiazide diuretics	group	Drug_2
10000333	174	187	beta-agonists	group	Drug_3
10000333	233	245	beta-agonist	group	Drug_4
10000333	effect	Drug_0	Drug_3
10000333	effect	Drug_2	Drug_3
10000333	effect	Drug_1	Drug_3

10000334|t|Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta-agonists with non-potassium sparing diuretics.
10000334	113	126	beta-agonists	group	Drug_0
10000334	132	163	non-potassium sparing diuretics	group	Drug_1
10000334	advise	Drug_0	Drug_1

10000335|t|BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
10000335	0	7	BROVANA	brand	Drug_0
10000335	23	37	beta2-agonists	group	Drug_1
10000335	114	142	monoamine oxidase inhibitors	group	Drug_2
10000335	144	169	tricyclic antidepressants	group	Drug_3
10000335	236	255	adrenergic agonists	group	Drug_4
10000335	advise	Drug_0	Drug_2
10000335	effect	Drug_2	Drug_4
10000335	advise	Drug_1	Drug_3
10000335	effect	Drug_3	Drug_4
10000335	advise	Drug_1	Drug_2
10000335	advise	Drug_0	Drug_3

10000336|t|The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline, theophylline) by patients receiving BROVANA has not been completely evaluated.
10000336	59	74	methylxanthines	group	Drug_0
10000336	82	95	aminophylline	drug	Drug_1
10000336	97	109	theophylline	drug	Drug_2
10000336	133	140	BROVANA	brand	Drug_3

10000337|t|In two combined 12-week placebo controlled trials that included BROVANA doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 BROVANA -treated subjects received concomitant theophylline at study entry.
10000337	154	161	BROVANA	brand	Drug_0
10000337	201	213	theophylline	drug	Drug_1

10000338|t|In a 12-month controlled trial that included a 50 mcg once daily BROVANA dose, 30 of the 528 BROVANA -treated subjects received concomitant theophylline at study entry.
10000338	93	100	BROVANA	brand	Drug_0
10000338	140	152	theophylline	drug	Drug_1

10000339|t|Beta-adrenergic receptor antagonists (beta-blockers) and BROVANA may interfere with the effect of each other when administered concurrently.
10000339	0	36	Beta-adrenergic receptor antagonists	group	Drug_0
10000339	38	51	beta-blockers	group	Drug_1
10000339	57	64	BROVANA	brand	Drug_2
10000339	effect	Drug_1	Drug_2
10000339	effect	Drug_0	Drug_2

10000340|t|Beta-blockers not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in COPD patients.
10000340	0	13	Beta-blockers	group	Drug_0
10000340	56	69	beta-agonists	group	Drug_1
10000340	effect	Drug_0	Drug_1

10000341|t|Heparin: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.
10000341	133	140	heparin	drug	Drug_0
10000341	118	128	Argatroban	drug	Drug_1

10000342|t|However, if Argatroban is to be initiated after cessation of heparin therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy.
10000342	167	177	Argatroban	drug	Drug_0
10000342	61	68	heparin	drug	Drug_1

10000343|t|Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).
10000343	158	165	aspirin	brand	Drug_0
10000343	268	281	acetaminophen	drug	Drug_1
10000343	380	390	Argatroban	drug	Drug_2

10000344|t|Oral anticoagulant agents: Pharmacokinetic drug-drug interactions between Argatroban and warfarin (7.5 mg single oral dose) have not been demonstrated.
10000344	5	25	anticoagulant agents	group	Drug_0
10000344	74	84	Argatroban	drug	Drug_1
10000344	89	97	warfarin	drug	Drug_2

10000345|t|However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).
10000345	32	42	Argatroban	drug	Drug_0
10000345	47	55	warfarin	drug	Drug_1
10000345	effect	Drug_0	Drug_1

10000346|t|Thrombolytic agents: The safety and effectiveness of Argatroban with thrombolytic agents have not been established.
10000346	69	88	thrombolytic agents	group	Drug_0
10000346	53	63	Argatroban	drug	Drug_1

10000347|t|Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.
10000347	38	48	Argatroban	drug	Drug_0
10000347	54	73	antiplatelet agents	group	Drug_1
10000347	75	88	thrombolytics	group	Drug_2
10000347	100	114	anticoagulants	group	Drug_3
10000347	effect	Drug_0	Drug_1
10000347	effect	Drug_0	Drug_2
10000347	effect	Drug_0	Drug_3

10000348|t|Drug-drug interactions have not been observed between Argatroban and digoxin or erythromycin.
10000348	54	64	Argatroban	drug	Drug_0
10000348	69	76	digoxin	drug	Drug_1
10000348	80	92	erythromycin	drug	Drug_2

10000349|t|Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.
10000349	56	68	aripiprazole	drug	Drug_0
10000349	98	105	ABILIFY	brand	Drug_1
10000349	141	163	centrally acting drugs	group	Drug_2
10000349	168	175	alcohol	drug	Drug_3
10000349	advise	Drug_1	Drug_3
10000349	advise	Drug_1	Drug_2

10000350|t|1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.
10000350	35	47	aripiprazole	drug	Drug_0
10000350	99	122	antihypertensive agents	group	Drug_1
10000350	effect	Drug_0	Drug_1

10000351|t|Potential for Other Drugs to Affect ABILIFY Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes.
10000351	36	43	ABILIFY	brand	Drug_0
10000351	44	56	Aripiprazole	brand	Drug_1

10000352|t|Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.
10000352	31	44	carbamazepine	drug	Drug_0
10000352	73	85	aripiprazole	drug	Drug_1
10000352	mechanism	Drug_0	Drug_1

10000353|t|Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
10000353	26	38	ketoconazole	drug	Drug_0
10000353	55	64	quinidine	drug	Drug_1
10000353	66	76	fluoxetine	drug	Drug_2
10000353	81	91	paroxetine	drug	Drug_3
10000353	105	117	aripiprazole	drug	Drug_4
10000353	mechanism	Drug_0	Drug_4
10000353	mechanism	Drug_3	Drug_4
10000353	mechanism	Drug_1	Drug_4
10000353	mechanism	Drug_2	Drug_4

10000354|t|Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.
10000354	34	46	ketoconazole	drug	Drug_0
10000354	134	146	aripiprazole	drug	Drug_1
10000354	mechanism	Drug_0	Drug_1

10000355|t|When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.
10000355	35	47	ketoconazole	drug	Drug_0
10000355	74	86	aripiprazole	drug	Drug_1
10000355	advise	Drug_0	Drug_1

10000356|t|Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.
10000356	72	81	quinidine	drug	Drug_0
10000356	159	171	aripiprazole	drug	Drug_1
10000356	228	247	dehydroaripiprazole	drug_n	Drug_2
10000356	mechanism	Drug_1	Drug_0

10000357|t|Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.
10000357	117	129	aripiprazole	drug	Drug_0
10000357	102	111	quinidine	drug	Drug_1
10000357	advise	Drug_1	Drug_0

10000358|t|Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions.
10000358	48	58	fluoxetine	drug	Drug_0
10000358	62	72	paroxetine	drug	Drug_1

10000359|t|Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.
10000359	35	48	carbamazepine	drug	Drug_0
10000359	188	200	aripiprazole	drug	Drug_1
10000359	228	248	dehydro-aripiprazole	drug_n	Drug_2
10000359	mechanism	Drug_0	Drug_1

10000360|t|When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.
10000360	5	18	carbamazepine	drug	Drug_0
10000360	53	65	aripiprazole	drug	Drug_1
10000360	advise	Drug_0	Drug_1

10000361|t|When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.
10000361	5	18	carbamazepine	drug	Drug_0
10000361	62	74	aripiprazole	drug	Drug_1
10000361	advise	Drug_0	Drug_1

10000362|t|No clinically significant effect of famotidine, valproate, or lithium was seen on the pharmacokinetics of aripiprazole (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions).
10000362	36	46	famotidine	drug	Drug_0
10000362	48	57	valproate	drug	Drug_1
10000362	62	69	lithium	drug	Drug_2
10000362	106	118	aripiprazole	drug	Drug_3

10000363|t|Potential for ABILIFY to Affect Other Drugs Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes.
10000363	14	21	ABILIFY	brand	Drug_0
10000363	44	56	Aripiprazole	drug	Drug_1

10000364|t|In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.
10000364	46	58	aripiprazole	drug	Drug_0
10000364	192	208	dextromethorphan	drug	Drug_1
10000364	169	177	warfarin	drug	Drug_2
10000364	157	167	omeprazole	drug	Drug_3

10000365|t|Additionally, aripiprazole and dehydroaripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
10000365	14	26	aripiprazole	drug	Drug_0
10000365	31	50	dehydroaripiprazole	drug_n	Drug_1

10000366|t|Alcohol: There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects.
10000366	0	7	Alcohol	drug	Drug_0
10000366	53	65	aripiprazole	drug	Drug_1
10000366	126	133	ethanol	drug	Drug_2

10000367|t|As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY
10000367	75	82	alcohol	drug	Drug_0
10000367	96	103	ABILIFY	brand	Drug_1
10000367	advise	Drug_0	Drug_1

10000368|t|Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).
10000368	24	32	TRISENOX	brand	Drug_0
10000368	121	136	antiarrhythmics	group	Drug_1
10000368	140	152	thioridazine	drug	Drug_2
10000368	200	209	diuretics	group	Drug_3
10000368	213	227	amphotericin B	drug	Drug_4
10000368	advise	Drug_0	Drug_4
10000368	advise	Drug_0	Drug_2
10000368	advise	Drug_0	Drug_1
10000368	advise	Drug_0	Drug_3

10000369|t|Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.
10000369	48	54	ELSPAR	brand	Drug_0
10000369	143	155	methotrexate	drug	Drug_1
10000369	effect	Drug_0	Drug_1

10000370|t|These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.
10000370	64	76	methotrexate	drug	Drug_0
10000370	121	127	ELSPAR	brand	Drug_1
10000370	advise	Drug_0	Drug_1

10000371|t|Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.
10000371	0	17	Uricosuric Agents	group	Drug_0
10000371	19	26	Aspirin	brand	Drug_1
10000371	55	65	probenecid	drug	Drug_2
10000371	67	81	sulfinpyrazone	drug	Drug_3
10000371	87	101	phenylbutazone	drug	Drug_4
10000371	effect	Drug_1	Drug_4
10000371	effect	Drug_1	Drug_2
10000371	effect	Drug_1	Drug_3

10000372|t|Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.
10000372	0	7	Alcohol	drug	Drug_0
10000372	39	46	aspirin	brand	Drug_1
10000372	effect	Drug_0	Drug_1

10000373|t|Corticosteroids: Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.
10000373	0	15	Corticosteroids	group	Drug_0
10000373	49	56	aspirin	brand	Drug_1
10000373	effect	Drug_0	Drug_1

10000374|t|Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
10000374	0	22	Pyrazolone Derivatives	group	Drug_0
10000374	24	38	phenylbutazone	drug	Drug_1
10000374	40	55	oxyphenbutazone	drug	Drug_2
10000374	70	78	dipyrone	drug	Drug_3
10000374	113	120	aspirin	drug	Drug_4
10000374	effect	Drug_3	Drug_4
10000374	effect	Drug_0	Drug_4
10000374	effect	Drug_1	Drug_4
10000374	effect	Drug_2	Drug_4

10000375|t|Nonsteroidal Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.
10000375	0	29	Nonsteroidal Antiinflammatory	drug	Drug_0
10000375	38	45	Aspirin	drug	Drug_1
10000375	103	133	nonsteroidal anti-inflammatory	drug	Drug_2
10000375	advise	Drug_1	Drug_2

10000376|t|Urinary Alkalinizers: Decrease aspirin effectiveness by increasing the rate of salicylate renal excretion.
10000376	31	38	aspirin	brand	Drug_0
10000376	79	89	salicylate	group	Drug_1

10000377|t|Phenobarbital: Decreases aspirin effectiveness by enzyme induction.
10000377	0	13	Phenobarbital	drug	Drug_0
10000377	25	32	aspirin	brand	Drug_1
10000377	mechanism	Drug_0	Drug_1

10000378|t|Phenytoin: Serum phenytoin levels may be increased by aspirin.
10000378	17	26	phenytoin	drug	Drug_0
10000378	54	61	aspirin	brand	Drug_1
10000378	effect	Drug_0	Drug_1

10000379|t|Propranolol: May decrease aspirins anti-inflammatory action by competing for the same receptors.
10000379	0	11	Propranolol	drug	Drug_0
10000379	26	34	aspirins	brand	Drug_1
10000379	effect	Drug_0	Drug_1

10000380|t|Antacids: Enteric Coated Aspirin should not be given concurrently with antacids, since an increase in the pH of the stomach may effect the enteric coating of the tablets.
10000380	71	79	antacids	group	Drug_0
10000380	25	32	Aspirin	brand	Drug_1
10000380	advise	Drug_1	Drug_0

10000381|t|Ketoconazole/Itraconazole, Macrolides, Including Erythromycin
10000381	0	12	Ketoconazole	drug	Drug_0
10000381	13	25	Itraconazole	drug	Drug_1
10000381	27	37	Macrolides	group	Drug_2
10000381	49	61	Erythromycin	drug	Drug_3

10000382|t|Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents.
10000382	35	44	reserpine	drug	Drug_0
10000382	90	109	beta-blocking agent	group	Drug_1
10000382	effect	Drug_0	Drug_1

10000383|t|Calcium channel blockers may also have an additive effect when given with TENORMIN .
10000383	0	24	Calcium channel blockers	group	Drug_0
10000383	74	82	TENORMIN	brand	Drug_1
10000383	effect	Drug_0	Drug_1

10000384|t|Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.
10000384	0	13	Beta blockers	group	Drug_0
10000384	89	98	clonidine	drug	Drug_1
10000384	effect	Drug_0	Drug_1

10000385|t|If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine.
10000385	41	53	beta blocker	group	Drug_0
10000385	120	129	clonidine	drug	Drug_1
10000385	advise	Drug_0	Drug_1

10000386|t|If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.
10000386	123	132	clonidine	drug	Drug_0
10000386	26	38	beta-blocker	group	Drug_1
10000386	68	81	beta blockers	group	Drug_2
10000386	advise	Drug_2	Drug_0

10000387|t|Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.
10000387	64	76	indomethacin	drug	Drug_0
10000387	118	131	beta blockers	group	Drug_1
10000387	effect	Drug_0	Drug_1

10000388|t|Information on concurrent usage of atenolol and aspirin is limited.
10000388	35	43	atenolol	drug	Drug_0
10000388	48	55	aspirin	brand	Drug_1

10000389|t|Data from several studies, ie, TIMI-II, ISIS-2, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting.
10000389	106	113	aspirin	brand	Drug_0
10000389	118	131	beta blockers	group	Drug_1

10000390|t|Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
10000390	218	227	albuterol	drug	Drug_0
10000390	35	44	STRATTERA	brand	Drug_1
10000390	180	194	beta2 agonists	group	Drug_2
10000390	advise	Drug_1	Drug_0

10000391|t|CYP2D6 inhibitors - Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine.
10000391	20	31	Atomoxetine	drug	Drug_0
10000391	82	102	4-hydroxyatomoxetine	drug_n	Drug_1

10000392|t|Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.
10000392	21	30	STRATTERA	brand	Drug_0
10000392	98	108	paroxetine	drug	Drug_1
10000392	110	120	fluoxetine	drug	Drug_2
10000392	126	135	quinidine	drug	Drug_3
10000392	advise	Drug_0	Drug_1
10000392	advise	Drug_0	Drug_3
10000392	advise	Drug_0	Drug_2

10000393|t|In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.
10000393	31	41	paroxetine	drug	Drug_0
10000393	45	55	fluoxetine	drug	Drug_1
10000393	157	168	atomoxetine	drug	Drug_2
10000393	mechanism	Drug_0	Drug_2
10000393	mechanism	Drug_1	Drug_2

10000394|t|The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (nicotinic acid), erythromycin, azole antifungals.
10000394	110	122	cyclosporine	drug	Drug_0
10000394	124	147	fibric acid derivatives	group	Drug_1
10000394	149	155	niacin	drug	Drug_2
10000394	157	171	nicotinic acid	drug	Drug_3
10000394	174	186	erythromycin	drug	Drug_4
10000394	188	205	azole antifungals	group	Drug_5

10000395|t|Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.
10000395	0	7	Antacid	group	Drug_0
10000395	98	110	atorvastatin	drug	Drug_1
10000395	31	40	Maalox TC	brand	Drug_2
10000395	mechanism	Drug_1	Drug_2

10000396|t|Antipyrine: Because atorvastatin does not affect the pharmacokinetics of antipyrine, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.
10000396	73	83	antipyrine	drug	Drug_0
10000396	20	32	atorvastatin	drug	Drug_1
10000396	109	114	drugs	drug	Drug_2

10000397|t|Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered.
10000397	83	93	colestipol	drug	Drug_0
10000397	98	110	atorvastatin	drug	Drug_1
10000397	mechanism	Drug_0	Drug_1

10000398|t|However, LDL-C reduction was greater when atorvastatin and colestipol were coadministered than when either drug was given alone.
10000398	42	54	atorvastatin	drug	Drug_0
10000398	59	69	colestipol	drug	Drug_1
10000398	effect	Drug_0	Drug_1

10000399|t|Cimetidine: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.
10000399	107	117	cimetidine	drug	Drug_0
10000399	12	24	Atorvastatin	drug	Drug_1

10000400|t|Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.
10000400	98	105	digoxin	drug	Drug_0
10000400	32	44	atorvastatin	drug	Drug_1
10000400	mechanism	Drug_1	Drug_0

10000401|t|Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.
10000401	146	158	erythromycin	drug	Drug_0
10000401	129	141	atorvastatin	drug	Drug_1
10000401	mechanism	Drug_1	Drug_0

10000402|t|Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.
10000402	5	19	Contraceptives	group	Drug_0
10000402	41	53	atorvastatin	drug	Drug_1
10000402	66	79	contraceptive	group	Drug_2
10000402	105	118	norethindrone	drug	Drug_3
10000402	123	140	ethinyl estradiol	drug	Drug_4
10000402	mechanism	Drug_1	Drug_3
10000402	mechanism	Drug_1	Drug_4
10000402	mechanism	Drug_1	Drug_2

10000403|t|These increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin.
10000403	60	73	contraceptive	group	Drug_0
10000403	93	105	atorvastatin	drug	Drug_1
10000403	advise	Drug_0	Drug_1

10000404|t|Warfarin: Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.
10000404	128	136	warfarin	drug	Drug_0
10000404	10	22	Atorvastatin	drug	Drug_1

10000405|t|Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.
10000405	34	61	HMG-CoA reductase inhibitor	group	Drug_0
10000405	184	196	ketoconazole	drug	Drug_1
10000405	198	212	spironolactone	drug	Drug_2
10000405	218	228	cimetidine	drug	Drug_3
10000405	advise	Drug_0	Drug_3
10000405	advise	Drug_0	Drug_2
10000405	advise	Drug_0	Drug_1

10000406|t|The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of phenytoin affected by the presence of atovaquone.
10000406	216	226	atovaquone	drug	Drug_0
10000406	178	187	phenytoin	drug	Drug_1

10000407|t|Rifampin: Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.
10000407	30	38	rifampin	drug	Drug_0
10000407	43	49	MEPRON	brand	Drug_1
10000407	127	137	atovaquone	drug	Drug_2
10000407	mechanism	Drug_0	Drug_1

10000408|t|Alternatives to rifampin should be considered during the course of PCP treatment with MEPRON.
10000408	16	24	rifampin	drug	Drug_0
10000408	86	92	MEPRON	brand	Drug_1
10000408	advise	Drug_0	Drug_1

10000409|t|Rifabutin, another rifamycin, is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin.
10000409	0	9	Rifabutin	drug	Drug_0
10000409	19	28	rifamycin	drug	Drug_1
10000409	126	134	rifampin	drug	Drug_2

10000410|t|No interaction trials have been conducted with MEPRON and rifabutin.
10000410	47	53	MEPRON	brand	Drug_0
10000410	58	67	rifabutin	drug	Drug_1

10000411|t|Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;
10000411	61	69	TRACRIUM	brand	Drug_0
10000411	79	88	enflurane	drug	Drug_1
10000411	effect	Drug_0	Drug_1

10000412|t|certain antibiotics, especially the aminoglycosides and polymyxins;
10000412	8	19	antibiotics	group	Drug_0
10000412	36	51	aminoglycosides	group	Drug_1
10000412	56	66	polymyxins	group	Drug_2

10000413|t|Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
10000413	61	69	TRACRIUM	brand	Drug_0
10000413	79	88	enflurane	drug	Drug_1
10000413	89	99	isoflurane	drug	Drug_2
10000413	100	109	halothane	drug	Drug_3
10000413	118	129	antibiotics	group	Drug_4
10000413	146	161	aminoglycosides	group	Drug_5
10000413	166	176	polymyxins	group	Drug_6
10000413	177	184	lithium	drug	Drug_7
10000413	185	194	magnesium	drug	Drug_8
10000413	201	213	procainamide	drug	Drug_9
10000413	218	227	quinidine	drug	Drug_10
10000413	effect	Drug_0	Drug_4
10000413	effect	Drug_0	Drug_7
10000413	effect	Drug_0	Drug_5
10000413	effect	Drug_0	Drug_1
10000413	effect	Drug_0	Drug_6
10000413	effect	Drug_0	Drug_3
10000413	effect	Drug_0	Drug_8
10000413	effect	Drug_0	Drug_9
10000413	effect	Drug_0	Drug_2
10000413	effect	Drug_0	Drug_10

10000414|t|The prior administration of succinylcholine does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by TRACRIUM.
10000414	28	43	succinylcholine	drug	Drug_0
10000414	160	168	TRACRIUM	brand	Drug_1
10000414	effect	Drug_0	Drug_1

10000415|t|TRACRIUM should not be administered until a patient has recovered from succinylcholine-induced neuromuscular block.
10000415	0	8	TRACRIUM	brand	Drug_0
10000415	71	86	succinylcholine	drug	Drug_1
10000415	advise	Drug_0	Drug_1

10000416|t|When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.
10000416	266	274	atropine	drug	Drug_0
10000416	225	236	pralidoxime	drug	Drug_1
10000416	effect	Drug_0	Drug_1
10000416	effect	Drug_1	Drug_0

10000417|t|The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.
10000417	147	155	atropine	drug	Drug_0
10000417	160	171	pralidoxime	drug	Drug_1
10000417	advise	Drug_0	Drug_1

10000418|t|Since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions.
10000418	6	18	barbiturates	group	Drug_0
10000418	42	61	anticholinesterases	group	Drug_1
10000418	advise	Drug_0	Drug_1

10000419|t|Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including Solganal and Myochrysine.
10000419	0	9	Auranofin	drug	Drug_0
10000419	82	97	gold medication	group	Drug_1
10000419	109	117	Solganal	brand	Drug_2
10000419	122	133	Myochrysine	brand	Drug_3
10000419	advise	Drug_0	Drug_2
10000419	advise	Drug_0	Drug_1
10000419	advise	Drug_0	Drug_3

10000420|t|Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.
10000420	0	9	Auranofin	drug	Drug_0
10000420	43	56	penicillamine	drug	Drug_1
10000420	58	63	Depen	brand	Drug_2
10000420	65	74	Cuprimine	brand	Drug_3
10000420	advise	Drug_0	Drug_2
10000420	advise	Drug_0	Drug_1
10000420	advise	Drug_0	Drug_3

10000421|t|MAO inhibitors prolong and intensify the effects of antihistamines.
10000421	0	14	MAO inhibitors	group	Drug_0
10000421	52	66	antihistamines	group	Drug_1
10000421	effect	Drug_0	Drug_1

10000422|t|Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.
10000422	19	33	antihistamines	group	Drug_0
10000422	39	46	alcohol	drug	Drug_1
10000422	48	73	tricyclic antidepressants	group	Drug_2
10000422	75	87	barbiturates	group	Drug_3
10000422	98	132	central nervous system depressants	group	Drug_4
10000422	effect	Drug_0	Drug_1
10000422	effect	Drug_0	Drug_2
10000422	effect	Drug_0	Drug_3
10000422	effect	Drug_0	Drug_4

10000423|t|When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur.
10000423	5	26	sympathomimetic drugs	group	Drug_0
10000423	59	87	monoamine oxidase inhibitors	group	Drug_1
10000423	effect	Drug_0	Drug_1

10000424|t|The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.
10000424	32	42	methyldopa	drug	Drug_0
10000424	44	56	mecamylamine	drug	Drug_1
10000424	58	67	reserpine	drug	Drug_2
10000424	73	91	veratrum alkaloids	drug	Drug_3
10000424	110	126	sympathomimetics	group	Drug_4
10000424	effect	Drug_0	Drug_4
10000424	effect	Drug_2	Drug_4
10000424	effect	Drug_1	Drug_4
10000424	effect	Drug_3	Drug_4

10000425|t|Beta-adrenergic blocking agents may also interact with sympathomimetics.
10000425	0	31	Beta-adrenergic blocking agents	group	Drug_0
10000425	55	71	sympathomimetics	group	Drug_1
10000425	int	Drug_0	Drug_1

10000426|t|Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis.
10000426	52	67	pseudoephedrine	drug	Drug_0
10000426	95	104	digitalis	group	Drug_1
10000426	effect	Drug_0	Drug_1

10000427|t|Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.
10000427	0	8	Antacids	group	Drug_0
10000427	44	59	pseudoephedrine	drug	Drug_1
10000427	67	73	kaolin	drug	Drug_2
10000427	mechanism	Drug_0	Drug_1
10000427	mechanism	Drug_1	Drug_2

10000428|t|Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.
10000428	95	106	allopurinol	drug	Drug_0
10000428	66	78	azathioprine	drug	Drug_1
10000428	mechanism	Drug_1	Drug_0

10000429|t|Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.
10000429	94	106	azathioprine	drug	Drug_0
10000429	36	47	allopurinol	drug	Drug_1
10000429	advise	Drug_0	Drug_1

10000430|t|Use with Angiotensln Converting Enzyme Inhibitors: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.
10000430	9	49	Angiotensln Converting Enzyme Inhibitors	group	Drug_0
10000430	62	102	angiotensin converting enzyme inhibitors	group	Drug_1
10000430	142	154	azathioprine	drug	Drug_2
10000430	effect	Drug_1	Drug_2

10000431|t|Co-administration of nelfinavir at steady-state with a single dose of azithromycin.
10000431	21	31	nelfinavir	drug	Drug_0
10000431	70	82	azithromycin	drug	Drug_1

10000432|t|Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.
10000432	21	31	nelfinavir	drug	Drug_0
10000432	125	137	azithromycin	drug	Drug_1
10000432	effect	Drug_0	Drug_1

10000433|t|Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.
10000433	155	167	azithromycin	drug	Drug_0
10000433	100	110	nelfinavir	drug	Drug_1
10000433	advise	Drug_0	Drug_1

10000434|t|Azithromycin did not affect the prothrombin time response to a single dose of warfarin.
10000434	0	12	Azithromycin	drug	Drug_0
10000434	78	86	warfarin	drug	Drug_1

10000435|t|However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.
10000435	111	123	azithromycin	drug	Drug_0
10000435	128	136	warfarin	drug	Drug_1
10000435	advise	Drug_0	Drug_1

10000436|t|Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.
10000436	18	28	macrolides	group	Drug_0
10000436	33	41	warfarin	drug	Drug_1
10000436	effect	Drug_0	Drug_1

10000437|t|When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
10000437	32	44	azithromycin	drug	Drug_0
10000437	92	104	atorvastatin	drug	Drug_1
10000437	106	119	carbamazepine	drug	Drug_2
10000437	121	131	cetirizine	drug	Drug_3
10000437	133	143	didanosine	drug	Drug_4
10000437	145	154	efavirenz	drug	Drug_5
10000437	156	167	fluconazole	drug	Drug_6
10000437	169	178	indinavir	drug	Drug_7
10000437	180	189	midazolam	drug	Drug_8
10000437	191	200	rifabutin	drug	Drug_9
10000437	202	212	sildenafil	drug	Drug_10
10000437	214	226	theophylline	drug	Drug_11
10000437	251	260	triazolam	drug	Drug_12
10000437	262	274	trimethoprim	drug	Drug_13
10000437	275	291	sulfamethoxazole	drug	Drug_14
10000437	295	305	zidovudine	drug	Drug_15
10000437	mechanism	Drug_0	Drug_11
10000437	mechanism	Drug_0	Drug_6
10000437	mechanism	Drug_0	Drug_9
10000437	mechanism	Drug_0	Drug_4
10000437	mechanism	Drug_0	Drug_2
10000437	mechanism	Drug_0	Drug_5
10000437	mechanism	Drug_0	Drug_10
10000437	mechanism	Drug_0	Drug_15
10000437	mechanism	Drug_0	Drug_7
10000437	mechanism	Drug_0	Drug_8
10000437	mechanism	Drug_0	Drug_12
10000437	mechanism	Drug_0	Drug_13
10000437	mechanism	Drug_0	Drug_1
10000437	mechanism	Drug_0	Drug_14
10000437	mechanism	Drug_0	Drug_3

10000438|t|Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.
10000438	23	32	efavirenz	drug	Drug_0
10000438	36	47	fluconazole	drug	Drug_1
10000438	95	107	azithromycin	drug	Drug_2
10000438	mechanism	Drug_1	Drug_2
10000438	mechanism	Drug_0	Drug_2

10000439|t|Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin elevated digoxin concentrations.
10000439	66	78	azithromycin	drug	Drug_0
10000439	179	186	digoxin	drug	Drug_1

10000440|t|Ergotamine or dihydroergotamine acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
10000440	0	10	Ergotamine	drug	Drug_0
10000440	14	31	dihydroergotamine	drug	Drug_1

10000441|t|Cyclosporine, hexobarbital and phenytoin concentrations.
10000441	0	12	Cyclosporine	drug	Drug_0
10000441	14	26	hexobarbital	drug	Drug_1
10000441	31	40	phenytoin	drug	Drug_2

10000442|t|Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.
10000442	0	10	Azlocillin	drug	Drug_0
10000442	57	65	amikacin	drug	Drug_1
10000442	67	80	ciprofloxacin	drug	Drug_2
10000442	82	92	gentamicin	drug	Drug_3
10000442	94	104	netilmicin	drug	Drug_4
10000442	109	119	tobramycin	drug	Drug_5
10000442	advise	Drug_0	Drug_1
10000442	advise	Drug_0	Drug_4
10000442	advise	Drug_0	Drug_5
10000442	advise	Drug_0	Drug_3
10000442	advise	Drug_0	Drug_2

10000443|t|Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.
10000443	47	55	baclofen	drug	Drug_0
10000443	79	87	morphine	drug	Drug_1
10000443	effect	Drug_0	Drug_1

10000444|t|SIDE EFFECTS (KEMSTRO) The most common adverse reaction during treatment with baclofen is transient drowsiness (10-63%).
10000444	14	21	KEMSTRO	brand	Drug_0
10000444	78	86	baclofen	drug	Drug_1

10000445|t|The adverse experience profile seen with KEMSTROTM was similar to that seen with baclofen tablets.
10000445	41	50	KEMSTROTM	brand	Drug_0
10000445	81	89	baclofen	drug	Drug_1

10000446|t|No drug interaction studies have been conducted for COLAZAL, however the use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon.
10000446	52	59	COLAZAL	brand	Drug_0
10000446	100	111	antibiotics	group	Drug_1
10000446	164	174	mesalamine	drug	Drug_2

10000447|t|No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil.
10000447	37	45	Simulect	brand	Drug_0
10000447	102	114	cyclosporine	drug	Drug_1
10000447	116	131	corticosteroids	group	Drug_2
10000447	144	156	azathioprine	drug	Drug_3
10000447	160	181	mycophenolate mofetil	drug	Drug_4

10000448|t|Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.
10000448	24	32	Simulect	brand	Drug_0
10000448	76	88	azathioprine	drug	Drug_1
10000448	93	114	mycophenolate mofetil	drug	Drug_2
10000448	168	180	cyclosporine	drug	Drug_3
10000448	201	216	corticosteroids	group	Drug_4
10000448	mechanism	Drug_0	Drug_1
10000448	mechanism	Drug_0	Drug_2

10000449|t|Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h).
10000449	37	45	Simulect	brand	Drug_0
10000449	82	94	azathioprine	drug	Drug_1
10000449	111	132	mycophenolate mofetil	drug	Drug_2

10000450|t|The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromonab-CD3.
10000450	73	81	Simulect	brand	Drug_0
10000450	130	142	azathioprine	drug	Drug_1
10000450	144	159	corticosteroids	group	Drug_2
10000450	161	173	cyclosporine	drug	Drug_3
10000450	175	196	mycophenolate mofetil	drug	Drug_4
10000450	202	215	muromonab-CD3	drug	Drug_5

10000451|t|Albuterol, Antihistamines, antidiabetic drugs, diuretics, digitalis.
10000451	0	9	Albuterol	drug	Drug_0
10000451	11	25	Antihistamines	group	Drug_1
10000451	27	45	antidiabetic drugs	group	Drug_2
10000451	47	56	diuretics	group	Drug_3
10000451	58	67	digitalis	group	Drug_4

10000452|t|Diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin.
10000452	23	32	diuretics	group	Drug_0
10000452	203	211	Lotensin	brand	Drug_1
10000452	effect	Drug_0	Drug_1

10000453|t|The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.
10000453	175	183	Lotensin	brand	Drug_0
10000453	98	106	diuretic	group	Drug_1
10000453	advise	Drug_1	Drug_0

10000454|t|Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics.
10000454	0	9	Potassium	drug	Drug_0
10000454	26	53	Potassium-Sparing Diuretics	group	Drug_1
10000454	102	120	thiazide diuretics	group	Drug_2
10000454	effect	Drug_1	Drug_2

10000455|t|Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.
10000455	0	27	Potassium-sparing diuretics	group	Drug_0
10000455	29	43	spironolactone	drug	Drug_1
10000455	45	54	amiloride	drug	Drug_2
10000455	56	67	triamterene	drug	Drug_3
10000455	84	93	potassium	drug	Drug_4

10000456|t|Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.
10000456	181	195	anticoagulants	group	Drug_0
10000456	45	53	warfarin	drug	Drug_1
10000456	58	71	acenocoumarol	drug	Drug_2

10000457|t|Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
10000457	149	156	lithium	drug	Drug_0
10000457	114	128	ACE inhibitors	group	Drug_1
10000457	mechanism	Drug_1	Drug_0

10000458|t|If a diuretic is also used, the risk of lithium toxicity may be increased.
10000458	5	13	diuretic	group	Drug_0
10000458	40	47	lithium	drug	Drug_1
10000458	effect	Drug_0	Drug_1

10000459|t|Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide, chlorthalidone, furosemide, digoxin, propranolol, atenolol, naproxen, or cimetidine.
10000459	73	81	Lotensin	brand	Drug_0
10000459	118	137	hydrochlorothiazide	drug	Drug_1
10000459	139	153	chlorthalidone	drug	Drug_2
10000459	155	165	furosemide	drug	Drug_3
10000459	167	174	digoxin	drug	Drug_4
10000459	176	187	propranolol	drug	Drug_5
10000459	189	197	atenolol	drug	Drug_6
10000459	199	207	naproxen	drug	Drug_7
10000459	212	222	cimetidine	drug	Drug_8

10000460|t|Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.
10000460	0	8	Lotensin	brand	Drug_0
10000460	42	73	beta-adrenergic-blocking agents	group	Drug_1
10000460	75	106	calcium-channel-blocking agents	group	Drug_2
10000460	108	117	diuretics	group	Drug_3
10000460	119	126	digoxin	drug	Drug_4
10000460	132	143	hydralazine	drug	Drug_5

10000461|t|Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
10000461	0	10	Benazepril	drug	Drug_0
10000461	23	37	ACE inhibitors	group	Drug_1
10000461	79	103	beta-adrenergic blockers	group	Drug_2
10000461	effect	Drug_1	Drug_2
10000461	effect	Drug_0	Drug_2

10000462|t|May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;
10000462	33	47	cholestyramine	drug	Drug_0
10000462	49	59	colestipol	drug	Drug_1
10000462	70	88	thiazide diuretics	group	Drug_2
10000462	105	113	diuretic	group	Drug_3
10000462	effect	Drug_0	Drug_2
10000462	effect	Drug_1	Drug_2

10000463|t|Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
10000463	0	11	Bentiromide	drug	Drug_0
10000463	30	43	acetaminophen	drug	Drug_1
10000463	51	58	Tylenol	brand	Drug_2
10000463	61	76	chloramphenicol	drug	Drug_3
10000463	84	97	Chloromycetin	brand	Drug_4
10000463	106	117	anesthetics	group	Drug_5
10000463	125	135	benzocaine	drug	Drug_6
10000463	140	149	lidocaine	drug	Drug_7
10000463	152	174	para-aminobenzoic acid	drug_n	Drug_8
10000463	176	180	PABA	drug_n	Drug_9
10000463	233	246	multivitamins	group	Drug_10
10000463	249	261	procainamide	drug	Drug_11
10000463	269	278	Pronestyl	brand	Drug_12
10000463	281	293	sulfonamides	group	Drug_13
10000463	313	331	thiazide diuretics	group	Drug_14
10000463	int	Drug_0	Drug_2
10000463	int	Drug_0	Drug_10
10000463	int	Drug_0	Drug_4
10000463	int	Drug_0	Drug_8
10000463	int	Drug_0	Drug_3
10000463	int	Drug_0	Drug_14
10000463	int	Drug_0	Drug_11
10000463	int	Drug_0	Drug_7
10000463	int	Drug_0	Drug_1
10000463	int	Drug_0	Drug_9
10000463	int	Drug_0	Drug_13
10000463	int	Drug_0	Drug_12
10000463	int	Drug_0	Drug_5
10000463	int	Drug_0	Drug_6

10000464|t|Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors.
10000464	39	61	sympathomimetic amines	group	Drug_0
10000464	122	150	monoamine oxidase inhibitors	group	Drug_1
10000464	effect	Drug_0	Drug_1

10000465|t|DIDREX should not be used concomitantly with other CNS stimulants.
10000465	0	6	DIDREX	brand	Drug_0
10000465	51	65	CNS stimulants	group	Drug_1
10000465	advise	Drug_0	Drug_1

10000466|t|Amphetamines may decrease the hypotensive effect of antihypertensives.
10000466	0	12	Amphetamines	group	Drug_0
10000466	52	69	antihypertensives	group	Drug_1
10000466	effect	Drug_0	Drug_1

10000467|t|Amphetamines may enhance the effects of tricyclic antidepressants.
10000467	0	12	Amphetamines	group	Drug_0
10000467	40	65	tricyclic antidepressants	group	Drug_1
10000467	effect	Drug_0	Drug_1

10000468|t|Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.
10000468	0	18	Urinary acidifying	drug	Drug_0
10000468	74	86	amphetamines	group	Drug_1
10000468	mechanism	Drug_0	Drug_1

10000469|t|Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
10000469	0	12	Benzthiazide	drug	Drug_0
10000469	31	38	alcohol	drug	Drug_1
10000469	40	53	blood thinner	group	Drug_2
10000469	56	74	decongestant drugs	group	Drug_3
10000469	129	136	lithium	drug	Drug_4
10000469	138	152	norepinephrine	drug	Drug_5
10000469	154	160	NSAIDs	group	Drug_6
10000469	166	171	Aleve	brand	Drug_7
10000469	175	184	Ibuprofen	drug	Drug_8
10000469	int	Drug_0	Drug_6
10000469	int	Drug_0	Drug_8
10000469	int	Drug_0	Drug_7
10000469	int	Drug_0	Drug_2
10000469	int	Drug_0	Drug_3
10000469	int	Drug_0	Drug_4
10000469	int	Drug_0	Drug_5
10000469	int	Drug_0	Drug_1

10000470|t|Antipsychotic drugs such as phenothiazines or haloperidol;
10000470	0	19	Antipsychotic drugs	group	Drug_0
10000470	28	42	phenothiazines	group	Drug_1
10000470	46	57	haloperidol	drug	Drug_2

10000471|t|Nitrates: The concomitant use of Bepridil with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris.
10000471	70	78	nitrates	group	Drug_0
10000471	33	41	Bepridil	drug	Drug_1

10000472|t|Sublingual nitroglycerin may be taken if necessary for the control of acute angina attacks during Bepridil therapy.
10000472	11	24	nitroglycerin	drug	Drug_0
10000472	98	106	Bepridil	drug	Drug_1

10000473|t|Beta-blocking Agents: The concomitant use of Bepridil and beta-blocking agents has been well tolerated in patients with stable angina.
10000473	58	78	beta-blocking agents	group	Drug_0
10000473	45	53	Bepridil	drug	Drug_1

10000474|t|Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.
10000474	197	204	digoxin	drug	Drug_0
10000474	54	76	bepridil hydrochloride	drug	Drug_1
10000474	mechanism	Drug_1	Drug_0

10000475|t|Limited clinical data in angina patients receiving concomitant bepridil hydrochloride and digoxin therapy indicate no discernible changes in serum digoxin levels.
10000475	63	85	bepridil hydrochloride	drug	Drug_0
10000475	90	97	digoxin	drug	Drug_1

10000476|t|Oral Hypoglycemics: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral hypoglycemic agents.
10000476	5	18	Hypoglycemics	group	Drug_0
10000476	20	28	Bepridil	drug	Drug_1
10000476	156	163	insulin	drug	Drug_2
10000476	172	191	hypoglycemic agents	group	Drug_3

10000477|t|In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.
10000477	86	108	bepridil hydrochloride	drug	Drug_0
10000477	120	142	anti-arrhythmic agents	group	Drug_1
10000477	151	160	quinidine	drug	Drug_2
10000477	165	177	procainamide	drug	Drug_3
10000477	179	197	cardiac glycosides	group	Drug_4
10000477	202	228	tricyclic anti-depressants	group	Drug_5

10000478|t|Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.
10000478	0	16	Anti-arrhythmics	group	Drug_0
10000478	21	47	tricyclic anti-depressants	group	Drug_1
10000478	115	137	bepridil hydrochloride	drug	Drug_2
10000478	effect	Drug_1	Drug_2
10000478	effect	Drug_0	Drug_2

10000479|t|Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.
10000479	0	18	Cardiac glycosides	group	Drug_0
10000479	88	110	bepridil hydrochloride	drug	Drug_1
10000479	effect	Drug_0	Drug_1

10000480|t|The following drugs have been coadministered with Kerlone and have not altered its pharmacokinetics: cimetidine, nifedipine, chlorthalidone, and hydrochlorothiazide.
10000480	50	57	Kerlone	brand	Drug_0
10000480	101	111	cimetidine	drug	Drug_1
10000480	113	123	nifedipine	drug	Drug_2
10000480	125	139	chlorthalidone	drug	Drug_3
10000480	145	164	hydrochlorothiazide	drug	Drug_4

10000481|t|Concomitant administration of Kerlone with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin.
10000481	30	37	Kerlone	brand	Drug_0
10000481	52	65	anticoagulant	group	Drug_1
10000481	136	144	warfarin	drug	Drug_2

10000482|t|Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.
10000482	37	46	reserpine	drug	Drug_0
10000482	92	105	beta-blocking	drug	Drug_1
10000482	effect	Drug_0	Drug_1

10000483|t|Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.
10000483	66	79	beta-blockers	group	Drug_0
10000483	206	215	clonidine	drug	Drug_1
10000483	112	124	beta-blocker	group	Drug_2
10000483	advise	Drug_0	Drug_1
10000483	advise	Drug_2	Drug_1

10000484|t|Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.
10000484	37	56	calcium antagonists	group	Drug_0
10000484	89	120	beta-adrenergic blocking agents	group	Drug_1
10000484	advise	Drug_0	Drug_1

10000485|t|Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.
10000485	116	147	beta-adrenergic blocking agents	group	Drug_0
10000485	161	179	calcium antagonist	group	Drug_1
10000485	effect	Drug_0	Drug_1

10000486|t|Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem.
10000486	44	62	calcium antagonist	group	Drug_0
10000486	70	96	dihydropyridine derivative	group	Drug_1
10000486	104	114	nifedipine	drug	Drug_2
10000486	249	258	verapamil	drug	Drug_3
10000486	262	271	diltiazem	drug	Drug_4

10000487|t|Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.
10000487	156	169	beta-blockers	group	Drug_0
10000487	104	115	epinephrine	drug	Drug_1
10000487	effect	Drug_0	Drug_1

10000488|t|In Study 1, patients with colorectal cancer were given irinotecan/5-FU/leucovorin (bolus-IFL) with or without AVASTIN.
10000488	55	65	irinotecan	drug	Drug_0
10000488	66	70	5-FU	drug	Drug_1
10000488	71	81	leucovorin	drug	Drug_2
10000488	110	117	AVASTIN	brand	Drug_3

10000489|t|Irinotecan concentrations were similar in patients receiving bolus-IFL alone and in combination with AVASTIN.
10000489	0	10	Irinotecan	drug	Drug_0
10000489	101	108	AVASTIN	brand	Drug_1

10000490|t|The concentrations of SN38, the active metabolite of irinotecan, were on average 33% higher in patients receiving bolus-IFL in combination with AVASTIN when compared with bolus-IFL alone.
10000490	22	26	SN38	drug_n	Drug_0
10000490	53	63	irinotecan	drug	Drug_1
10000490	144	151	AVASTIN	brand	Drug_2

10000491|t|Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain.
10000491	90	94	SN38	drug_n	Drug_0
10000491	135	145	irinotecan	drug	Drug_1
10000491	150	157	AVASTIN	brand	Drug_2

10000492|t|On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
10000492	237	247	bexarotene	drug	Drug_0
10000492	69	81	ketoconazole	drug	Drug_1
10000492	83	95	itraconazole	drug	Drug_2
10000492	97	109	erythromycin	drug	Drug_3
10000492	111	122	gemfibrozil	drug	Drug_4
10000492	mechanism	Drug_2	Drug_0
10000492	mechanism	Drug_1	Drug_0
10000492	mechanism	Drug_3	Drug_0
10000492	mechanism	Drug_4	Drug_0

10000493|t|Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.
10000493	13	21	rifampin	drug	Drug_0
10000493	23	32	phenytoin	drug	Drug_1
10000493	34	47	phenobarbital	drug	Drug_2
10000493	123	133	bexarotene	drug	Drug_3
10000493	mechanism	Drug_1	Drug_3
10000493	mechanism	Drug_2	Drug_3
10000493	mechanism	Drug_0	Drug_3

10000494|t|Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.
10000494	30	39	Targretin	brand	Drug_0
10000494	212	223	gemfibrozil	drug	Drug_1
10000494	127	137	bexarotene	drug	Drug_2
10000494	mechanism	Drug_0	Drug_1

10000495|t|Under similar conditions, bexarotene concentrations were not affected by concomitant atorvastatin administration.
10000495	26	36	bexarotene	drug	Drug_0
10000495	85	97	atorvastatin	drug	Drug_1

10000496|t|Concomitant administration of gemfibrozil with Targretin capsules is not recommended.
10000496	30	41	gemfibrozil	drug	Drug_0
10000496	47	56	Targretin	brand	Drug_1
10000496	advise	Drug_0	Drug_1

10000497|t|When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.
10000497	146	153	Bezalip	brand	Drug_0
10000497	158	172	Bezalip retard	brand	Drug_1
10000497	199	234	anticoagulants of the coumarin type	group	Drug_2
10000497	effect	Drug_0	Drug_2
10000497	effect	Drug_1	Drug_2

10000498|t|For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters
10000498	33	46	anticoagulant	drug	Drug_0
10000498	119	126	Bezalip	brand	Drug_1
10000498	advise	Drug_0	Drug_1
10000498	advise	Drug_0	Drug_1

10000499|t|- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.
10000499	16	30	sulphonylureas	group	Drug_0
10000499	35	42	insulin	drug	Drug_1
10000499	62	69	Bezalip	brand	Drug_2
10000499	73	87	Bezalip retard	brand	Drug_3
10000499	effect	Drug_1	Drug_2
10000499	effect	Drug_1	Drug_3
10000499	effect	Drug_0	Drug_2
10000499	effect	Drug_0	Drug_3

10000500|t|- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate.
10000500	211	229	immuno-suppressant	group	Drug_0
10000500	254	265	bezafibrate	drug	Drug_1
10000500	effect	Drug_0	Drug_1

10000501|t|- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
10000501	209	216	Bezalip	brand	Drug_0
10000501	220	234	Bezalip retard	brand	Drug_1
10000501	59	80	anion-exchange resins	group	Drug_2
10000501	87	102	cholestryramine	drug	Drug_3
10000501	advise	Drug_1	Drug_3
10000501	advise	Drug_1	Drug_2
10000501	advise	Drug_0	Drug_2
10000501	advise	Drug_0	Drug_3

10000502|t|- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.
10000502	2	30	Perhexiline hydrogen maleate	drug	Drug_0
10000502	34	48	MAO-inhibitors	group	Drug_1
10000502	117	124	Bezalip	brand	Drug_2
10000502	128	142	Bezalip retard	brand	Drug_3
10000502	advise	Drug_0	Drug_2
10000502	advise	Drug_0	Drug_3
10000502	advise	Drug_1	Drug_2
10000502	advise	Drug_1	Drug_3

10000503|t|In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.
10000503	28	35	CASODEX	brand	Drug_0
10000503	49	71	coumarin anticoagulant	group	Drug_1
10000503	82	90	warfarin	drug	Drug_2
10000503	mechanism	Drug_0	Drug_1
10000503	mechanism	Drug_0	Drug_2

10000504|t|It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.
10000504	26	33	CASODEX	brand	Drug_0
10000504	75	98	coumarin anticoagulants	group	Drug_1
10000504	168	181	anticoagulant	group	Drug_2
10000504	advise	Drug_0	Drug_2
10000504	advise	Drug_0	Drug_1

10000505|t|Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
10000505	31	46	anticholinergic	group	Drug_0
10000505	102	110	AKINETON	brand	Drug_1
10000505	212	231	narcotic analgesics	group	Drug_2
10000505	240	250	meperidine	drug	Drug_3
10000505	256	270	phenothiazines	group	Drug_4
10000505	281	295	antipsychotics	group	Drug_5
10000505	297	322	tricyclic antidepressants	group	Drug_6
10000505	332	347	antiarrhythmics	group	Drug_7
10000505	360	369	quinidine	drug	Drug_8
10000505	381	395	antihistamines	group	Drug_9
10000505	effect	Drug_0	Drug_3
10000505	effect	Drug_1	Drug_5
10000505	effect	Drug_0	Drug_9
10000505	effect	Drug_1	Drug_7
10000505	effect	Drug_1	Drug_6
10000505	effect	Drug_1	Drug_8
10000505	effect	Drug_0	Drug_8
10000505	effect	Drug_1	Drug_4
10000505	effect	Drug_0	Drug_6
10000505	effect	Drug_0	Drug_5
10000505	effect	Drug_1	Drug_3
10000505	effect	Drug_0	Drug_2
10000505	effect	Drug_1	Drug_9
10000505	effect	Drug_0	Drug_7
10000505	effect	Drug_1	Drug_2
10000505	effect	Drug_0	Drug_4

10000506|t|ZEBETA should not be combined with other beta-blocking agents.
10000506	0	6	ZEBETA	brand	Drug_0
10000506	41	61	beta-blocking agents	group	Drug_1
10000506	advise	Drug_0	Drug_1

10000507|t|Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.
10000507	58	67	reserpine	drug	Drug_0
10000507	71	83	guanethidine	drug	Drug_1
10000507	167	173	ZEBETA	brand	Drug_2
10000507	effect	Drug_1	Drug_2
10000507	effect	Drug_0	Drug_2

10000508|t|In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.
10000508	177	186	clonidine	drug	Drug_0
10000508	112	118	ZEBETA	brand	Drug_1
10000508	advise	Drug_1	Drug_0

10000509|t|ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
10000509	0	6	ZEBETA	brand	Drug_0
10000509	37	59	myocardial depressants	group	Drug_1
10000509	108	127	calcium antagonists	group	Drug_2
10000509	149	165	phenylalkylamine	group	Drug_3
10000509	167	176	verapamil	drug	Drug_4
10000509	182	197	benzothiazepine	group	Drug_5
10000509	199	208	diltiazem	drug	Drug_6
10000509	223	244	antiarrhythmic agents	group	Drug_7
10000509	254	266	disopyramide	drug	Drug_8
10000509	advise	Drug_0	Drug_6
10000509	advise	Drug_0	Drug_5
10000509	advise	Drug_0	Drug_7
10000509	advise	Drug_0	Drug_4
10000509	advise	Drug_0	Drug_8
10000509	advise	Drug_0	Drug_3
10000509	advise	Drug_0	Drug_2
10000509	advise	Drug_0	Drug_1

10000510|t|Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.
10000510	18	26	rifampin	drug	Drug_0
10000510	122	128	ZEBETA	brand	Drug_1
10000510	mechanism	Drug_0	Drug_1

10000511|t|Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics, digoxin, and cimetidine.
10000511	118	136	thiazide diuretics	group	Drug_0
10000511	138	145	digoxin	drug	Drug_1
10000511	151	161	cimetidine	drug	Drug_2

10000512|t|There was no effect of ZEBETA on prothrombin time in patients on stable doses of warfarin.
10000512	23	29	ZEBETA	brand	Drug_0
10000512	81	89	warfarin	drug	Drug_1

10000513|t|If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.
10000513	111	118	steroid	group	Drug_0
10000513	46	56	bitolterol	drug	Drug_1
10000513	advise	Drug_0	Drug_1
10000513	advise	Drug_1	Drug_0

10000514|t|This allows bitolterol to open air passages, increasing the effectiveness of the steroid.
10000514	12	22	bitolterol	drug	Drug_0
10000514	81	88	steroid	group	Drug_1
10000514	effect	Drug_0	Drug_1

10000515|t|In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
10000515	73	81	Angiomax	brand	Drug_0
10000515	87	94	heparin	drug	Drug_1
10000515	96	104	warfarin	drug	Drug_2
10000515	106	119	thrombolytics	group	Drug_3
10000515	effect	Drug_0	Drug_3
10000515	effect	Drug_0	Drug_2
10000515	effect	Drug_0	Drug_1

10000516|t|There is no experience with co-administration of Angiomax and plasma expanders such as dextran.
10000516	49	57	Angiomax	brand	Drug_0
10000516	87	94	dextran	drug	Drug_1

10000517|t|Among 494 subjects who received Angiomax in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive bivalirudin antibody tests.
10000517	32	40	Angiomax	brand	Drug_0
10000517	135	146	bivalirudin	drug	Drug_1

10000518|t|Certain antibiotic, cisplatin, cyclosporine, diuretic, foscarnet, and vaccines.
10000518	8	18	antibiotic	group	Drug_0
10000518	20	29	cisplatin	drug	Drug_1
10000518	31	43	cyclosporine	drug	Drug_2
10000518	45	53	diuretic	group	Drug_3
10000518	55	64	foscarnet	drug	Drug_4
10000518	70	78	vaccines	group	Drug_5

10000519|t|Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.
10000519	17	36	antidiabetic agents	group	Drug_0
10000519	47	54	VELCADE	brand	Drug_1
10000519	160	183	antidiabetic medication	group	Drug_2
10000519	advise	Drug_0	Drug_1

10000520|t|Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.
10000520	0	23	Hormonal Contraceptives	group	Drug_0
10000520	82	96	Contraceptives	group	Drug_1
10000520	158	166	bosentan	drug	Drug_2
10000520	180	202	hormonal contraceptive	group	Drug_3
10000520	203	214	Ortho-Novum	brand	Drug_4
10000520	245	258	norethindrone	drug	Drug_5
10000520	263	280	ethinyl estradiol	drug	Drug_6
10000520	mechanism	Drug_2	Drug_4

10000521|t|Therefore, hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER is co-administered.
10000521	11	34	hormonal contraceptives	group	Drug_0
10000521	125	133	TRACLEER	brand	Drug_1
10000521	effect	Drug_0	Drug_1

10000522|t|Specific interaction studies have demonstrated the following: Cyclosporine A: During the first day of concomitant administration, trough concentrations of bosentan were increased by about 30-fold.
10000522	62	76	Cyclosporine A	drug	Drug_0
10000522	155	163	bosentan	drug	Drug_1

10000523|t|Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A.
10000523	13	21	bosentan	drug	Drug_0
10000523	92	106	cyclosporine A	drug	Drug_1
10000523	mechanism	Drug_0	Drug_1

10000524|t|The concomitant administration of bosentan and cyclosporine A is contraindicated.
10000524	34	42	bosentan	drug	Drug_0
10000524	47	61	cyclosporine A	drug	Drug_1
10000524	advise	Drug_0	Drug_1

10000525|t|Co-administration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A4 substrate) by approximately 50%.
10000525	21	29	bosentan	drug	Drug_0
10000525	69	83	cyclosporine A	drug	Drug_1
10000525	mechanism	Drug_0	Drug_1

10000526|t|Tacrolimus: Co-administration of tacrolimus and bosentan has not been studied in man.
10000526	33	43	tacrolimus	drug	Drug_0
10000526	48	56	bosentan	drug	Drug_1

10000527|t|Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.
10000527	21	31	tacrolimus	drug	Drug_0
10000527	101	109	bosentan	drug	Drug_1
10000527	mechanism	Drug_0	Drug_1

10000528|t|Caution should be exercised if tacrolimus and bosentan are used together.
10000528	31	41	tacrolimus	drug	Drug_0
10000528	46	54	bosentan	drug	Drug_1
10000528	advise	Drug_0	Drug_1

10000529|t|Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.
10000529	45	53	TRACLEER	brand	Drug_0
10000529	58	67	glyburide	drug	Drug_1
10000529	104	123	hypoglycemic agents	group	Drug_2
10000529	advise	Drug_0	Drug_1

10000530|t|Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.
10000530	21	29	bosentan	drug	Drug_0
10000530	69	78	glyburide	drug	Drug_1
10000530	mechanism	Drug_0	Drug_1

10000531|t|Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A4.
10000531	0	8	Bosentan	drug	Drug_0
10000531	72	91	hypoglycemic agents	group	Drug_1
10000531	mechanism	Drug_0	Drug_1

10000532|t|Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.
10000532	62	74	ketoconazole	drug	Drug_0
10000532	142	150	bosentan	drug	Drug_1
10000532	mechanism	Drug_1	Drug_0

10000533|t|Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.
10000533	100	111	simvastatin	drug	Drug_0
10000533	22	29	Statins	group	Drug_1
10000533	52	60	bosentan	drug	Drug_2
10000533	mechanism	Drug_2	Drug_0

10000534|t|Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
10000534	0	8	Bosentan	drug	Drug_0
10000534	67	74	statins	group	Drug_1
10000534	127	137	lovastatin	drug	Drug_2
10000534	142	154	atorvastatin	drug	Drug_3
10000534	mechanism	Drug_0	Drug_1
10000534	mechanism	Drug_0	Drug_2
10000534	mechanism	Drug_0	Drug_3

10000535|t|Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.
10000535	34	41	statins	group	Drug_0
10000535	89	97	TRACLEER	brand	Drug_1
10000535	130	136	statin	group	Drug_2
10000535	advise	Drug_0	Drug_1

10000536|t|Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.
10000536	0	8	Warfarin	drug	Drug_0
10000536	31	39	bosentan	drug	Drug_1
10000536	109	119	S-warfarin	drug	Drug_2
10000536	145	155	R-warfarin	drug	Drug_3
10000536	mechanism	Drug_1	Drug_2
10000536	mechanism	Drug_1	Drug_3

10000537|t|Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.
10000537	359	367	bosentan	drug	Drug_0
10000537	262	270	warfarin	drug	Drug_1

10000538|t|Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.
10000538	96	103	digoxin	drug	Drug_0
10000538	108	118	nimodipine	drug	Drug_1
10000538	124	132	losartan	drug	Drug_2
10000538	179	187	bosentan	drug	Drug_3

10000539|t|Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
10000539	21	26	BOTOX	brand	Drug_0
10000539	31	46	aminoglycosides	group	Drug_1
10000539	114	135	curare-like compounds	group	Drug_2
10000539	196	201	toxin	drug	Drug_3
10000539	advise	Drug_0	Drug_1
10000539	advise	Drug_0	Drug_2

10000540|t|Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
10000540	21	28	MYOBLOC	brand	Drug_0
10000540	33	48	aminoglycosides	group	Drug_1
10000540	116	137	curare-like compounds	group	Drug_2
10000540	198	203	toxin	drug	Drug_3
10000540	advise	Drug_0	Drug_1
10000540	advise	Drug_0	Drug_2

10000541|t|Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection.
10000541	0	9	Digitalis	group	Drug_0
10000541	88	106	Bretylium Tosylate	drug	Drug_1
10000541	effect	Drug_0	Drug_1

10000542|t|The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.
10000542	23	37	catecholamines	group	Drug_0
10000542	46	54	dopamine	drug	Drug_1
10000542	58	72	norepinephrine	drug	Drug_2
10000542	89	107	Bretylium Tosylate	drug	Drug_3
10000542	effect	Drug_1	Drug_3
10000542	effect	Drug_0	Drug_3
10000542	effect	Drug_2	Drug_3

10000543|t|Although there is little published information on concomitant administration of lidocaine and Bretylium Tosylate, these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy.
10000543	80	89	lidocaine	drug	Drug_0
10000543	94	112	Bretylium Tosylate	drug	Drug_1

10000544|t|Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
10000544	72	82	ALPHAGAN P	brand	Drug_0
10000544	143	158	CNS depressants	group	Drug_1
10000544	160	167	alcohol	drug	Drug_2
10000544	169	181	barbiturates	group	Drug_3
10000544	183	190	opiates	group	Drug_4
10000544	192	201	sedatives	group	Drug_5
10000544	206	217	anesthetics	group	Drug_6
10000544	advise	Drug_0	Drug_5
10000544	advise	Drug_0	Drug_2
10000544	advise	Drug_0	Drug_3
10000544	advise	Drug_0	Drug_1
10000544	advise	Drug_0	Drug_4
10000544	advise	Drug_0	Drug_6

10000545|t|Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised.
10000545	43	56	beta-blockers	group	Drug_0
10000545	84	102	anti-hypertensives	group	Drug_1
10000545	110	128	cardiac glycosides	group	Drug_2

10000546|t|Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.
10000546	0	25	Tricyclic antidepressants	group	Drug_0
10000546	89	98	clonidine	drug	Drug_1
10000546	163	173	ALPHAGAN P	brand	Drug_2
10000546	effect	Drug_0	Drug_1

10000547|t|AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor.
10000547	0	5	AZOPT	brand	Drug_0
10000547	7	19	brinzolamide	drug	Drug_1
10000547	57	85	carbonic anhydrase inhibitor	group	Drug_2

10000548|t|However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy.
10000548	39	68	carbonic anhydrase inhibitors	group	Drug_0
10000548	135	145	salicylate	drug	Drug_1
10000548	int	Drug_0	Drug_1

10000549|t|Therefore, the potential for such drug interaction should be considered in patients receiving AZOPT (brinzolamide ophthalmic suspension) 1%.
10000549	94	99	AZOPT	brand	Drug_0
10000549	101	113	brinzolamide	drug	Drug_1

10000550|t|The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.
10000550	159	181	bromocriptine mesylate	drug	Drug_0
10000550	116	123	alcohol	drug	Drug_1
10000550	effect	Drug_1	Drug_0

10000551|t|Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.
10000551	0	22	Bromocriptine mesylate	drug	Drug_0
10000551	41	61	dopamine antagonists	group	Drug_1
10000551	63	77	butyrophenones	group	Drug_2
10000551	int	Drug_0	Drug_2
10000551	int	Drug_0	Drug_1

10000552|t|Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.
10000552	64	86	bromocriptine mesylate	drug	Drug_0
10000552	88	102	phenothiazines	group	Drug_1
10000552	104	115	haloperidol	drug	Drug_2
10000552	117	131	metoclopramide	drug	Drug_3
10000552	133	141	pimozide	drug	Drug_4
10000552	effect	Drug_0	Drug_4
10000552	effect	Drug_0	Drug_2
10000552	effect	Drug_0	Drug_3
10000552	effect	Drug_0	Drug_1

10000553|t|Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.
10000553	19	41	bromocriptine mesylate	drug	Drug_0
10000553	53	68	ergot alkaloids	group	Drug_1
10000553	advise	Drug_0	Drug_1

10000554|t|Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
10000554	0	18	Dexbrompheniramine	drug	Drug_0
10000554	37	44	alcohol	drug	Drug_1
10000554	54	69	CNS depressants	group	Drug_2
10000554	491	505	antihistamines	group	Drug_3
10000554	161	177	anticholinergics	group	Drug_4
10000554	344	378	monoamine oxidase (MAO) inhibitors	group	Drug_5
10000554	effect	Drug_0	Drug_1
10000554	effect	Drug_0	Drug_5
10000554	effect	Drug_0	Drug_4
10000554	effect	Drug_0	Drug_2

10000555|t|This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
10000555	28	35	alcohol	drug	Drug_0
10000555	45	60	CNS depressants	group	Drug_1
10000555	482	496	antihistamines	group	Drug_2
10000555	152	168	anticholinergics	group	Drug_3
10000555	335	369	monoamine oxidase (MAO) inhibitors	group	Drug_4

10000556|t|Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.
10000556	35	47	ketoconazole	drug	Drug_0
10000556	192	202	budesonide	drug	Drug_1
10000556	mechanism	Drug_0	Drug_1

10000557|t|If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
10000557	57	69	ketoconazole	drug	Drug_0
10000557	71	84	intraconazole	drug	Drug_1
10000557	86	95	ritonavir	drug	Drug_2
10000557	97	106	indinavir	drug	Drug_3
10000557	108	118	saquinavir	drug	Drug_4
10000557	120	132	erythromycin	drug	Drug_5
10000557	171	181	budesonide	drug	Drug_6
10000557	advise	Drug_0	Drug_6
10000557	advise	Drug_1	Drug_6
10000557	advise	Drug_4	Drug_6
10000557	advise	Drug_5	Drug_6
10000557	advise	Drug_2	Drug_6
10000557	advise	Drug_3	Drug_6

10000558|t|- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions.
10000558	125	135	bumetanide	drug	Drug_0
10000558	156	182	aminoglycoside antibiotics	group	Drug_1
10000558	advise	Drug_0	Drug_1

10000559|t|- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.
10000559	148	155	lithium	drug	Drug_0
10000559	54	63	diuretics	group	Drug_1
10000559	73	83	bumetanide	drug	Drug_2
10000559	advise	Drug_0	Drug_2
10000559	advise	Drug_0	Drug_1

10000560|t|- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.
10000560	32	42	probenecid	drug	Drug_0
10000560	103	113	bumetanide	drug	Drug_1
10000560	effect	Drug_0	Drug_1

10000561|t|This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.
10000561	28	38	probenecid	drug	Drug_0
10000561	196	206	bumetanide	drug	Drug_1
10000561	mechanism	Drug_0	Drug_1

10000562|t|Thus, probenecid should not be administered concurrently with bumetanide.
10000562	6	16	probenecid	drug	Drug_0
10000562	62	72	bumetanide	drug	Drug_1
10000562	advise	Drug_0	Drug_1

10000563|t|- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.
10000563	16	28	Indomethacin	drug	Drug_0
10000563	137	147	bumetanide	drug	Drug_1
10000563	effect	Drug_0	Drug_1
10000563	mechanism	Drug_0	Drug_1

10000564|t|- Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.
10000564	2	19	Antihypertensives	group	Drug_0
10000564	21	31	Bumetanide	drug	Drug_1
10000564	69	91	antihypertensive drugs	group	Drug_2
10000564	effect	Drug_1	Drug_2

10000565|t|- Anticoagulants: Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity.
10000565	2	16	Anticoagulants	group	Drug_0
10000565	59	69	bumetanide	drug	Drug_1
10000565	91	99	warfarin	drug	Drug_2

10000566|t|The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
10000566	28	48	anesthetic solutions	group	Drug_0
10000566	60	71	epinephrine	drug	Drug_1
10000566	75	89	norepinephrine	drug	Drug_2
10000566	112	140	monoamine oxidase inhibitors	group	Drug_3
10000566	144	169	tricyclic antidepressants	group	Drug_4
10000566	effect	Drug_1	Drug_3
10000566	effect	Drug_1	Drug_4
10000566	effect	Drug_2	Drug_3
10000566	effect	Drug_2	Drug_4

10000567|t|Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
10000567	29	46	vasopressor drugs	group	Drug_0
10000567	54	79	ergot-type oxytocic drugs	group	Drug_1

10000568|t|Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
10000568	0	14	Phenothiazines	group	Drug_0
10000568	19	33	butyrophenones	group	Drug_1
10000568	78	89	epinephrine	drug	Drug_2
10000568	effect	Drug_1	Drug_2
10000568	effect	Drug_0	Drug_2

10000569|t|Buprenorphine is metabolized to norbuprenorphine by cytochrome CYP 3A4.
10000569	0	13	Buprenorphine	drug	Drug_0
10000569	32	48	norbuprenorphine	drug_n	Drug_1

10000570|t|Because CYP 3A4 inhibitors may increase plasma concentrations of buprenorphine, patients already on CYP 3A4 inhibitors such as azole antifungals (e.g.
10000570	65	78	buprenorphine	drug	Drug_0
10000570	127	144	azole antifungals	group	Drug_1

10000571|t|ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
10000571	0	12	ketoconazole	drug	Drug_0
10000571	15	36	macrolide antibiotics	group	Drug_1
10000571	43	55	erythromycin	drug	Drug_2
10000571	62	85	HIV protease inhibitors	group	Drug_3
10000571	92	101	ritonavir	drug	Drug_4
10000571	103	112	indinavir	drug	Drug_5
10000571	117	127	saquinavir	drug	Drug_6
10000571	155	162	SUBUTEX	brand	Drug_7
10000571	166	174	SUBOXONE	brand	Drug_8

10000572|t|Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines.
10000572	64	77	buprenorphine	drug	Drug_0
10000572	82	97	benzodiazepines	group	Drug_1
10000572	int	Drug_0	Drug_1

10000573|t|There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.
10000573	141	154	buprenorphine	drug	Drug_0
10000573	159	174	benzodiazepines	drug	Drug_1
10000573	effect	Drug_0	Drug_1

10000574|t|In many of these cases, buprenorphine was misused by self-injection of crushed SUBUTEX tablets.
10000574	24	37	buprenorphine	drug	Drug_0
10000574	79	86	SUBUTEX	brand	Drug_1

10000575|t|SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.
10000575	0	7	SUBUTEX	brand	Drug_0
10000575	12	20	SUBOXONE	brand	Drug_1
10000575	70	85	benzodiazepines	group	Drug_2
10000575	advise	Drug_0	Drug_2
10000575	advise	Drug_1	Drug_2

10000576|t|Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.
10000576	92	107	benzodiazepines	group	Drug_0
10000576	135	143	SUBOXONE	brand	Drug_1
10000576	147	154	SUBUTEX	brand	Drug_2
10000576	advise	Drug_0	Drug_2
10000576	advise	Drug_0	Drug_1

10000577|t|In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by the CYP2B6 isoenzyme.
10000577	31	40	bupropion	drug	Drug_0
10000577	69	85	hydroxybupropion	drug_n	Drug_1

10000578|t|Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).
10000578	63	73	WELLBUTRIN	brand	Drug_0
10000578	124	136	orphenadrine	drug	Drug_1
10000578	141	157	cyclophosphamide	drug	Drug_2
10000578	int	Drug_0	Drug_2
10000578	int	Drug_0	Drug_1

10000579|t|The threohydrobupropion metabolite of bupropion does not appear to be produced by the cytochrome P450 isoenzymes.
10000579	4	23	threohydrobupropion	drug_n	Drug_0
10000579	38	47	bupropion	drug	Drug_1

10000580|t|The effects of concomitant administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites were studied in 24 healthy young male volunteers.
10000580	45	55	cimetidine	drug	Drug_0
10000580	83	92	bupropion	drug	Drug_1

10000581|t|Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of cimetidine, the pharmacokinetics of bupropion and hydroxybupropion were unaffected.
10000581	97	107	cimetidine	drug	Drug_0
10000581	133	142	bupropion	drug	Drug_1
10000581	147	163	hydroxybupropion	drug_n	Drug_2

10000582|t|However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of threohydrobupropion and erythrohydrobupropion.
10000582	105	124	threohydrobupropion	drug_n	Drug_0
10000582	129	150	erythrohydrobupropion	drug_n	Drug_1

10000583|t|While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).
10000583	77	86	bupropion	drug	Drug_0
10000583	94	107	carbamazepine	drug	Drug_1
10000583	109	122	phenobarbital	drug	Drug_2
10000583	124	133	phenytoin	drug	Drug_3
10000583	mechanism	Drug_0	Drug_3
10000583	mechanism	Drug_0	Drug_1
10000583	mechanism	Drug_0	Drug_2

10000584|t|Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.
10000584	78	93	antidepressants	group	Drug_0
10000584	107	117	tricyclics	group	Drug_1
10000584	120	133	beta-blockers	group	Drug_2
10000584	135	150	antiarrhythmics	drug	Drug_3
10000584	156	170	antipsychotics	group	Drug_4

10000585|t|Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro.
10000585	57	66	bupropion	drug	Drug_0
10000585	71	87	hydroxybupropion	drug_n	Drug_1

10000586|t|In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.
10000586	125	134	bupropion	drug	Drug_0
10000586	247	258	desipramine	drug	Drug_1
10000586	mechanism	Drug_0	Drug_1

10000587|t|Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
10000587	32	41	bupropion	drug	Drug_0
10000587	112	127	antidepressants	group	Drug_1
10000587	135	148	nortriptyline	drug	Drug_2
10000587	150	160	imipramine	drug	Drug_3
10000587	162	173	desipramine	drug	Drug_4
10000587	175	185	paroxetine	drug	Drug_5
10000587	187	197	fluoxetine	drug	Drug_6
10000587	199	209	sertraline	drug	Drug_7
10000587	212	226	antipsychotics	group	Drug_8
10000587	234	245	haloperidol	drug	Drug_9
10000587	247	258	risperidone	drug	Drug_10
10000587	260	272	thioridazine	drug	Drug_11
10000587	275	288	beta-blockers	group	Drug_12
10000587	296	306	metoprolol	drug	Drug_13
10000587	313	336	Type 1C antiarrhythmics	group	Drug_14
10000587	344	355	propafenone	drug	Drug_15
10000587	357	367	flecainide	drug	Drug_16
10000587	advise	Drug_0	Drug_12
10000587	advise	Drug_0	Drug_7
10000587	advise	Drug_0	Drug_8
10000587	advise	Drug_0	Drug_13
10000587	advise	Drug_0	Drug_15
10000587	advise	Drug_0	Drug_5
10000587	advise	Drug_0	Drug_3
10000587	advise	Drug_0	Drug_9
10000587	advise	Drug_0	Drug_14
10000587	advise	Drug_0	Drug_2
10000587	advise	Drug_0	Drug_10
10000587	advise	Drug_0	Drug_6
10000587	advise	Drug_0	Drug_16
10000587	advise	Drug_0	Drug_11
10000587	advise	Drug_0	Drug_4
10000587	advise	Drug_0	Drug_1

10000588|t|MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .
10000588	0	14	MAO Inhibitors	group	Drug_0
10000588	74	83	bupropion	drug	Drug_1
10000588	103	116	MAO inhibitor	group	Drug_2
10000588	117	127	phenelzine	drug	Drug_3
10000588	effect	Drug_1	Drug_3

10000589|t|Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.
10000589	154	162	levodopa	drug	Drug_0
10000589	166	176	amantadine	drug	Drug_1
10000589	119	128	bupropion	drug	Drug_2
10000589	effect	Drug_2	Drug_0
10000589	effect	Drug_2	Drug_1

10000590|t|Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.
10000590	18	28	WELLBUTRIN	brand	Drug_0
10000590	66	74	levodopa	drug	Drug_1
10000590	78	88	amantadine	drug	Drug_2
10000590	advise	Drug_0	Drug_1
10000590	advise	Drug_0	Drug_2

10000591|t|Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
10000591	65	75	WELLBUTRIN	brand	Drug_0
10000591	94	108	antipsychotics	group	Drug_1
10000591	116	131	antidepressants	group	Drug_2
10000591	133	145	theophylline	drug	Drug_3
10000591	156	164	steroids	group	Drug_4
10000591	advise	Drug_0	Drug_2
10000591	advise	Drug_0	Drug_4
10000591	advise	Drug_0	Drug_3
10000591	advise	Drug_0	Drug_1

10000592|t|Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.
10000592	162	169	alcohol	drug	Drug_0
10000592	192	202	WELLBUTRIN	brand	Drug_1
10000592	effect	Drug_0	Drug_1

10000593|t|The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)
10000593	19	26	alcohol	drug	Drug_0
10000593	49	59	WELLBUTRIN	brand	Drug_1
10000593	advise	Drug_0	Drug_1

10000594|t|It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.
10000594	23	46	buspirone hydrochloride	drug	Drug_0
10000594	78	92	MAO inhibitors	group	Drug_1
10000594	241	254	buspirone HCl	drug	Drug_2
10000594	176	194	psychotropic drugs	group	Drug_3
10000594	advise	Drug_0	Drug_1

10000595|t|There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
10000595	59	82	trazodone hydrochloride	drug	Drug_0
10000595	84	91	Desyrel	brand	Drug_1
10000595	97	110	buspirone HCl	drug	Drug_2
10000595	effect	Drug_1	Drug_2
10000595	effect	Drug_0	Drug_2

10000596|t|In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.
10000596	63	76	buspirone HCl	drug	Drug_0
10000596	121	132	haloperidol	drug	Drug_1
10000596	mechanism	Drug_0	Drug_1

10000597|t|In vitro, buspirone does not displace tightly bound drugs like phenytoin, propranolol, and warfarin from serum proteins.
10000597	10	19	buspirone	drug	Drug_0
10000597	63	72	phenytoin	drug	Drug_1
10000597	74	85	propranolol	drug	Drug_2
10000597	91	99	warfarin	drug	Drug_3

10000598|t|However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin.
10000598	70	79	buspirone	drug	Drug_0
10000598	131	139	warfarin	drug	Drug_1
10000598	effect	Drug_0	Drug_1

10000599|t|The patient was also chronically receiving phenytoin, phenobarbital, digoxin, and levothyroxine sodium.
10000599	43	52	phenytoin	drug	Drug_0
10000599	54	67	phenobarbital	drug	Drug_1
10000599	69	76	digoxin	drug	Drug_2
10000599	82	102	levothyroxine sodium	drug	Drug_3

10000600|t|In vitro, buspirone may displace less firmly bound drugs like digoxin.
10000600	10	19	buspirone	drug	Drug_0
10000600	62	69	digoxin	drug	Drug_1
10000600	mechanism	Drug_0	Drug_1

10000601|t|Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
10000601	87	101	anticoagulants	group	Drug_0
10000601	103	116	blood thinner	group	Drug_1
10000601	120	133	carbamazepine	drug	Drug_2
10000601	135	148	corticotropin	drug	Drug_3
10000601	525	537	barbiturates	group	Drug_4
10000601	209	249	central nervous system (CNS) depressants	group	Drug_5
10000601	340	357	divalproex sodium	drug	Drug_6
10000601	359	372	valproic acid	drug	Drug_7
10000601	583	597	contraceptives	group	Drug_8
10000601	514	523	estrogens	group	Drug_9
10000601	effect	Drug_4	Drug_8

10000602|t|The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.
10000602	19	29	butalbital	drug	Drug_0
10000602	49	83	monoamine oxidase (MAO) inhibitors	group	Drug_1
10000602	effect	Drug_0	Drug_1

10000603|t|Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
10000603	0	10	Butalbital	drug	Drug_0
10000603	12	25	acetaminophen	drug	Drug_1
10000603	30	38	caffeine	drug	Drug_2
10000603	73	91	narcotic analgesic	group	Drug_3
10000603	94	101	alcohol	drug	Drug_4
10000603	111	122	anesthetics	group	Drug_5
10000603	124	137	tranquilizers	group	Drug_6
10000603	146	162	chlordiazepoxide	drug	Drug_7
10000603	164	182	sedative-hypnotics	group	Drug_8
10000603	193	208	CNS depressants	group	Drug_9
10000603	effect	Drug_1	Drug_6
10000603	effect	Drug_2	Drug_9
10000603	effect	Drug_1	Drug_5
10000603	effect	Drug_2	Drug_6
10000603	effect	Drug_1	Drug_4
10000603	effect	Drug_1	Drug_9
10000603	effect	Drug_0	Drug_9
10000603	effect	Drug_0	Drug_8
10000603	effect	Drug_0	Drug_4
10000603	effect	Drug_0	Drug_6
10000603	effect	Drug_2	Drug_7
10000603	effect	Drug_1	Drug_8
10000603	effect	Drug_2	Drug_3
10000603	effect	Drug_0	Drug_5
10000603	effect	Drug_2	Drug_5
10000603	effect	Drug_2	Drug_4
10000603	effect	Drug_2	Drug_8
10000603	effect	Drug_0	Drug_3
10000603	effect	Drug_0	Drug_7
10000603	effect	Drug_1	Drug_3
10000603	effect	Drug_1	Drug_7

10000604|t|Potential drug interactions between Mentax (butenafine HCl cream) Cream, 1%, and other drugs have not been systematically evaluated.
10000604	36	42	Mentax	brand	Drug_0
10000604	44	58	butenafine HCl	drug	Drug_1

10000605|t|Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
10000605	18	29	butorphanol	drug	Drug_0
10000605	35	69	central nervous system depressants	group	Drug_1
10000605	77	84	alcohol	drug	Drug_2
10000605	86	98	barbiturates	group	Drug_3
10000605	100	113	tranquilizers	group	Drug_4
10000605	119	133	antihistamines	group	Drug_5
10000605	159	192	central nervous system depressant	group	Drug_6
10000605	effect	Drug_0	Drug_5
10000605	effect	Drug_0	Drug_3
10000605	effect	Drug_0	Drug_2
10000605	effect	Drug_0	Drug_4
10000605	effect	Drug_0	Drug_1

10000606|t|When used concurrently with such drugs, the dose of butorphanol should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of opioids.
10000606	52	63	butorphanol	drug	Drug_0
10000606	231	238	opioids	group	Drug_1

10000607|t|In healthy volunteers, the pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of a single 6-mg subcutaneous dose of sumatriptan.
10000607	62	73	butorphanol	drug	Drug_0
10000607	90	99	STADOL NS	brand	Drug_1
10000607	180	191	sumatriptan	drug	Drug_2

10000608|t|However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.
10000608	73	84	butorphanol	drug	Drug_0
10000608	179	188	STADOL NS	brand	Drug_1
10000608	237	248	sumatriptan	drug	Drug_2
10000608	mechanism	Drug_1	Drug_2

10000609|t|When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.
10000609	9	18	STADOL NS	brand	Drug_0
10000609	57	68	sumatriptan	drug	Drug_1
10000609	93	104	butorphanol	drug	Drug_2
10000609	mechanism	Drug_0	Drug_1

10000610|t|In neither case were the pharmacokinetics of sumatriptan affected by coadministration with STADOL NS.
10000610	45	56	sumatriptan	drug	Drug_0
10000610	91	100	STADOL NS	brand	Drug_1

10000611|t|These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.
10000611	51	60	STADOL NS	brand	Drug_0
10000611	117	128	sumatriptan	drug	Drug_1
10000611	effect	Drug_0	Drug_1

10000612|t|The safety of using STADOL NS and IMITREX (sumatriptan) Nasal Spray during the same episode of migraine has not been established.
10000612	20	29	STADOL NS	brand	Drug_0
10000612	34	41	IMITREX	brand	Drug_1
10000612	43	54	sumatriptan	drug	Drug_2

10000613|t|The pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of cimetidine (300 mg QID).
10000613	39	50	butorphanol	drug	Drug_0
10000613	67	76	STADOL NS	brand	Drug_1
10000613	122	132	cimetidine	drug	Drug_2

10000614|t|Conversely, the administration of STADOL NS (1 mg butorphanol QID) did not alter the pharmacokinetics of a 300-mg dose of cimetidine.
10000614	34	43	STADOL NS	brand	Drug_0
10000614	50	61	butorphanol	drug	Drug_1
10000614	122	132	cimetidine	drug	Drug_2

10000615|t|It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.
10000615	34	45	butorphanol	drug	Drug_0
10000615	126	138	erythromycin	drug	Drug_1
10000615	advise	Drug_0	Drug_1

10000616|t|The fraction of STADOL NS absorbed is unaffected by the concomitant administration of a nasal vasoconstrictor (oxymetazoline), but the rate of absorption is decreased.
10000616	16	25	STADOL NS	brand	Drug_0
10000616	88	109	nasal vasoconstrictor	group	Drug_1
10000616	111	124	oxymetazoline	drug	Drug_2

10000617|t|Therefore, a slower onset can be anticipated if STADOL NS is administered concomitantly with, or immediately following, a nasal vasoconstrictor.
10000617	48	57	STADOL NS	brand	Drug_0
10000617	122	143	nasal vasoconstrictor	group	Drug_1
10000617	effect	Drug_0	Drug_1

10000618|t|No information is available about the use of butorphanol concurrently with MAO inhibitors.
10000618	45	56	butorphanol	drug	Drug_0
10000618	75	89	MAO inhibitors	group	Drug_1

10000619|t|DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.
10000619	0	8	DOSTINEX	brand	Drug_0
10000619	78	92	phenothiazines	group	Drug_1
10000619	94	108	butyrophenones	group	Drug_2
10000619	110	123	thioxanthines	group	Drug_3
10000619	128	142	metoclopramide	drug	Drug_4
10000619	advise	Drug_0	Drug_1
10000619	advise	Drug_0	Drug_2
10000619	advise	Drug_0	Drug_4
10000619	advise	Drug_0	Drug_3

10000620|t|Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
10000620	273	281	caffeine	drug	Drug_0
10000620	154	164	cimetidine	drug	Drug_1
10000620	169	181	ketoconazole	drug	Drug_2
10000620	301	314	phenobarbital	drug	Drug_3
10000620	319	328	phenytoin	drug	Drug_4
10000620	advise	Drug_0	Drug_3
10000620	advise	Drug_0	Drug_1
10000620	advise	Drug_0	Drug_2
10000620	advise	Drug_0	Drug_4

10000621|t|Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.
10000621	0	8	Caffeine	drug	Drug_0
10000621	40	50	ketoprofen	drug	Drug_1
10000621	effect	Drug_0	Drug_1

10000622|t|Interconversion between caffeine and theophylline has been reported in preterm neonates.
10000622	24	32	caffeine	drug	Drug_0
10000622	37	49	theophylline	drug	Drug_1

10000623|t|Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
10000623	17	36	vitamin D analogues	group	Drug_0
10000623	38	48	Vitamin D2	drug	Drug_1
10000623	50	60	Vitamin D3	drug	Drug_2
10000623	62	72	Calcitriol	drug	Drug_3
10000623	78	87	Calcidiol	drug	Drug_4
10000623	106	120	Cholestyramine	drug	Drug_5
10000623	174	194	fat soluble vitamins	group	Drug_6
10000623	mechanism	Drug_5	Drug_6

10000624|t|Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
10000624	49	58	phenytoin	drug	Drug_0
10000624	62	75	phenobarbital	drug	Drug_1
10000624	117	126	vitamin D	group	Drug_2
10000624	171	181	calcitriol	drug	Drug_3
10000624	mechanism	Drug_1	Drug_3
10000624	mechanism	Drug_0	Drug_3

10000625|t|Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
10000625	21	31	calcitriol	drug	Drug_0
10000625	80	89	Rocaltrol	brand	Drug_1

10000626|t|Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
10000626	63	72	thiazides	group	Drug_0
10000626	78	87	vitamin D	group	Drug_1
10000626	effect	Drug_0	Drug_1

10000627|t|Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
10000627	95	104	digitalis	group	Drug_0
10000627	11	20	Vitamin D	group	Drug_1
10000627	advise	Drug_1	Drug_0

10000628|t|Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
10000628	14	26	Ketoconazole	drug	Drug_0
10000628	79	88	vitamin D	group	Drug_1
10000628	mechanism	Drug_0	Drug_1

10000629|t|However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.
10000629	45	57	ketoconazole	drug	Drug_0
10000629	63	72	vitamin D	group	Drug_1

10000630|t|Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
10000630	131	146	corticosteroids	group	Drug_0
10000630	72	91	vitamin D analogues	group	Drug_1
10000630	mechanism	Drug_1	Drug_0

10000631|t|Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.
10000631	0	9	Vitamin D	group	Drug_0
10000631	46	65	vitamin D analogues	group	Drug_1

10000632|t|Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
10000632	11	20	Magnesium	drug	Drug_0
10000632	50	58	antacids	group	Drug_1
10000632	140	149	vitamin D	group	Drug_2
10000632	advise	Drug_1	Drug_2
10000632	advise	Drug_0	Drug_2

10000633|t|Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
10000633	17	36	vitamin D analogues	group	Drug_0
10000633	38	48	Vitamin D2	drug	Drug_1
10000633	50	60	Vitamin D3	drug	Drug_2
10000633	62	72	Calcitriol	drug	Drug_3
10000633	78	87	Calcidiol	drug	Drug_4
10000633	106	120	Cholestyramine	drug	Drug_5
10000633	174	194	fat soluble vitamins	group	Drug_6
10000633	mechanism	Drug_5	Drug_6

10000634|t|Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
10000634	49	58	phenytoin	drug	Drug_0
10000634	62	75	phenobarbital	drug	Drug_1
10000634	117	126	vitamin D	group	Drug_2
10000634	171	181	calcitriol	drug	Drug_3
10000634	mechanism	Drug_0	Drug_3
10000634	mechanism	Drug_1	Drug_3

10000635|t|Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
10000635	21	31	calcitriol	drug	Drug_0
10000635	80	89	Rocaltrol	brand	Drug_1

10000636|t|Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.
10000636	11	20	Thiazides	group	Drug_0
10000636	75	82	calcium	drug	Drug_1

10000637|t|Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
10000637	63	72	thiazides	group	Drug_0
10000637	78	87	vitamin D	group	Drug_1
10000637	effect	Drug_0	Drug_1

10000638|t|Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
10000638	95	104	digitalis	group	Drug_0
10000638	11	20	Vitamin D	group	Drug_1
10000638	advise	Drug_1	Drug_0

10000639|t|Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
10000639	14	26	Ketoconazole	drug	Drug_0
10000639	79	88	vitamin D	group	Drug_1
10000639	mechanism	Drug_0	Drug_1

10000640|t|However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.
10000640	45	57	ketoconazole	drug	Drug_0
10000640	63	72	vitamin D	group	Drug_1

10000641|t|Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
10000641	131	146	corticosteroids	group	Drug_0
10000641	72	91	vitamin D analogues	group	Drug_1
10000641	mechanism	Drug_1	Drug_0

10000642|t|Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.
10000642	0	9	Vitamin D	group	Drug_0
10000642	46	65	vitamin D analogues	group	Drug_1

10000643|t|Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
10000643	11	20	Magnesium	drug	Drug_0
10000643	50	58	antacids	group	Drug_1
10000643	140	149	vitamin D	group	Drug_2
10000643	advise	Drug_0	Drug_2
10000643	advise	Drug_1	Drug_2

10000644|t|Concomitant use with other calcium-containing medicines (including antacids) may cause too much calcium in the blood or urine, which may increase the chance of side effects.
10000644	96	103	calcium	drug	Drug_0
10000644	67	75	antacids	group	Drug_1

10000645|t|Using calcium acetate with digitalis glycosides (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.
10000645	6	21	calcium acetate	drug	Drug_0
10000645	27	47	digitalis glycosides	group	Drug_1
10000645	99	106	calcium	drug	Drug_2
10000645	effect	Drug_0	Drug_1

10000646|t|May interact with cefamandole naftate, cephalothin sodium, magnesium sulfate, prednisolone sodium succinate, and prochlorperazine edisylate.
10000646	18	37	cefamandole naftate	drug	Drug_0
10000646	39	57	cephalothin sodium	drug	Drug_1
10000646	59	76	magnesium sulfate	drug	Drug_2
10000646	78	107	prednisolone sodium succinate	drug	Drug_3
10000646	113	139	prochlorperazine edisylate	drug	Drug_4

10000647|t|No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
10000647	66	87	candesartan cilexetil	drug	Drug_0
10000647	119	128	glyburide	drug	Drug_1
10000647	130	140	nifedipine	drug	Drug_2
10000647	142	149	digoxin	drug	Drug_3
10000647	151	159	warfarin	drug	Drug_4
10000647	161	180	hydrochlorothiazide	drug	Drug_5
10000647	191	205	contraceptives	group	Drug_6
10000647	243	252	enalapril	drug	Drug_7

10000648|t|Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.
10000648	130	137	lithium	drug	Drug_0
10000648	143	157	ACE inhibitors	group	Drug_1
10000648	173	208	angiotensin II receptor antagonists	group	Drug_2
10000648	mechanism	Drug_0	Drug_2
10000648	mechanism	Drug_0	Drug_1

10000649|t|An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.
10000649	151	158	lithium	drug	Drug_0
10000649	111	118	ATACAND	brand	Drug_1
10000649	mechanism	Drug_0	Drug_1

10000650|t|Antacid: The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.
10000650	81	88	antacid	group	Drug_0
10000650	26	44	aluminum hydroxide	drug	Drug_1
10000650	50	69	magnesium hydroxide	drug	Drug_2
10000650	90	96	Maalox	brand	Drug_3
10000650	126	138	capecitabine	drug	Drug_4

10000651|t|There was a small increase in plasma concentrations of capecitabine and one metabolite (5-DFCR);
10000651	55	67	capecitabine	drug	Drug_0
10000651	88	94	5-DFCR	drug_n	Drug_1

10000652|t|there was no effect on the 3 major metabolites (5-DFUR, 5-FU and FBAL).
10000652	48	54	5-DFUR	drug_n	Drug_0
10000652	56	60	5-FU	drug_n	Drug_1
10000652	65	69	FBAL	drug_n	Drug_2

10000653|t|Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
10000653	0	23	Coumarin Anticoagulants	group	Drug_0
10000653	109	121	capecitabine	drug	Drug_1
10000653	141	175	coumarin-derivative anticoagulants	group	Drug_2
10000653	184	192	warfarin	drug	Drug_3
10000653	197	210	phenprocoumon	drug	Drug_4
10000653	effect	Drug_1	Drug_4
10000653	effect	Drug_1	Drug_2

10000654|t|Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).
10000654	16	50	coumarin-derivative anticoagulants	group	Drug_0
10000654	70	82	capecitabine	drug	Drug_1
10000654	advise	Drug_0	Drug_1

10000655|t|Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.
10000655	97	107	leucovorin	drug	Drug_0
10000655	33	47	5-fluorouracil	drug	Drug_1
10000655	mechanism	Drug_1	Drug_0

10000656|t|Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.
10000656	116	126	leucovorin	drug	Drug_0
10000656	131	143	fluorouracil	drug	Drug_1
10000656	effect	Drug_0	Drug_1

10000657|t|Hypotension   Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.
10000657	95	103	diuretic	group	Drug_0
10000657	56	65	diuretics	group	Drug_1
10000657	338	347	captopril	drug	Drug_2
10000657	effect	Drug_1	Drug_2

10000658|t|The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).
10000658	210	219	captopril	drug	Drug_0
10000658	99	107	diuretic	group	Drug_1
10000658	effect	Drug_0	Drug_1

10000659|t|Agents Having Vasodilator Activity: Data on the effect of concomitant use of other vasodilators in patients receiving captopril for heart failure are not available;
10000659	83	95	vasodilators	group	Drug_0
10000659	118	127	captopril	drug	Drug_1

10000660|t|therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.
10000660	11	24	nitroglycerin	drug	Drug_0
10000660	34	42	nitrates	group	Drug_1
10000660	174	183	captopril	drug	Drug_2
10000660	advise	Drug_0	Drug_2
10000660	advise	Drug_1	Drug_2

10000661|t|Agents Causing Renin Release Captopril's effect will be augmented by antihypertensive agents that cause renin release.
10000661	29	38	Captopril	drug	Drug_0
10000661	69	92	antihypertensive agents	group	Drug_1
10000661	effect	Drug_0	Drug_1

10000662|t|For example, diuretics (e.g., thiazides) may activate the renin-angiotensin-aldosterone system.
10000662	13	22	diuretics	group	Drug_0
10000662	30	39	thiazides	group	Drug_1

10000663|t|Agents Affecting Sympathetic Activity The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics.
10000663	148	157	captopril	drug	Drug_0
10000663	172	181	diuretics	group	Drug_1

10000664|t|Therefore, agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) should be used with caution.
10000664	56	82	ganglionic blocking agents	group	Drug_0
10000664	86	119	adrenergic neuron blocking agents	group	Drug_1

10000665|t|Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive.
10000665	0	30	Beta-adrenergic blocking drugs	group	Drug_0
10000665	75	84	captopril	drug	Drug_1
10000665	effect	Drug_0	Drug_1

10000666|t|Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.
10000666	0	27	Potassium-sparing diuretics	group	Drug_0
10000666	36	50	spironolactone	drug	Drug_1
10000666	52	63	triamterene	drug	Drug_2
10000666	68	77	amiloride	drug	Drug_3
10000666	82	91	potassium	drug	Drug_4

10000667|t|Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.
10000667	75	87	indomethacin	drug	Drug_0
10000667	130	139	captopril	drug	Drug_1
10000667	effect	Drug_0	Drug_1

10000668|t|Other nonsteroidal anti-inflammatory agents (e.g., aspirin) may also have this effect.
10000668	6	43	nonsteroidal anti-inflammatory agents	group	Drug_0
10000668	51	58	aspirin	brand	Drug_1

10000669|t|Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
10000669	126	133	lithium	drug	Drug_0
10000669	138	151	ACE inhibitor	group	Drug_1
10000669	effect	Drug_0	Drug_1

10000670|t|If a diuretic is also used, it may increase the risk of lithium toxicity.
10000670	5	13	diuretic	group	Drug_0
10000670	56	63	lithium	drug	Drug_1
10000670	effect	Drug_0	Drug_1

10000671|t|Cardiac Glycosides: In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-digoxin interaction could be found.
10000671	0	18	Cardiac Glycosides	group	Drug_0
10000671	102	111	captopril	drug	Drug_1
10000671	112	119	digoxin	drug	Drug_2

10000672|t|Loop Diuretics: Furosemide administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.
10000672	0	14	Loop Diuretics	group	Drug_0
10000672	16	26	Furosemide	drug	Drug_1
10000672	107	116	captopril	drug	Drug_2

10000673|t|Allopurinol: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and allopurinol were administered concomitantly for 6 days.
10000673	122	133	allopurinol	drug	Drug_0
10000673	108	117	captopril	drug	Drug_1

10000674|t|Agents that Inhibit Cytochrome P450 Isoenzymes and/or Epoxide Hydrolase Carbamazepine is metabolized mainly by cytochrome P450 (CYP) 3A4 to the active carbamazepine 10,11-epoxide, which is further metabolized to the trans-diol by epoxide hydrolase.
10000674	72	85	Carbamazepine	drug	Drug_0
10000674	151	178	carbamazepine 10,11-epoxide	drug	Drug_1

10000675|t|Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
10000675	102	111	EQUETROTM	brand	Drug_0
10000675	131	144	Acetazolamide	drug	Drug_1
10000675	146	163	azole antifungals	group	Drug_2
10000675	165	175	cimetidine	drug	Drug_3
10000675	177	191	clarithromycin	drug	Drug_4
10000675	196	208	dalfopristin	drug	Drug_5
10000675	210	217	danazol	drug	Drug_6
10000675	219	230	delavirdine	drug	Drug_7
10000675	232	241	diltiazem	drug	Drug_8
10000675	243	255	erythromycin	drug	Drug_9
10000675	260	270	fluoxetine	drug	Drug_10
10000675	272	283	fluvoxamine	drug	Drug_11
10000675	303	312	isoniazid	drug	Drug_12
10000675	314	326	itraconazole	drug	Drug_13
10000675	328	340	ketoconazole	drug	Drug_14
10000675	342	352	loratadine	drug	Drug_15
10000675	354	364	nefazodone	drug	Drug_16
10000675	366	377	niacinamide	drug	Drug_17
10000675	379	391	nicotinamide	drug	Drug_18
10000675	393	412	protease inhibitors	group	Drug_19
10000675	414	426	propoxyphene	drug	Drug_20
10000675	428	435	quinine	drug	Drug_21
10000675	437	449	quinupristin	drug	Drug_22
10000675	451	465	troleandomycin	drug	Drug_23
10000675	467	476	valproate	drug	Drug_24
10000675	481	490	verapamil	drug	Drug_25
10000675	492	500	zileuton	drug	Drug_26
10000675	mechanism	Drug_0	Drug_4
10000675	mechanism	Drug_0	Drug_9
10000675	mechanism	Drug_0	Drug_8
10000675	mechanism	Drug_0	Drug_26
10000675	mechanism	Drug_0	Drug_14
10000675	mechanism	Drug_0	Drug_2
10000675	mechanism	Drug_0	Drug_19
10000675	mechanism	Drug_0	Drug_6
10000675	mechanism	Drug_0	Drug_10
10000675	mechanism	Drug_0	Drug_11
10000675	mechanism	Drug_0	Drug_20
10000675	mechanism	Drug_0	Drug_17
10000675	mechanism	Drug_0	Drug_5
10000675	mechanism	Drug_0	Drug_18
10000675	mechanism	Drug_0	Drug_13
10000675	mechanism	Drug_0	Drug_16
10000675	mechanism	Drug_0	Drug_3
10000675	mechanism	Drug_0	Drug_22
10000675	mechanism	Drug_0	Drug_15
10000675	mechanism	Drug_0	Drug_12
10000675	mechanism	Drug_0	Drug_24
10000675	mechanism	Drug_0	Drug_23
10000675	mechanism	Drug_0	Drug_1
10000675	mechanism	Drug_0	Drug_21
10000675	mechanism	Drug_0	Drug_25
10000675	mechanism	Drug_0	Drug_7

10000676|t|Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
10000676	441	450	EQUETROTM	brand	Drug_0
10000676	126	135	Cisplatin	drug	Drug_1
10000676	137	152	doxorubicin HCL	drug	Drug_2
10000676	154	163	felbamate	drug	Drug_3
10000676	165	173	rifampin	drug	Drug_4
10000676	175	188	phenobarbital	drug	Drug_5
10000676	190	199	Phenytoin	drug	Drug_6
10000676	204	213	primidone	drug	Drug_7
10000676	215	227	methsuximide	drug	Drug_8
10000676	233	245	theophylline	drug	Drug_9
10000676	mechanism	Drug_0	Drug_3
10000676	mechanism	Drug_0	Drug_5
10000676	mechanism	Drug_0	Drug_7
10000676	mechanism	Drug_0	Drug_9
10000676	mechanism	Drug_0	Drug_1
10000676	mechanism	Drug_0	Drug_6
10000676	mechanism	Drug_0	Drug_2
10000676	mechanism	Drug_0	Drug_8
10000676	mechanism	Drug_0	Drug_4

10000677|t|Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
10000677	96	105	EQUETROTM	brand	Drug_0
10000677	157	170	Acetaminophen	drug	Drug_1
10000677	172	182	alprazolam	drug	Drug_2
10000677	184	197	amitriptyline	drug	Drug_3
10000677	199	208	bupropion	drug	Drug_4
10000677	210	219	buspirone	drug	Drug_5
10000677	221	231	citalopram	drug	Drug_6
10000677	233	241	clobazam	drug	Drug_7
10000677	243	253	clonazepam	drug	Drug_8
10000677	255	264	clozapine	drug	Drug_9
10000677	266	277	cyclosporin	drug	Drug_10
10000677	279	290	delavirdine	drug	Drug_11
10000677	292	303	desipramine	drug	Drug_12
10000677	305	313	diazepam	drug	Drug_13
10000677	315	324	dicumarol	drug	Drug_14
10000677	326	337	doxycycline	drug	Drug_15
10000677	339	351	ethosuximide	drug	Drug_16
10000677	353	362	felbamate	drug	Drug_17
10000677	364	374	felodipine	drug	Drug_18
10000677	376	391	glucocorticoids	group	Drug_19
10000677	393	404	haloperidol	drug	Drug_20
10000677	406	418	itraconazole	drug	Drug_21
10000677	420	431	lamotrigine	drug	Drug_22
10000677	433	446	levothyroxine	drug	Drug_23
10000677	448	457	lorazepam	drug	Drug_24
10000677	459	468	methadone	drug	Drug_25
10000677	470	479	midazolam	drug	Drug_26
10000677	481	492	mirtazapine	drug	Drug_27
10000677	494	507	nortriptyline	drug	Drug_28
10000677	509	519	olanzapine	drug	Drug_29
10000677	526	540	contraceptives	group	Drug_30
10000677	545	558	oxcarbazepine	drug	Drug_31
10000677	560	569	Phenytoin	drug	Drug_32
10000677	574	586	praziquantel	drug	Drug_33
10000677	588	607	protease inhibitors	group	Drug_34
10000677	609	619	quetiapine	drug	Drug_35
10000677	621	632	risperidone	drug	Drug_36
10000677	634	646	theophylline	drug	Drug_37
10000677	648	658	topiramate	drug	Drug_38
10000677	660	669	tiagabine	drug	Drug_39
10000677	671	679	tramadol	drug	Drug_40
10000677	681	690	triazolam	drug	Drug_41
10000677	692	701	valproate	drug	Drug_42
10000677	703	711	warfarin	drug	Drug_43
10000677	717	728	ziprasidone	drug	Drug_44
10000677	734	744	zonisamide	drug	Drug_45
10000677	mechanism	Drug_0	Drug_12
10000677	mechanism	Drug_0	Drug_19
10000677	mechanism	Drug_0	Drug_29
10000677	mechanism	Drug_0	Drug_43
10000677	mechanism	Drug_0	Drug_24
10000677	mechanism	Drug_0	Drug_31
10000677	mechanism	Drug_0	Drug_1
10000677	mechanism	Drug_0	Drug_13
10000677	mechanism	Drug_0	Drug_45
10000677	mechanism	Drug_0	Drug_27
10000677	mechanism	Drug_0	Drug_38
10000677	mechanism	Drug_0	Drug_16
10000677	mechanism	Drug_0	Drug_41
10000677	mechanism	Drug_0	Drug_40
10000677	mechanism	Drug_0	Drug_7
10000677	mechanism	Drug_0	Drug_6
10000677	mechanism	Drug_0	Drug_28
10000677	mechanism	Drug_0	Drug_21
10000677	mechanism	Drug_0	Drug_26
10000677	mechanism	Drug_0	Drug_35
10000677	mechanism	Drug_0	Drug_14
10000677	mechanism	Drug_0	Drug_34
10000677	mechanism	Drug_0	Drug_10
10000677	mechanism	Drug_0	Drug_23
10000677	mechanism	Drug_0	Drug_30
10000677	mechanism	Drug_0	Drug_33
10000677	mechanism	Drug_0	Drug_37
10000677	mechanism	Drug_0	Drug_5
10000677	mechanism	Drug_0	Drug_22
10000677	mechanism	Drug_0	Drug_17
10000677	mechanism	Drug_0	Drug_36
10000677	mechanism	Drug_0	Drug_25
10000677	mechanism	Drug_0	Drug_18
10000677	mechanism	Drug_0	Drug_15
10000677	mechanism	Drug_0	Drug_32
10000677	mechanism	Drug_0	Drug_3
10000677	mechanism	Drug_0	Drug_44
10000677	mechanism	Drug_0	Drug_39
10000677	mechanism	Drug_0	Drug_20
10000677	mechanism	Drug_0	Drug_8
10000677	mechanism	Drug_0	Drug_42
10000677	mechanism	Drug_0	Drug_11
10000677	mechanism	Drug_0	Drug_9
10000677	mechanism	Drug_0	Drug_2
10000677	mechanism	Drug_0	Drug_4

10000678|t|Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
10000678	48	61	Carbamazepine	drug	Drug_0
10000678	314	323	EQUETROTM	brand	Drug_1
10000678	126	142	Clomipramine HCl	drug	Drug_2
10000678	144	153	Phenytoin	drug	Drug_3
10000678	162	171	primidone	drug	Drug_4
10000678	mechanism	Drug_1	Drug_4
10000678	mechanism	Drug_1	Drug_2
10000678	mechanism	Drug_1	Drug_3

10000679|t|Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.
10000679	94	107	carbamazepine	drug	Drug_0
10000679	112	119	lithium	drug	Drug_1
10000679	effect	Drug_0	Drug_1

10000680|t|Given the anticonvulsant properties of carbamazepine, EQUETROTM may reduce the thyroid function as has been reported with other anticonvulsants.
10000680	39	52	carbamazepine	drug	Drug_0
10000680	54	63	EQUETROTM	brand	Drug_1
10000680	128	143	anticonvulsants	group	Drug_2

10000681|t|Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.
10000681	14	33	anti-malarial drugs	group	Drug_0
10000681	43	54	chloroquine	drug	Drug_1
10000681	59	69	mefloquine	drug	Drug_2
10000681	102	115	carbamazepine	drug	Drug_3
10000681	effect	Drug_1	Drug_3
10000681	effect	Drug_0	Drug_3
10000681	effect	Drug_2	Drug_3

10000682|t|Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.
10000682	63	72	EQUETROTM	brand	Drug_0
10000682	93	115	centrally acting drugs	group	Drug_1
10000682	120	127	alcohol	drug	Drug_2
10000682	advise	Drug_0	Drug_1
10000682	advise	Drug_0	Drug_2

10000683|t|Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.
10000683	0	9	Geocillin	brand	Drug_0
10000683	11	39	carbenicillin indanyl sodium	drug	Drug_1
10000683	117	127	probenecid	drug	Drug_2
10000683	mechanism	Drug_1	Drug_2
10000683	mechanism	Drug_0	Drug_2

10000684|t|Caution should be exercised when the following drugs are administered concomitantly with LODOSYN (Carbidopa) given with levodopa or carbidopa-levodopa combination products.
10000684	89	96	LODOSYN	brand	Drug_0
10000684	132	141	carbidopa	drug	Drug_1
10000684	142	150	levodopa	drug	Drug_2

10000685|t|Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
10000685	0	32	Dopamine D2 receptor antagonists	group	Drug_0
10000685	40	54	phenothiazines	group	Drug_1
10000685	56	70	butyrophenones	group	Drug_2
10000685	72	83	risperidone	drug	Drug_3
10000685	89	98	isoniazid	drug	Drug_4
10000685	137	145	levodopa	drug	Drug_5
10000685	effect	Drug_2	Drug_5
10000685	effect	Drug_4	Drug_5
10000685	effect	Drug_3	Drug_5
10000685	effect	Drug_1	Drug_5
10000685	effect	Drug_0	Drug_5

10000686|t|In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.
10000686	39	47	levodopa	drug	Drug_0
10000686	107	116	phenytoin	drug	Drug_1
10000686	121	131	papaverine	drug	Drug_2
10000686	effect	Drug_0	Drug_1
10000686	effect	Drug_0	Drug_2

10000687|t|Patients taking these drugs with LODOSYN and levodopa or carbidopa-levodopa combination products should be carefully observed for loss of therapeutic response.
10000687	33	40	LODOSYN	brand	Drug_0
10000687	67	75	levodopa	drug	Drug_1
10000687	57	66	carbidopa	drug	Drug_2

10000688|t|Iron salts may reduce the bioavailability of carbidopa and levodopa.
10000688	0	4	Iron	drug	Drug_0
10000688	45	54	carbidopa	drug	Drug_1
10000688	59	67	levodopa	drug	Drug_2
10000688	mechanism	Drug_0	Drug_2
10000688	mechanism	Drug_0	Drug_1

10000689|t|Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.
10000689	101	115	metoclopramide	drug	Drug_0
10000689	60	68	levodopa	drug	Drug_1
10000689	mechanism	Drug_0	Drug_1

10000690|t|Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.
10000690	71	77	iodine	drug	Drug_0
10000690	116	127	Carbimazole	drug	Drug_1
10000690	effect	Drug_0	Drug_1
10000690	effect	Drug_0	Drug_1

10000691|t|Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.
10000691	23	30	digoxin	drug	Drug_0
10000691	35	44	digitoxin	drug	Drug_1
10000691	77	95	antithyroid agents	group	Drug_2
10000691	mechanism	Drug_0	Drug_2
10000691	mechanism	Drug_1	Drug_2

10000692|t|Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.
10000692	0	18	Antithyroid agents	group	Drug_0
10000692	52	70	sodium iodide I131	drug	Drug_1
10000692	142	153	Carbimazole	drug	Drug_2
10000692	effect	Drug_0	Drug_1

10000693|t|Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.
10000693	0	14	Antihistamines	group	Drug_0
10000693	42	67	tricyclic antidepressants	group	Drug_1
10000693	69	81	barbiturates	group	Drug_2
10000693	83	90	alcohol	drug	Drug_3
10000693	102	117	CNS depressants	group	Drug_4
10000693	effect	Drug_0	Drug_1
10000693	effect	Drug_0	Drug_4
10000693	effect	Drug_0	Drug_2
10000693	effect	Drug_0	Drug_3

10000694|t|MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
10000694	0	14	MAO inhibitors	group	Drug_0
10000694	68	82	antihistamines	group	Drug_1
10000694	effect	Drug_0	Drug_1

10000695|t|Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.
10000695	0	22	Sympathomimetic amines	group	Drug_0
10000695	66	75	reserpine	drug	Drug_1
10000695	77	95	veratrum alkaloids	group	Drug_2
10000695	97	107	methyldopa	drug	Drug_3
10000695	112	124	mecamylamine	drug	Drug_4
10000695	effect	Drug_0	Drug_3
10000695	effect	Drug_0	Drug_4
10000695	effect	Drug_0	Drug_2
10000695	effect	Drug_0	Drug_1

10000696|t|Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.
10000696	11	27	sympathomimetics	group	Drug_0
10000696	47	61	MAO inhibitors	group	Drug_1
10000696	66	90	beta adrenergic blockers	group	Drug_2
10000696	effect	Drug_0	Drug_1
10000696	effect	Drug_0	Drug_2

10000697|t|HEMABATE may augment the activity of other oxytocic agents.
10000697	0	8	HEMABATE	brand	Drug_0
10000697	43	58	oxytocic agents	group	Drug_1
10000697	effect	Drug_0	Drug_1

10000698|t|Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.
10000698	0	8	Ocupress	brand	Drug_0
10000698	69	99	beta-adrenergic blocking agent	group	Drug_1
10000698	advise	Drug_0	Drug_1

10000699|t|Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
10000699	55	67	beta-blocker	group	Drug_0
10000699	144	153	reserpine	drug	Drug_1
10000699	advise	Drug_0	Drug_1

10000700|t|poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
10000700	21	32	debrisoquin	drug	Drug_0
10000700	263	273	carvedilol	drug	Drug_1
10000700	103	112	quinidine	drug	Drug_2
10000700	114	124	fluoxetine	drug	Drug_3
10000700	126	136	paroxetine	drug	Drug_4
10000700	142	153	propafenone	drug	Drug_5
10000700	effect	Drug_4	Drug_1
10000700	effect	Drug_5	Drug_1
10000700	effect	Drug_3	Drug_1
10000700	effect	Drug_2	Drug_1

10000701|t|Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.
10000701	53	86	agents with b-blocking properties	group	Drug_0
10000701	137	146	reserpine	drug	Drug_1
10000701	151	179	monoamine oxidase inhibitors	group	Drug_2
10000701	effect	Drug_0	Drug_2
10000701	effect	Drug_0	Drug_1

10000702|t|Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.
10000702	41	50	clonidine	drug	Drug_0
10000702	56	89	agents with b-blocking properties	group	Drug_1
10000702	effect	Drug_0	Drug_1

10000703|t|When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.
10000703	32	65	agents with b-blocking properties	group	Drug_0
10000703	70	79	clonidine	drug	Drug_1
10000703	105	121	b-blocking agent	group	Drug_2
10000703	advise	Drug_0	Drug_1

10000704|t|Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.
10000704	46	58	cyclosporine	drug	Drug_0
10000704	112	122	carvedilol	drug	Drug_1
10000704	mechanism	Drug_0	Drug_1

10000705|t|Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.
10000705	205	217	cyclosporine	drug	Drug_0
10000705	165	175	carvedilol	drug	Drug_1
10000705	advise	Drug_0	Drug_1
10000705	advise	Drug_1	Drug_0

10000706|t|Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.
10000706	64	71	digoxin	drug	Drug_0
10000706	76	86	carvedilol	drug	Drug_1
10000706	mechanism	Drug_0	Drug_1

10000707|t|Both digoxin and COREG slow AV conduction.
10000707	5	12	digoxin	drug	Drug_0
10000707	17	22	COREG	brand	Drug_1
10000707	effect	Drug_0	Drug_1

10000708|t|Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.
10000708	35	42	digoxin	drug	Drug_0
10000708	103	108	COREG	brand	Drug_1
10000708	advise	Drug_0	Drug_1

10000709|t|Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.
10000709	47	55	Rifampin	drug	Drug_0
10000709	89	99	carvedilol	drug	Drug_1
10000709	mechanism	Drug_0	Drug_1

10000710|t|Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.
10000710	0	24	Calcium Channel Blockers	group	Drug_0
10000710	128	133	COREG	brand	Drug_1
10000710	158	167	diltiazem	drug	Drug_2
10000710	effect	Drug_1	Drug_2

10000711|t|As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.
10000711	14	47	agents with b-blocking properties	group	Drug_0
10000711	52	57	COREG	brand	Drug_1
10000711	92	116	calcium channel blockers	group	Drug_2
10000711	124	133	verapamil	drug	Drug_3
10000711	137	146	diltiazem	drug	Drug_4
10000711	advise	Drug_1	Drug_3
10000711	advise	Drug_1	Drug_4

10000712|t|Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.
10000712	112	119	insulin	drug	Drug_0
10000712	129	142	hypoglycemics	group	Drug_1
10000712	31	64	Agents with b-blocking properties	group	Drug_2
10000712	effect	Drug_2	Drug_0
10000712	effect	Drug_2	Drug_1

10000713|t|Therefore, in patients taking insulin or oral hypoglycemics, regular monitoring of blood glucose is recommended.
10000713	30	37	insulin	drug	Drug_0
10000713	46	59	hypoglycemics	group	Drug_1

10000714|t|Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, mycophenolate, nelfinavir, or tacrolimus.
10000714	73	81	CANCIDAS	brand	Drug_0
10000714	101	113	itraconazole	drug	Drug_1
10000714	115	129	amphotericin B	drug	Drug_2
10000714	131	144	mycophenolate	drug	Drug_3
10000714	146	156	nelfinavir	drug	Drug_4
10000714	161	171	tacrolimus	drug	Drug_5

10000715|t|CANCIDAS has no effect on the pharmacokinetics of itraconazole, amphotericin B, or the active metabolite of mycophenolate.
10000715	0	8	CANCIDAS	brand	Drug_0
10000715	50	62	itraconazole	drug	Drug_1
10000715	64	78	amphotericin B	drug	Drug_2

10000716|t|CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.
10000716	268	276	CANCIDAS	brand	Drug_0
10000716	344	354	tacrolimus	drug	Drug_1
10000716	mechanism	Drug_0	Drug_1

10000717|t|In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.
10000717	25	37	cyclosporine	drug	Drug_0
10000717	99	110	caspofungin	drug	Drug_1
10000717	mechanism	Drug_0	Drug_1

10000718|t|CANCIDAS did not increase the plasma levels of cyclosporine.
10000718	0	8	CANCIDAS	brand	Drug_0
10000718	47	59	cyclosporine	drug	Drug_1

10000719|t|There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.
10000719	57	65	CANCIDAS	brand	Drug_0
10000719	70	82	cyclosporine	drug	Drug_1
10000719	effect	Drug_0	Drug_1

10000720|t|A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.
10000720	35	43	rifampin	drug	Drug_0
10000720	94	105	caspofungin	drug	Drug_1
10000720	mechanism	Drug_0	Drug_1

10000721|t|Patients on rifampin should receive 70 mg of CANCIDAS daily.
10000721	12	20	rifampin	drug	Drug_0
10000721	45	53	CANCIDAS	brand	Drug_1
10000721	advise	Drug_0	Drug_1

10000722|t|In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
10000722	146	155	efavirenz	drug	Drug_0
10000722	157	167	nevirapine	drug	Drug_1
10000722	169	178	phenytoin	drug	Drug_2
10000722	180	193	dexamethasone	drug	Drug_3
10000722	198	211	carbamazepine	drug	Drug_4
10000722	218	226	CANCIDAS	brand	Drug_5
10000722	277	288	caspofungin	drug	Drug_6
10000722	mechanism	Drug_1	Drug_5
10000722	mechanism	Drug_4	Drug_5
10000722	mechanism	Drug_0	Drug_5
10000722	mechanism	Drug_3	Drug_5
10000722	mechanism	Drug_2	Drug_5

10000723|t|When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
10000723	173	181	CANCIDAS	brand	Drug_0
10000723	74	83	efavirenz	drug	Drug_1
10000723	85	95	nevirapine	drug	Drug_2
10000723	97	106	phenytoin	drug	Drug_3
10000723	108	121	dexamethasone	drug	Drug_4
10000723	126	139	carbamazepine	drug	Drug_5
10000723	advise	Drug_0	Drug_3
10000723	advise	Drug_0	Drug_4
10000723	advise	Drug_0	Drug_5
10000723	advise	Drug_0	Drug_2
10000723	advise	Drug_0	Drug_1

10000724|t|Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.
10000724	0	10	Probenecid	drug	Drug_0
10000724	51	65	cephalosporins	group	Drug_1
10000724	132	145	cephalosporin	group	Drug_2
10000724	mechanism	Drug_0	Drug_1

10000725|t|Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.
10000725	0	8	Antacids	group	Drug_0
10000725	10	18	aluminum	drug	Drug_1
10000725	23	32	magnesium	drug	Drug_2
10000725	83	91	cefdinir	drug	Drug_3
10000725	112	121	Maalox TC	brand	Drug_4
10000725	mechanism	Drug_3	Drug_4

10000726|t|There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir.
10000726	125	133	cefdinir	drug	Drug_0
10000726	69	76	antacid	group	Drug_1

10000727|t|If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.
10000727	3	11	antacids	group	Drug_0
10000727	49	56	OMNICEF	brand	Drug_1
10000727	110	117	antacid	group	Drug_2
10000727	advise	Drug_1	Drug_2

10000728|t|Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.
10000728	48	58	probenecid	drug	Drug_0
10000728	26	46	b-lactam antibiotics	group	Drug_1
10000728	169	177	cefdinir	drug	Drug_2
10000728	mechanism	Drug_1	Drug_2
10000728	mechanism	Drug_0	Drug_2

10000729|t|Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
10000729	0	16	Iron Supplements	group	Drug_0
10000729	216	220	iron	drug	Drug_1
10000729	77	85	cefdinir	drug	Drug_2
10000729	105	120	iron supplement	group	Drug_3
10000729	170	178	vitamins	group	Drug_4
10000729	mechanism	Drug_2	Drug_1
10000729	mechanism	Drug_2	Drug_1

10000730|t|If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.
10000730	3	19	iron supplements	group	Drug_0
10000730	57	64	OMNICEF	brand	Drug_1
10000730	advise	Drug_0	Drug_1

10000731|t|The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.
10000731	68	72	iron	drug_n	Drug_0
10000731	105	113	cefdinir	drug	Drug_1

10000732|t|Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics.
10000732	75	79	iron	drug_n	Drug_0
10000732	115	123	cefdinir	drug	Drug_1

10000733|t|Therefore, OMNICEF for Oral Suspension can be administered with iron-fortified infant formula.
10000733	11	18	OMNICEF	brand	Drug_0
10000733	64	68	iron	drug_n	Drug_1

10000734|t|The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.
10000734	77	85	cefdinir	drug	Drug_0
10000734	116	120	iron	drug	Drug_1
10000734	mechanism	Drug_0	Drug_1

10000735|t|Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide.
10000735	112	125	nitroprusside	drug	Drug_0
10000735	152	169	nitroferricyanide	drug	Drug_1

10000736|t|Oral Contraceptives Multiple doses of cefditoren pivoxil had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral contraceptives.
10000736	155	169	contraceptives	group	Drug_0
10000736	38	56	cefditoren pivoxil	drug	Drug_1
10000736	98	115	ethinyl estradiol	drug	Drug_2

10000737|t|Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.
10000737	76	94	cefditoren pivoxil	drug	Drug_0
10000737	123	131	antacids	group	Drug_1
10000737	advise	Drug_0	Drug_1

10000738|t|H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.
10000738	0	23	H2-Receptor Antagonists	group	Drug_0
10000738	90	100	famotidine	drug	Drug_1
10000738	164	182	cefditoren pivoxil	drug	Drug_2
10000738	mechanism	Drug_1	Drug_2

10000739|t|Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with H2 receptor antagonists.
10000739	76	94	cefditoren pivoxil	drug	Drug_0
10000739	123	146	H2 receptor antagonists	group	Drug_1

10000740|t|Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.
10000740	69	79	probenecid	drug	Drug_0
10000740	26	46	b-lactam antibiotics	group	Drug_1
10000740	85	103	cefditoren pivoxil	drug	Drug_2
10000740	154	164	cefditoren	drug	Drug_3
10000740	mechanism	Drug_0	Drug_2
10000740	mechanism	Drug_1	Drug_2

10000741|t|Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.
10000741	62	77	aminoglycosides	group	Drug_0
10000741	106	114	MAXIPIME	brand	Drug_1
10000741	187	213	aminoglycoside antibiotics	group	Drug_2
10000741	advise	Drug_0	Drug_1

10000742|t|Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.
10000742	79	93	cephalosporins	group	Drug_0
10000742	106	115	diuretics	group	Drug_1
10000742	124	134	furosemide	drug	Drug_2
10000742	effect	Drug_0	Drug_2
10000742	effect	Drug_0	Drug_1

10000743|t|Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.
10000743	24	37	carbamazepine	drug	Drug_0
10000743	97	103	SUPRAX	brand	Drug_1
10000743	mechanism	Drug_0	Drug_1

10000744|t|Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.
10000744	0	8	Warfarin	drug	Drug_0
10000744	13	27	Anticoagulants	group	Drug_1
10000744	115	123	cefixime	drug	Drug_2
10000744	effect	Drug_0	Drug_2
10000744	effect	Drug_1	Drug_2

10000745|t|Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide.
10000745	112	125	nitroprusside	drug	Drug_0
10000745	151	168	nitroferricyanide	drug	Drug_1

10000746|t|Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
10000746	83	97	cephalosporins	group	Drug_0
10000746	102	128	aminoglycoside antibiotics	group	Drug_1
10000746	effect	Drug_0	Drug_1

10000747|t|Drug/Laboratory Test Interactions Cephalosporins, including cefotaxime sodium, are known to occasionally induce a positive direct Coombs test.
10000747	34	48	Cephalosporins	group	Drug_0
10000747	60	77	cefotaxime sodium	drug	Drug_1

10000748|t|If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.
10000748	3	10	CEFOTAN	brand	Drug_0
10000748	18	32	aminoglycoside	group	Drug_1
10000748	effect	Drug_0	Drug_1

10000749|t|As with other cephalosporins, high concentrations of cefotetan may interfere with measurement of serum and urine creatinine levels by Jaffe  reaction and produce false increases in the levels of creatinine reported.
10000749	14	28	cephalosporins	group	Drug_0
10000749	53	62	cefotetan	drug	Drug_1

10000750|t|Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
10000750	83	97	cephalosporins	group	Drug_0
10000750	102	128	aminoglycoside antibiotics	group	Drug_1
10000750	effect	Drug_0	Drug_1

10000751|t|Drug/Laboratory Test Interactions As with cephalothin, high concentrations of cefoxitin ( 100 micrograms/mL) may interfere with measurement of serum and urine creatinine levels by the Jaff  reaction, and produce false increases of modest degree in the levels of creatinine reported.
10000751	42	53	cephalothin	drug	Drug_0
10000751	78	87	cefoxitin	drug	Drug_1

10000752|t|Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.
10000752	73	99	aminoglycoside antibiotics	group	Drug_0
10000752	104	129	cephalosporin antibiotics	group	Drug_1
10000752	effect	Drug_0	Drug_1

10000753|t|Concomitant administration of probenecid doubled the AUC for cefprozil.
10000753	30	40	probenecid	drug	Drug_0
10000753	61	70	cefprozil	drug	Drug_1
10000753	mechanism	Drug_0	Drug_1

10000754|t|The bioavailability of the capsule formulation of cefprozil was not affected when administered 5 minutes following an antacid.
10000754	50	59	cefprozil	drug	Drug_0
10000754	118	125	antacid	group	Drug_1

10000755|t|Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.
10000755	73	87	cephalosporins	group	Drug_0
10000755	93	119	aminoglycoside antibiotics	group	Drug_1
10000755	130	139	diuretics	group	Drug_2
10000755	148	158	furosemide	drug	Drug_3
10000755	effect	Drug_0	Drug_2
10000755	effect	Drug_0	Drug_3
10000755	effect	Drug_0	Drug_1

10000756|t|Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycosidic antibiotics.
10000756	82	97	aminoglycosides	group	Drug_0
10000756	208	235	aminoglycosidic antibiotics	group	Drug_1

10000757|t|Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.
10000757	0	15	Chloramphenicol	drug	Drug_0
10000757	53	76	beta-lactam antibiotics	group	Drug_1
10000757	88	99	ceftazidime	drug	Drug_2
10000757	effect	Drug_0	Drug_1
10000757	effect	Drug_0	Drug_2

10000758|t|Theophylline: Twelve healthy male volunteers were administered one 200-mg ceftibuten capsule twice daily for 6 days.
10000758	0	12	Theophylline	drug	Drug_0
10000758	74	84	ceftibuten	drug	Drug_1

10000759|t|With the morning dose of ceftibuten on day 6, each volunteer received a single intravenous infusion of theophylline (4 mg/kg).
10000759	25	35	ceftibuten	drug	Drug_0
10000759	103	115	theophylline	drug	Drug_1

10000760|t|The effect of ceftibuten on the pharmacokinetics of theophylline administered orally has not been investigated.
10000760	14	24	ceftibuten	drug	Drug_0
10000760	52	64	theophylline	drug	Drug_1

10000761|t|Antacids or H 2 -receptor antagonists: The effect of increased gastric pH on the bioavailability of ceftibuten was evaluated in 18 healthy adult volunteers.
10000761	0	8	Antacids	group	Drug_0
10000761	12	37	H 2 -receptor antagonists	group	Drug_1
10000761	100	110	ceftibuten	drug	Drug_2

10000762|t|A single dose of liquid antacid did not affect the C max or AUC of ceftibuten;
10000762	24	31	antacid	group	Drug_0
10000762	67	77	ceftibuten	drug	Drug_1

10000763|t|however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.
10000763	19	29	ranitidine	drug	Drug_0
10000763	88	98	ceftibuten	drug	Drug_1
10000763	mechanism	Drug_0	Drug_1
10000763	mechanism	Drug_0	Drug_1

10000764|t|Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.
10000764	51	58	Cefizox	brand	Drug_0
10000764	139	153	cephalosporins	group	Drug_1
10000764	158	173	aminoglycosides	group	Drug_2
10000764	effect	Drug_1	Drug_2

10000765|t|Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.
10000765	22	31	celecoxib	drug	Drug_0
10000765	90	101	fluconazole	drug	Drug_1
10000765	106	113	lithium	drug	Drug_2
10000765	int	Drug_0	Drug_2
10000765	int	Drug_0	Drug_1

10000766|t|Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.
10000766	16	52	nonsteroidal anti-inflammatory drugs	group	Drug_0
10000766	54	60	NSAIDs	group	Drug_1
10000766	107	117	furosemide	drug	Drug_2
10000766	122	136	ACE inhibitors	group	Drug_3
10000766	int	Drug_1	Drug_2
10000766	int	Drug_1	Drug_3
10000766	int	Drug_0	Drug_2
10000766	int	Drug_0	Drug_3

10000767|t|The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.
10000767	12	21	celecoxib	drug	Drug_0
10000767	73	82	glyburide	drug	Drug_1
10000767	84	96	ketoconazole	drug	Drug_2
10000767	98	110	methotrexate	drug	Drug_3
10000767	112	121	phenytoin	drug	Drug_4
10000767	123	134	tolbutamide	drug	Drug_5
10000767	140	148	warfarin	drug	Drug_6

10000768|t|ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.
10000768	0	14	ACE inhibitors	group	Drug_0
10000768	37	43	NSAIDs	group	Drug_1
10000768	88	134	Angiotensin Converting Enzyme (ACE) inhibitors	group	Drug_2
10000768	effect	Drug_1	Drug_2

10000769|t|This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors.
10000769	66	74	CELEBREX	brand	Drug_0
10000769	94	108	ACE-inhibitors	group	Drug_1
10000769	advise	Drug_0	Drug_1

10000770|t|Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
10000770	130	140	furosemide	drug	Drug_0
10000770	86	92	NSAIDs	group	Drug_1
10000770	145	154	thiazides	group	Drug_2
10000770	effect	Drug_1	Drug_0
10000770	effect	Drug_1	Drug_2

10000771|t|Aspirin: CELEBREX can be used with low dose aspirin.
10000771	44	51	aspirin	brand	Drug_0
10000771	9	17	CELEBREX	brand	Drug_1
10000771	advise	Drug_1	Drug_0

10000772|t|However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.
10000772	39	46	aspirin	brand	Drug_0
10000772	153	161	CELEBREX	brand	Drug_1
10000772	effect	Drug_0	Drug_1

10000773|t|Because of its lack of platelet effects, CELEBREX is not a substitute for aspirin for cardiovascular prophylaxis.
10000773	41	49	CELEBREX	brand	Drug_0
10000773	74	81	aspirin	brand	Drug_1

10000774|t|Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.
10000774	43	54	fluconazole	drug	Drug_0
10000774	103	112	celecoxib	drug	Drug_1
10000774	mechanism	Drug_0	Drug_1

10000775|t|This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).
10000775	42	51	celecoxib	drug	Drug_0
10000775	79	90	fluconazole	drug	Drug_1
10000775	mechanism	Drug_0	Drug_1

10000776|t|CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.
10000776	0	8	CELEBREX	brand	Drug_0
10000776	83	94	fluconazole	drug	Drug_1
10000776	advise	Drug_0	Drug_1

10000777|t|Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.
10000777	219	226	lithium	drug	Drug_0
10000777	165	173	CELEBREX	brand	Drug_1
10000777	mechanism	Drug_0	Drug_1

10000778|t|Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.
10000778	12	19	lithium	drug	Drug_0
10000778	63	71	CELEBREX	brand	Drug_1
10000778	advise	Drug_0	Drug_1

10000779|t|Methotrexate: In an interaction study of rheumatoid arthritis patients taking methotrexate, CELEBREX did not have a significant effect on the pharmacokinetics of methotrexate.
10000779	162	174	methotrexate	drug	Drug_0
10000779	92	100	CELEBREX	brand	Drug_1

10000780|t|Warfarin: The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.
10000780	153	161	warfarin	drug	Drug_0
10000780	24	33	celecoxib	drug	Drug_1

10000781|t|In these subjects, celecoxib did not alter the anticoagulant effect of warfarin as determined by prothrombin time.
10000781	19	28	celecoxib	drug	Drug_0
10000781	71	79	warfarin	drug	Drug_1

10000782|t|However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.
10000782	51	59	CELEBREX	brand	Drug_0
10000782	65	73	warfarin	drug	Drug_1
10000782	advise	Drug_0	Drug_1

10000783|t|Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.
10000783	179	188	metformin	drug	Drug_0
10000783	60	70	cephalexin	drug	Drug_1
10000783	mechanism	Drug_1	Drug_0

10000784|t|No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.
10000784	53	63	cephalexin	drug	Drug_0
10000784	68	77	metformin	drug	Drug_1

10000785|t|Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.
10000785	103	113	cephalexin	drug	Drug_0
10000785	118	127	metformin	drug	Drug_1
10000785	mechanism	Drug_0	Drug_1

10000786|t|Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.
10000786	136	145	metformin	drug	Drug_0
10000786	121	131	cephalexin	drug	Drug_1
10000786	advise	Drug_1	Drug_0

10000787|t|Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.
10000787	87	97	probenecid	drug	Drug_0
10000787	26	35	b-lactams	group	Drug_1
10000787	60	70	cephalexin	drug	Drug_2
10000787	mechanism	Drug_2	Drug_0

10000788|t|Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle.
10000788	0	23	Immunosuppressive Drugs	group	Drug_0
10000788	25	48	Fibric Acid Derivatives	group	Drug_1
10000788	50	56	Niacin	drug	Drug_2
10000788	58	72	Nicotinic Acid	drug	Drug_3
10000788	74	86	Erythromycin	drug	Drug_4
10000788	88	105	Azole Antifungals	group	Drug_5

10000789|t|ANTACID (Magnesium-Aluminum Hydroxide): Cerivastatin plasma concentrations were not affected by co-administration of antacid.
10000789	117	124	antacid	group	Drug_0
10000789	9	37	Magnesium-Aluminum Hydroxide	drug	Drug_1
10000789	40	52	Cerivastatin	drug	Drug_2

10000790|t|CIMETlDINE: Cerivastatin plasma concentrations were not affected by co-administration of cimetidine.
10000790	0	10	CIMETlDINE	drug	Drug_0
10000790	12	24	Cerivastatin	drug	Drug_1
10000790	89	99	cimetidine	drug	Drug_2
